Page last updated: 2024-11-08

eplerenone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Eplerenone: A spironolactone derivative and selective ALDOSTERONE RECEPTOR antagonist that is used in the management of HYPERTENSION and CONGESTIVE HEART FAILURE, post-MYOCARDIAL INFARCTION. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID443872
CHEMBL ID1095097
CHEBI ID31547
SCHEMBL ID21515
MeSH IDM0371594

Synonyms (85)

Synonym
AC-4213
methyl (1'r,2r,2's,9'r,10'r,11's,15's,17'r)-2',15'-dimethyl-5,5'-dioxo-18'-oxaspiro[oxolane-2,14'-pentacyclo[8.8.0.0^{1,17}.0^{2,7}.0^{11,15}]octadecan]-6'-ene-9'-carboxylate
gtpl2876
epoxymexrenone
sc-66110 ,
9,11alpha-epoxy-17-hydroxy-3-oxo-17alpha-pregn-4-ene-7alpha,21-dicarboxylic acid, gamma-lactone, methyl ester
pregn-4-ene-7,21-dicarboxylic acid, 9,11-epoxy-17-hydroxy-3-oxo-, gamma-lactone, methyl ester, (7alpha,11alpha,17alpha)-
inspra
cgp 30083
selara
cgp-30083
eplerenone [usan]
eplerenon
eplerenone
107724-20-9
7alpha-methoxycarbonyl-3-oxo-9,11alpha-epoxy-17alpha-pregn-4-ene-21,17-carbolactone
CHEBI:31547 ,
DB00700
eplerenone (jp17/usan/inn)
inspra (tn)
D01115
NCGC00159559-02
sc-6611o
CHEMBL1095097 ,
bdbm50318300
6995v82d0b ,
eplerenone [usan:inn:ban]
spiro(cyclopenta(7,8)phenanthro(4b,5-b)oxirene-7(3h),2'(3'h)-furan)-10-carboxylic acid, 2,4,4',4a,5',5a,6,6a,8,9,9a,9b,10,11-tetradecahydro-4a,6a-dimethyl-2,5'-dioxo-, methyl ester, (4as,4br,5ar,6as,7 r,9as,9br,10r)-
sc 6110
unii-6995v82d0b
(+)-eplerenone
hsdb 7522
tox21_111746
dtxcid0026094
dtxsid2046094 ,
cas-107724-20-9
9,11alpha-epoxy-17-hydroxy-3-oxo-17alpha-pregn-4-ene-7alpha,21-dicarboxylic acid gamma-lactone methyl ester
E0905
AKOS015962307
eplerenone [who-dd]
eplerenone [mi]
eplerenone [usp-rs]
eplerenone [mart.]
eplerenone [inn]
eplerenone [hsdb]
eplerenone [vandf]
eplerenone [jan]
eplerenone [orange book]
pregn-4-ene-7,21-dicarboxylic acid, 9,11-epoxy-17-hydroxy-3-oxo-, g-lactone, methyl ester, (7.alpha.,11.alpha.,17.alpha)-
eplerenone [ep monograph]
S1707
HY-B0251
JUKPWJGBANNWMW-VWBFHTRKSA-N
SCHEMBL21515
NCGC00159559-03
tox21_111746_1
KS-1406
AB01274707-01
(7?,11?,17?)-9,11-epoxy-17-hydroxy-3-oxo-pregn-4-ene-7,21-dicarboxylic acid ?-lactone methyl ester
epleremone
methyl dimethyl-5'-dioxo-spiro[[?]-[?],2'-tetrahydrofuran]carboxylate

c24h30o6

(7?,11?,17?)-9,11-epoxy-17-hydroxy-3-o xo-pregn-4-ene-7,21-dicarboxylic acid ?-lactone methyl ester

HB2527
AB01274707_02
sr-01000942233
SR-01000942233-1
eplerenone, >=98% (hplc)
ynu ,
Q423804
HMS3677K08
methyl (1'r,2s,2's,9'r,10'r,11's,15's,17'r)-2',15'-dimethyl-5,5'-dioxo-18'-oxaspiro[oxolane-2,14'-pentacyclo[8.8.0.0^{1,17}.0^{2,7}.0^{11,15}]octadecan]-6'-ene-9'-carboxylate
HMS3413K08
CCG-268820
A895400
eplerenone- bio-x
BE164415
EN300-6492952
eplerenonum
eplerenona
eplerenone (usp-rs)
eplerenone (mart.)
9,11alpha-epoxy-7alpha-(methoxycarbonyl)-3-oxo-17alpha-pregn-4-ene-21,17-carbolactone
c03da04
eplerenone (ep monograph)

Research Excerpts

Overview

Eplerenone (EPL) is a selective mineralocorticoid receptor antagonist that is primarily used to treat hypertension. The drug is a member of antihypertensives used individually or in combination with other medicines.

ExcerptReferenceRelevance
"Eplerenone (EPL) is a selective mineralocorticoid receptor antagonist that is primarily used to treat hypertension."( Eplerenone repurposing in management of chorioretinopathy: Mechanism, nanomedicine-based delivery applications and future trends.
Abdelhakeem, E; El-Nabarawi, M; Shamma, R, 2022
)
2.89
"Eplerenone is a selective mineralocorticoid receptor antagonist. "( Role of eplerenone in the threatment of cardiovascular diseases.
Málek, F, 2023
)
2.79
"Eplerenone is a member of antihypertensives used individually or in combination with other medicines. "( Improvement of dissolution profile of eplerenone with solidified self-emulsifying drug delivery systems (S-SEDDS).
Ranna, R; Tas, C; Uner, B; Ustundag Okur, N, 2023
)
2.62
"Oral eplerenone is a safe and effective treatment option for both acute and chronic CSCR. "( Oral Mineralocorticoid-Receptor Antagonists: Choroidal Parameters Changes Using OCT in Central Serous Chorioretinopathy.
Faghihi, H; Faghihi, S; Ghassemi, F; Kadivar, S; Mohammadzadeh, V; Nabavi, A, 2019
)
1.03
"Eplerenone is a drug that protects the cardiovascular system. "( Improved 11α-hydroxycanrenone production by modification of cytochrome P450 monooxygenase gene in Aspergillus ochraceus.
Cai, B; Guan, S; Li, Q; Liu, Y; Rong, S; Shi, L; Zhang, S, 2021
)
2.06
"Eplerenone (Epl) is a selective mineralocorticoid-receptor antagonist used for chronic central serous chorioretinopathy treatment. "( Effective Ocular Delivery of Eplerenone Using Nanoengineered Lipid Carriers in Rabbit Model.
Abdelhakeem, E; El-Nabarawi, M; Shamma, R, 2021
)
2.36
"Eplerenone (Inspra®) is a selective mineralocorticoid receptor antagonist (MRA). "( Eplerenone: a review of its use in patients with chronic systolic heart failure and mild symptoms.
Dhillon, S, 2013
)
3.28
"Eplerenone is a highly selective aldosterone blocker, which has the potential to lower blood pressure (BP) in patients with hypertension. "( The velocity of home blood pressure reduction in response to low-dose eplerenone combined with other antihypertensive drugs determined by exponential decay function analysis.
Asayama, K; Elnagar, N; Hosaka, M; Imai, Y; Ishikura, K; Mano, N; Obara, T; Ohkubo, T; Satoh, M, 2014
)
2.08
"Eplerenone is a selective mineralocorticoid receptor antagonist; however, little is known about its effects on insulin action."( Effect of eplerenone on insulin action in essential hypertension: a randomised, controlled, crossover study.
Atkinson, AB; Bell, PM; Ennis, C; Hunter, SJ; McMurray, EM; Wallace, IR, 2014
)
1.53
"As eplerenone was found to be a compound of great resistance to the above stress factors with the exception of high doses of ionizing radiation (≥ 200 kGy) when its degradation was above 1%, it is possible to sterilize eplerenone by radiation method with the standard dose of 25 kGy."( The influence of ionizing radiation, temperature, and light on eplerenone in the solid state.
Cwiertnia, B; Dettlaff, K; Dołhań, A; Garbacki, P; Jelińska, A; Kycler, W; Ogrodowczyk, M, 2014
)
1.16
"Eplerenone is a selective mineralocorticoid receptor antagonist that has been recently included in the treatment of patients with chronic heart failure (CHF) and reduced systolic function. "( Eplerenone in chronic heart failure with depressed systolic function.
Iellamo, F; Volterrani, M, 2015
)
3.3
"Eplerenone appears to be a safe and effective treatment for chronic CSCR, with a probable mechanism of action on the pathophysiology of this disease."( [Eplerenone treatment in chronic central serous chorioretinopathy].
Denis, D; Gascon, P; Ho Wang Yin, G; Hoffart, L; Matonti, F; Sampo, M; Soler, V, 2016
)
2.07
"Eplerenone is a nonsteroidal mineralocorticoid antagonist demonstrated to abrogate mineralocorticoid excess."( Efficacy of Eplerenone in the Management of Mineralocorticoid Excess in Men With Metastatic Castration-resistant Prostate Cancer Treated With Abiraterone Without Prednisone.
Agarwal, N; Alex, A; Bailey, E; Batten, J; Boucher, K; Gaston, D; Gill, D; Gupta, S; Hahn, A; Stenehjem, D, 2017
)
1.56
"Eplerenone is an aldosterone receptor blocker that is chemically derived from spironolactone. "( Eplerenone for hypertension.
Kinkade, A; Masson, SC; Stabler, SN; Tam, TS; Tejani, AM; Tsang, MP; Tung, A; Wu, MH, 2017
)
3.34
"Eplerenone is an aldosterone receptor antagonist indicated for the treatment of hypertension and congestive heart failure. "( The clinical pharmacology of eplerenone.
Benge, CD; Muldowney, JA; Schoenhard, JA, 2009
)
2.09
"Eplerenone is claimed to be a more selective blocker of the mineralocorticoid receptor than spironolactone being associated with fewer antiandrogenic side-effects. "( A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism.
Connell, JM; MacDonald, TM; McInnes, GT; Ménard, J; Parthasarathy, HK; Ruilope, LM; White, WB; Williams, B; Williams, GH; Young, WF, 2011
)
2.04
"Eplerenone is a selective mineralocorticoid receptor (MR) antagonist, and its potential protective role in cardiovascular injury has been reported by several studies. "( Hepatoprotective effect of the selective mineralocorticoid receptor antagonist, eplerenone against carbon tetrachloride-induced liver injury in rats.
Abdel-Raheem, IT; Taye, A,
)
1.8
"Eplerenone (Inspra) is an aldosterone receptor antagonist approved for the treatment of hypertension and heart failure after a myocardial infarction. "( Prostate effect in dogs with the aldosterone receptor blocker eplerenone.
Bell, RR; John-Baptiste, A; Levin, S; McMahon, E, 2013
)
2.07
"Eplerenone is a selective aldosterone blocker. "( Eplerenone--a novel selective aldosterone blocker.
Carter, BL; Zillich, AJ, 2002
)
3.2
"Eplerenone appears to be a promising drug in a new class of agents called selective aldosterone blockers. "( Eplerenone--a novel selective aldosterone blocker.
Carter, BL; Zillich, AJ, 2002
)
3.2
"Eplerenone is a selective aldosterone blocker that effectively lowers BP in both white and black patients with hypertension and provides meaningful further antihypertensive efficacy when added to patients whose hypertension is inadequately controlled by angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers."( Clinical implications of aldosterone blockade.
Weber, MA, 2002
)
1.76
"Eplerenone is a novel selective aldosterone blocker."( Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure.
Goldstein, S; McMahon, EG; Mishima, T; Morita, H; Rudolph, AE; Sabbah, HN; Sharov, VG; Suzuki, G; Tanhehco, EJ; Todor, A, 2002
)
1.31
"Eplerenone is a new aldosterone receptor antagonist that will be used in the treatment of hypertension. "( Eplerenone: a new aldosterone receptor antagonist--are the FDAs restrictions appropriate?
Sica, DA,
)
3.02
"Eplerenone is a highly selective aldosterone blocker, which is under development for the treatment of hypertension and heart failure. "( Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension.
Duprez, D; Krause, S; Kuse-Hamilton, J; Roniker, B; St Hillaire, R; Weber, MA; White, WB, 2003
)
2.02
"Eplerenone is a highly selective aldosterone blocking agent, which was recently approved for the treatment of hypertension and has also been shown to reduce mortality in post-myocardial infarction patients with heart failure. "( Assessment of the novel selective aldosterone blocker eplerenone using ambulatory and clinical blood pressure in patients with systemic hypertension.
Carr, AA; Jordan, R; Krause, S; Oigman, W; Roniker, B; White, WB, 2003
)
2.01
"Eplerenone is a selective aldosterone receptor blocker that displays little interaction with androgen and progesterone receptors."( Eplerenone: a selective aldosterone blocker.
Stier, CT, 2003
)
2.48
"Eplerenone is a new selective aldosterone blocker."( Role of a selective aldosterone blocker in mice with chronic heart failure.
Carretero, OA; Liu, YH; Peterson, E; Rhaleb, NE; Rudolph, AE; Wang, D; Xu, J; Yang, XP, 2004
)
1.04
"Eplerenone is an effective alternative for spironolactone."( The resurrection of spironolactone on its golden anniversary.
Futterman, LG; Lemberg, L, 2004
)
1.04
"Eplerenone is a specific aldosterone receptor antagonist that has been shown to have antihypertensive efficacy and to reduce end-organ manifestations in experimental animal models. "( Eplerenone: a new selective aldosterone receptor antagonist.
Weinberger, MH, 2004
)
3.21
"Eplerenone (Inspra) is a selective aldosterone blocker. "( Eplerenone : a review of its use in left ventricular systolic dysfunction and heart failure after acute myocardial infarction.
Keating, GM; Plosker, GL, 2004
)
3.21
"Eplerenone is an effective blocker of nongenomic effects of aldosterone in vascular tissue."( Eplerenone blocks nongenomic effects of aldosterone on the Na+/H+ exchanger, intracellular Ca2+ levels, and vasoconstriction in mesenteric resistance vessels.
Delpiano, AM; Hitschfeld, C; Lavandero, S; Lobos, L; Marusic, ET; Michea, L, 2005
)
2.49
"Eplerenone is a newer aldosterone antagonist that is much more selective, with minimal affinity for progesterone and androgenic receptors; therefore, there are very few reports of adverse sexual effects."( Eplerenone in hypertension.
Burgess, E, 2004
)
2.49
"Eplerenone is a selective aldosterone blocker (SAB) approved for the treatment of essential hypertension. "( Eplerenone: a review of its use in essential hypertension.
Croom, KF; Perry, CM, 2005
)
3.21
"Eplerenone is a next generation aldosterone receptor antagonist selective for aldosterone receptors alone."( Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis.
Sica, DA, 2005
)
1.05
"Eplerenone (Inspra) is a selective aldosterone blocker. "( Eplerenone : a pharmacoeconomic review of its use in patients with post-myocardial infarction heart failure.
Croom, KF; Plosker, GL, 2005
)
3.21
"Eplerenone is a new medicine that reduces the risk of death after myocardial infarction (MI) but produces additional cost to the health system."( Willingness to pay for a reduction in mortality risk after a myocardial infarction: an application of the contingent valuation method to the case of eplerenone.
de Bobadilla, JF; Farreras, V; Pinto-Prades, JL, 2008
)
1.27

Effects

Eplerenone has been specifically developed to bind selectively to the mineralocorticoid receptors in order to minimize binding to the progesterone and androgen receptors. It has been demonstrated as being cost effective for the treatment of patients with systolic heart failure (HF)

ExcerptReferenceRelevance
"Eplerenone has a very low affinity for the glucocorticoid receptor (GR)."( Differences in the determinants of eplerenone, spironolactone and aldosterone binding to the mineralocorticoid receptor.
Fuller, PJ; Rogerson, FM; Smith, BJ; Yao, Y, 2004
)
1.32
"Eplerenone has minimal, if any, effect upon reducing PCI-related adverse events in the PCI-treated cohort."( Effect of eplerenone in percutaneous coronary intervention-treated post-myocardial infarction patients with left ventricular systolic dysfunction: a subanalysis of the EPHESUS trial.
Adlam, D; Fay, R; Gunn, J; Iqbal, J; Parviz, Y; Pitt, B; Squire, I; Zannad, F, 2014
)
1.53
"Eplerenone has been specifically developed to bind selectively to the mineralocorticoid receptors in order to minimize binding to the progesterone and androgen receptors."( Mineralocorticoid receptor antagonists, a class beyond spironolactone--Focus on the special pharmacologic properties of eplerenone.
Lalic, N; Milinkovic, I; Pelliccia, F; Ristic, A; Rosano, G; Seferovic, J; Seferovic, PM; Simeunovic, D; Zivkovic, I, 2015
)
1.35
"Eplerenone has been demonstrated as being cost effective for the treatment of patients with systolic heart failure (HF) and mild symptoms in several jurisdictions; however, its cost effectiveness is unknown in the context of Alberta, Canada."( Cost Effectiveness of Eplerenone for the Treatment of Systolic Heart Failure with Mild Symptoms in Alberta, Canada.
Ezekowitz, JA; Kaul, P; Thanh, NX; Tran, DT, 2016
)
2.19
"Eplerenone has been reported to have anti-hypertensive and protective effects on cardiovascular and renal injury in salt-sensitive hypertensive animal models, such as the Dahl salt-sensitive (DS) hypertensive rat and leptin receptor-deficient spontaneously hypertensive rat (SHR/cp)."( Effects of eplerenone, a selective mineralocorticoid receptor antagonist, on clinical and experimental salt-sensitive hypertension.
Takeda, Y, 2009
)
1.46
"Eplerenone has additionally the potential to prevent increased vascular stiffness in salt-loaded ZDF-rats."( Eplerenone prevents salt-induced vascular stiffness in Zucker diabetic fatty rats: a preliminary report.
Amann, K; Birner, C; Brunner, S; Endemann, DH; Fredersdorf, S; Griese, DP; Kreuzer, P; Luchner, A; Resch, M; Riegger, GA; Schach, C; Schmid, P; Weil, J, 2011
)
2.53
"Eplerenone has already been approved for the treatment of systemic hypertension and has been evaluated in numerous hypertension subgroups, including patients with low plasma renin activity; diabetes; LVH; uncontrolled blood pressure while receiving monotherapy with angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, calcium channel blockers, or beta-blockers; and in black patients."( Eplerenone: a selective aldosterone blocker.
Stier, CT, 2003
)
2.48
"Eplerenone has been shown to be beneficial both as monotherapy and combination therapy for lowering elevated blood pressure in patients with hypertension."( Eplerenone: a selective aldosterone receptor antagonist for hypertension and heart failure.
Anderson, JR; Moore, TD; Nawarskas, JJ,
)
2.3
"Eplerenone has not been studied in ESRD in a therapeutic or safety capacity."( Aldosterone-receptor antagonism and end-stage renal disease.
Gehr, TW; McLaughlin, N; Sica, DA, 2004
)
1.04
"Eplerenone has a very low affinity for the glucocorticoid receptor (GR)."( Differences in the determinants of eplerenone, spironolactone and aldosterone binding to the mineralocorticoid receptor.
Fuller, PJ; Rogerson, FM; Smith, BJ; Yao, Y, 2004
)
1.32
"Eplerenone has the advantage, compared with spironolactone, to be better tolerated in terms of "hormonal" adverse effects."( [The revived interest in aldosterone antagonists].
Waeber, B, 2006
)
1.06

Actions

ExcerptReferenceRelevance
"Eplerenone reduced the increase of Ad and P-disp with a decrease of PINP and PIIIP, which might translate into reduction of atrial fibrosis. "( Eplerenone might affect atrial fibrosis in patients with hypertension.
Fukunami, M; Furukawa, Y; Iwasaki, Y; Kawasaki, M; Kikuchi, A; Morita, T; Okuyama, Y; Sakata, Y; Tamaki, S; Yamada, T, 2017
)
3.34

Treatment

Eplerenone treatment of patients with PA reduces blood pressure, increases serum potassium level, and improves vascular status. Treatment significantly reduced insulin resistance, suppressed macrophage infiltration and ROS production in adipose tissues, and corrected the mRNA levels of obesity-related genes.

ExcerptReferenceRelevance
"Eplerenone pre-treatment significantly could improve IR-induced pathological changes and kidney function and increase the renal antioxidant factors compared to the IR group (P < 0.05). "( Eplerenone reduces renal ischaemia/reperfusion injury by modulating Klotho, NF-κB and SIRT1/SIRT3/PGC-1α signalling pathways.
Bagheri, Y; Barati, A; Hosseiniyan Khatibi, SM; Kamrani Moghaddam, F; Malekinejad, Z; Meybodi, SM; Moradi, K; Nouraei, S; Rahbar Saadat, Y; Zununi Vahed, S, 2023
)
3.8
"Eplerenone treatment improved the clinical stability particularly during short period following hospitalization for AHF, translated by lower diuretic doses, natriuretic peptide levels, indirect markers of filling pressure and venous congestion, and a smaller LV volume."( Effect of eplerenone on clinical stability of Japanese patients with acute heart failure.
Asakura, M; Chikamori, T; Ferreira, JP; Ito, S; Kitakaze, M; Kobayashi, M; Matsue, Y; Yamashina, A, 2023
)
2.76
"Eplerenone treatment produced a significant improvement in motor coordination and spontaneous locomotor activity in rats and modulated the key inflammatory mediators in OA (TNF-α, NF-κβ, and IL-6). "( Eplerenone modulates the inflammatory response in monosodium iodoacetate-induced knee osteoarthritis in rats: Involvement of RANKL/OPG axis.
Mostafa, RE; Salama, AAA, 2023
)
3.8
"Eplerenone treatment also abolished the cortisol-induced inhibition of macrophage migration, suggesting a role for MR in cortisol-mediated anti-inflammatory action."( The Mineralocorticoid Receptor Plays a Crucial Role in Macrophage Development and Function.
Faught, E; Schaaf, MJM, 2023
)
1.63
"Eplerenone treatment was associated with lower prescribed loop diuretic doses throughout the follow-up; lower doses were observed at 90 days and decreased further at 180 days and beyond."( Reduced Diuretic Dose in Patients Treated With Eplerenone: Data From the EPHESUS Trial.
Damman, K; Duarte, K; Eschalier, R; Fay, R; Ferreira, JP; Girerd, N; Gustafsson, F; Pitt, B; Rossignol, P; Schou, M; Tala, S; Zannad, F, 2020
)
1.54
"Eplerenone treatment led to a loop diuretic dose reduction during follow-up without evidence of treatment effect modification by loop diuretics. "( Reduced Diuretic Dose in Patients Treated With Eplerenone: Data From the EPHESUS Trial.
Damman, K; Duarte, K; Eschalier, R; Fay, R; Ferreira, JP; Girerd, N; Gustafsson, F; Pitt, B; Rossignol, P; Schou, M; Tala, S; Zannad, F, 2020
)
2.26
"Eplerenone treatment alone decreased a number of important muscle-specific genes."( Gene expression effects of glucocorticoid and mineralocorticoid receptor agonists and antagonists on normal human skeletal muscle.
Chadwick, JA; Gomez-Sanchez, CE; Gomez-Sanchez, EP; Hauck, JS; Rafael-Fortney, JA, 2017
)
1.18
"Eplerenone pretreatment reduced the arterial pressure, cardiac inotropy, and lusitropy."( Eplerenone pretreatment protects the myocardium against ischaemia/reperfusion injury through the phosphatidylinositol 3-kinase/Akt-dependent pathway in diabetic rats.
Agrawal, YO; Chandrayan, G; Goyal, SN; Mahajan, UB; Ojha, S; Patil, CR; Patil, PD, 2018
)
2.64
"Eplerenone treatment increased log RHI from 0.56 ± 0.25 to 0.69 ± 0.25 (P < 0.01) and NID from 12.8 ± 5.8 to 14.9 ± 6.9% (P = 0.02) and it decreased baPWV from 1540 ± 263 to 1505 ± 281 (P = 0.04) and ROCK activity from 1.20 ± 0.54 to 0.89 ± 0.42 (P < 0.01), whereas there was no significant change in FMD (increase from 4.6 ± 3.4 to 4.6 ± 3.6%, P = 0.99) or brachial IMT (decrease from 0.28 ± 0.07 to 0.28 ± 0.04 mm, P = 0.14)."( Eplerenone improves endothelial function and arterial stiffness and inhibits Rho-associated kinase activity in patients with idiopathic hyperaldosteronism: a pilot study.
Aibara, Y; Chayama, K; Goto, C; Hashimoto, H; Higashi, Y; Kajikawa, M; Kihara, Y; Kishimoto, S; Liao, JK; Maruhashi, T; Matsui, S; Nakashima, A; Noma, K; Oki, K; Takaeko, Y; Yusoff, FM, 2019
)
2.68
"The eplerenone-treated patients in the highest sodium excretion tertile exhibited significantly greater reduction in UACR than the placebo subjects in the same tertile (-22.5% vs."( Mineralocorticoid receptor blockade suppresses dietary salt-induced ACEI/ARB-resistant albuminuria in non-diabetic hypertension: a sub-analysis of evaluate study.
Ayuzawa, N; Fujita, T; Hirohama, D; Isshiki, M; Kawakami-Mori, F; Kawarazaki, W; Marumo, T; Nagase, M; Nishimoto, M; Oba, S; Ohtsu, H; Shibata, S; Shimosawa, T; Ueda, K, 2019
)
0.99
"Eplerenone treatment was associated with a significant reduction in central macular thickness, subretinal fluid level, and an improvement in visual acuity. "( Mineralocorticoid receptor antagonism in the treatment of chronic central serous chorioretinopathy: a pilot study.
Behar-Cohen, F; Beydoun, T; Bousquet, E; Hassan, L; Offret, O; Zhao, M,
)
1.57
"Eplerenone treatment exacerbated the Ang II-mediated increase in plasma and heart aldosterone 2.3- and 1.8-fold, respectively, while ARB treatment reduced both."( Angiotensin and mineralocorticoid receptor antagonism attenuates cardiac oxidative stress in angiotensin II-infused rats.
Conte, D; Minas, JN; Nishiyama, A; Ortiz, RM; Thorwald, MA; Vázquez-Medina, JP, 2015
)
1.14
"Eplerenone treatment of patients with PA reduces blood pressure, increases serum potassium level, and improves vascular status."( Eplerenone improves carotid intima-media thickness (IMT) in patients with primary aldosteronism.
Anzai, K; Kawate, H; Matsuda, Y; Matsuzaki, C; Nomura, M; Ohnaka, K; Sakamoto, R; Shibue, K; Takayanagi, R, 2016
)
2.6
"Eplerenone treatment was well tolerated and safe and followed by significant decrease of ambulatory blood pressure."( Effect of eplerenone on parathyroid hormone levels in patients with primary hyperparathyroidism: results from the EPATH randomized, placebo-controlled trial.
Aberer, F; Alesutan, I; Belyavskiy, E; Brussee, H; Dimai, HP; Fahrleitner-Pammer, A; Gaksch, M; Grübler, M; Haas, J; Hartaigh, BÓ; Horina, JH; Lang, F; März, W; Meinitzer, A; Ofner-Ziegenfuss, L; Pieske, B; Pieske-Kraigher, E; Pilz, S; Ritz, E; Rus-Machan, J; Schwetz, V; Stiegler, C; Tomaschitz, A; Verheyen, N; Verheyen, S; Voelkl, J, 2016
)
1.56
"Eplerenone treatment significantly reduced insulin resistance, suppressed macrophage infiltration and ROS production in adipose tissues, and corrected the mRNA levels of obesity-related genes in obese mice."( Blockade of mineralocorticoid receptor reverses adipocyte dysfunction and insulin resistance in obese mice.
Fujita, K; Funahashi, T; Hibuse, T; Hirata, A; Hiuge, A; Kihara, S; Maeda, N; Okada, T; Shimomura, I, 2009
)
1.07
"Eplerenone-treated rats showed reduced anxiety-like behaviour manifested by both conventional and ethological parameters related to exploration and risk assessment behaviour in the elevated plus-maze test and partially in the open-field test."( Eplerenone, a selective mineralocorticoid receptor blocker, exerts anxiolytic effects accompanied by changes in stress hormone release.
Bakos, J; Hlavacova, N; Jezova, D, 2010
)
2.52
"Eplerenone treatment had no significant impact on any biomarker at 6 months but attenuated the increase in pro-collagen type-III aminoterminal peptide at 12 months (p = 0.006)."( Natural history of markers of collagen turnover in patients with early diastolic dysfunction and impact of eplerenone.
Baugh, JA; Dawkins, IR; Ledwidge, MT; Mak, GJ; McDonald, KM; Murphy, NF; Patle, AK; Phelan, DM; Watson, CJ, 2009
)
1.29
"Eplerenone treatment significantly reduced mean 24-h systolic/diastolic BP levels (143/80 mmHg to 132/74 mmHg, both p < 0.002). "( Efficacy of eplerenone added to renin-angiotensin blockade in elderly hypertensive patients: the Jichi-Eplerenone Treatment (JET) study.
Hoshide, S; Kanemaru, Y; Kario, K; Nagata, M; Sasaki, K; Shimada, K; Tamaki, N; Yano, Y, 2011
)
2.19
"Eplerenone treatment was associated with a 38% reduction in UPE after 12 months. "( The long-term antiproteinuric effect of eplerenone, a selective aldosterone blocker, in patients with non-diabetic chronic kidney disease.
Hosoya, T; Ishii, T; Kawamura, T; Okonogi, H; Tsuboi, N, 2012
)
2.09
"Eplerenone treatment significantly inhibited the infiltration of CD4+, CD8+ T cells and macrophages into the kidneys."( The selective mineralocorticoid receptor antagonist eplerenone is protective in mild anti-GBM glomeru-lonephritis.
Eller, K; Huber, JM; Kirsch, AH; Mayer, G; Rosenkranz, AR; Tagwerker, A; Zitt, E, 2011
)
1.34
"Eplerenone pre-treatment significantly attenuated the inflammatory responses caused by CCl(4) as evident by the decreased serum TNF-α level."( Hepatoprotective effect of the selective mineralocorticoid receptor antagonist, eplerenone against carbon tetrachloride-induced liver injury in rats.
Abdel-Raheem, IT; Taye, A,
)
1.08
"Eplerenone treatment affected neither basal nor postprandial glucose and lipid levels in our study population."( Effect of low dose mineralocorticoid receptor antagonist eplerenone on glucose and lipid metabolism in healthy adult males.
Adler, GK; Krug, AW; Lichtman, AH; Rao, AD; Stelzner, L; Williams, GH, 2013
)
2.08
"Eplerenone treatment was continued for up to 14 months in a subset of patients."( Long-term safety and efficacy of the selective aldosterone blocker eplerenone in patients with essential hypertension.
Burgess, ED; Kleiman, JH; Krause, S; Lacourcière, Y; Maurath, C; Oparil, S; Roniker, B; Ruilope-Urioste, LM, 2003
)
1.28
"Eplerenone treatment in RVP dogs significantly suppressed sustained atrial tachyarrhythmia inducibility, nonuniformly prolonged atrial ERPs and attenuated LV diastolic dysfunction without modifying left atrial or LV dilation or ejection fractions in CHF."( Selective aldosterone blockade suppresses atrial tachyarrhythmias in heart failure.
Hoit, BD; Martovitz, NL; Ryu, K; Shroff, SC; Stambler, BS, 2006
)
1.06
"Eplerenone-treated HF rats had lower plasma TNF-alpha, interleukin (IL)-1beta and IL-6, less COX-2 staining of small blood vessels penetrating PVN, fewer PVN neurons expressing Fra-like activity (indicating chronic neuronal activation), and fewer PVN neurons staining for TNF-alpha, IL-1beta, and CRH than vehicle-treated HF rats."( Novel effect of mineralocorticoid receptor antagonism to reduce proinflammatory cytokines and hypothalamic activation in rats with ischemia-induced heart failure.
Beltz, T; Felder, RB; Johnson, AK; Johnson, RF; Kang, YM; Weiss, RM; Yu, Y; Zhang, ZH, 2006
)
1.06
"Eplerenone treatment may reduce adverse CV events in diabetic patients with LVSD and signs of CHF following AMI."( Eplerenone improves prognosis in postmyocardial infarction diabetic patients with heart failure: results from EPHESUS.
Abuissa, H; O'Keefe, JH; Pitt, B, 2008
)
3.23
"Treatment with eplerenone prevented the worsening of cirrhosis by blocking this ligand-independent activation of the MR."( The selective mineralocorticoid receptor antagonist eplerenone prevents decompensation of the liver in cirrhosis.
Gekle, M; Hammer, S; Mildenberger, S; Pohl, S; Rabe, S; Schreier, B; Wolf, A; Zipprich, A, 2018
)
1.07
"When treated with eplerenone, chronic CSCR shows a significant reduction in SRF, with baseline BCVA and 3-month SRF height being important predictive factors. "( Predictors of Outcome During Eplerenone Therapy in Chronic Central Serous Chorioretinopathy:A Prospective, Open-Label Pilot Clinical Study.
Agrawal, H; Chhablani, J; Peguda, HK; Rajesh, B, 2018
)
1.11
"Treatment with eplerenone (100 mg/kg/d) attenuated left ventricular hypertrophy and fully prevented fibrosis, dilatation, and failure."( Atrial natriuretic peptide locally counteracts the deleterious effects of cardiomyocyte mineralocorticoid receptor activation.
Baba, HA; Frantz, S; Gaßner, B; Kuhn, M; Nakagawa, H; Nikolaev, VO; Oberwinkler, H; Saito, Y; Umbenhauer, S; Wagner, H, 2014
)
0.74
"The treatment with eplerenone significantly increased serum potassium levels, whereas the treatment with indapamide significantly decreased them."( Effects of a selective aldosterone blocker and thiazide-type diuretic on blood pressure and organ damage in hypertensive patients.
Hayashi, S; Ishizuka, A; Iwashima, Y; Kawano, Y; Kishida, M; Nakamura, S; Ohta, Y; Yoshihara, F, 2015
)
0.74
"Treatment with eplerenone added to the patient's baseline medications improves the degree of arterial stiffness as early as at two months after the beginning of treatment, independent of the blood pressure-lowering actions of these drugs in patients with uncontrolled hypertension."( Effects of Add-on Therapy Consisting of a Selective Mineralocorticoid Receptor Blocker on Arterial Stiffness in Patients with Uncontrolled Hypertension.
Hasegawa, J; Hongo, K; Mori, C; Murashima, E; Sato, N; Shibata, T; Tsutsumi, J; Yoshimura, M, 2015
)
0.77
"Treatment with eplerenone has been associated with decreased blood pressure and improved survival for patients with heart failure and reduced left ventricular ejection fraction."( Safety profile of mineralocorticoid receptor antagonists: Spironolactone and eplerenone.
Gaudio, C; Greco, C; Lainscak, M; Pelliccia, F; Rosano, G; Schiariti, M; Speziale, G; Vitale, C, 2015
)
0.99
"Treatment with eplerenone at a dose of 100 mg/kg body weight/d reduced heart weight/body weight ratios, interstitial fibrosis and blood pressure to levels similar to those seen in wild type mice, in association with reduced transcription of atrial natriuretic peptide, brain natriuretic peptide, transforming growth factor-beta1, collagen I and collagen III."( The specific mineralocorticoid receptor blocker eplerenone attenuates left ventricular remodeling in mice lacking the gene encoding guanylyl cyclase-A.
Imagawa, K; Kawata, H; Kishimoto, I; Nakao, K; Naya, N; Saito, Y; Somekawa, S; Takeda, Y; Uemura, S; Zhang, Q, 2008
)
0.94
"Pre-treatment with eplerenone or Y27632 prevented the aldosterone-induced cell hypertrophy, actin polymerization, the increase in alpha-SMA expression and the increases of collagen type I, III, IV mRNA levels in RMCs."( Aldosterone induces myofibroblastic transdifferentiation and collagen gene expression through the Rho-kinase dependent signaling pathway in rat mesangial cells.
Diah, S; Gang, L; Hamid, MR; Hitomi, H; Kimura, S; Nagai, Y; Nishiyama, A; Tamiya, T; Zhang, GX; Zhang, W, 2008
)
0.66
"Treatment with eplerenone in Dahl salt-sensitive rats was associated with significant improvements in kidney to body weight ratio, urinary protein excretion and renal injury scores and decreased renal (pro)renin receptor protein expression and angiotensinogen and AT1R mRNA levels and kidney Ang II content."( Effect of mineralocorticoid receptor blockade on the renal renin-angiotensin system in Dahl salt-sensitive hypertensive rats.
Demura, M; Karashima, S; Takeda, Y; Usukura, M; Yamagishi, M; Yoneda, T; Zhu, A, 2009
)
0.69
"Treatment with eplerenone markedly decreased the gene expression and reduced the albuminuria and renal morphological changes."( Effects of mineralocorticoid receptor blockade on glucocorticoid-induced renal injury in adrenalectomized rats.
Fujisawa, Y; Hitomi, H; Ihara, G; Kiyomoto, H; Kobori, H; Kohno, M; Nagai, Y; Nakano, D; Nishiyama, A; Ohashi, N; Rafiq, K, 2011
)
0.71
"Treatment with eplerenone reduced systemic osteopontin (58.3 +/- 4.2 ng/mL), albuminuria (41.5 +/- 7.2 mg/24 hours), and proinflammatory gene expression: osteopontin (OPN), monocyte chemoattractant protein-1 (MCP-1), interleukin-6 (IL-6), and interleukin-1beta (IL-1beta)."( Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats.
Blasi, ER; Blomme, EA; McMahon, EG; Polly, ML; Rocha, R; Rudolph, AE, 2003
)
0.66
"Treatment with eplerenone reduced (p < 0.05) SAP and normalized aortic media/lumen ratio and acetylcholine relaxations."( Eplerenone reduces oxidative stress and enhances eNOS in SHR: vascular functional and structural consequences.
Aragoncillo, P; Balfagón, G; Cachofeiro, V; Cediel, E; De las Heras, N; Lahera, V; Oubiña, MP; Sanz-Rosa, D,
)
1.91
"Cotreatment with eplerenone (2 micromol/L) attenuated these effects."( Mineralocorticoid receptor blocker increases angiotensin-converting enzyme 2 activity in congestive heart failure patients.
Abassi, Z; Gamliel-Lazarovich, A; Hamoud, S; Hayek, T; Kaplan, M; Karry, R; Keidar, S; Pavlotzky, E, 2005
)
0.66
"Treatment with eplerenone in the subgroup of patients with LVEF ( Evaluation of eplerenone in the subgroup of EPHESUS patients with baseline left ventricular ejection fraction Anderson, JL; Corbalan, R; Gheorghiade, M; Klug, EQ; Mukherjee, R; Parkhomenko, A; Pitt, B; Solomon, H; van Veldhuisen, DJ; Zannad, F, 2006)1.03
"Treatment with eplerenone plus standard therapy in patients with post-AMI HF and LVEF ( Evaluation of eplerenone in the subgroup of EPHESUS patients with baseline left ventricular ejection fraction Anderson, JL; Corbalan, R; Gheorghiade, M; Klug, EQ; Mukherjee, R; Parkhomenko, A; Pitt, B; Solomon, H; van Veldhuisen, DJ; Zannad, F, 2006)1.05
"Treatment with eplerenone, a selective aldosterone receptor blocker, almost completely prevented podocyte damage and proteinuria, with normalization of elevated reduced nicotinamide-adenine dinucleotide phosphate oxidase activity."( Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1.
Fujita, T; Kawachi, H; Nagase, M; Shibata, S; Yoshida, S, 2007
)
0.68
"Treatment with eplerenone at a dose of 1.67 mg/g chow significantly reduced the ischemic area, ischemic volume, and neurological deficit, without a blood pressure-lowering effect."( Pretreatment with eplerenone reduces stroke volume in mouse middle cerebral artery occlusion model.
Gao, XY; Horiuchi, M; Ide, A; Iwai, M; Iwanami, J; Li, JM; Min, LJ; Mogi, M; Okamoto, S; Tsukuda, K, 2007
)
1.01
"Treatment with eplerenone in diabetic patients with CHF following AMI reduced the risk of the primary endpoint, a composite of CV mortality or CV hospitalization, by 17% (p = 0.031). "( Eplerenone improves prognosis in postmyocardial infarction diabetic patients with heart failure: results from EPHESUS.
Abuissa, H; O'Keefe, JH; Pitt, B, 2008
)
2.14

Toxicity

Eplerenone was both efficacious and safe when carefully monitored, even in subgroups at high risk of developing hyperkalemia or WRF. Rates of any adverse event were significantly higher with eplerenon than placebo (odds ratio 1.0). EplerenONE was well tolerated, with a rate of adverse events comparable to that of placebo.

ExcerptReferenceRelevance
"8%) were withdrawn due to treatment-emergent adverse events."( Long-term safety and efficacy of the selective aldosterone blocker eplerenone in patients with essential hypertension.
Burgess, ED; Kleiman, JH; Krause, S; Lacourcière, Y; Maurath, C; Oparil, S; Roniker, B; Ruilope-Urioste, LM, 2003
)
0.56
" Up to date, many articles evaluating beneficial and adverse effects of CsA have been published."( [Novel action of aldosterone in CsA nephrotoxicity].
Bobadilla, NA; Pérez-Rojas, JM,
)
0.13
" Eplerenone was well tolerated, with a rate of adverse events comparable to that of placebo."( The efficacy and safety of the novel aldosterone antagonist eplerenone in children with hypertension: a randomized, double-blind, dose-response study.
Davis, I; Flynn, JT; Li, JS; Ogawa, M; Portman, R; Pressler, ML; Shi, H, 2010
)
1.51
"To evaluate the literature supporting the safe use of mineralocorticoid antagonists (MRAs) in patients with end-stage renal disease who are receiving hemodialysis."( Safety of mineralocorticoid receptor antagonists in patients receiving hemodialysis.
Baker, WL; White, WB, 2012
)
0.38
"0 mmol/l, and of hospitalization for hyperkalemia or discontinuation of study medication due to adverse events."( Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure).
Eschalier, R; Krum, H; McMurray, JJ; Pitt, B; Pocock, SJ; Rossignol, P; Shi, H; Swedberg, K; van Veldhuisen, DJ; Vincent, J; Zannad, F, 2013
)
0.7
"0 mmol/l, eplerenone was both efficacious and safe when carefully monitored, even in subgroups at high risk of developing hyperkalemia or WRF."( Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure).
Eschalier, R; Krum, H; McMurray, JJ; Pitt, B; Pocock, SJ; Rossignol, P; Shi, H; Swedberg, K; van Veldhuisen, DJ; Vincent, J; Zannad, F, 2013
)
1.1
" Clinical experience with Spironolactone is well established, as is its adverse effects profile."( Converging indications of aldosterone antagonists (spironolactone and eplerenone): a narrative review of safety profiles.
Danjuma, MI; Makaronidis, J; Mukherjee, I; Osula, S, 2014
)
0.64
" The range of adverse effects experienced with spironolactone has led to its modification and the consequent synthesis of eplerenone."( Efficacy and safety of mineralocorticoid receptors in mild to moderate arterial hypertension.
Gaudio, C; Greco, C; Patti, G; Pelliccia, F; Rosano, G; Volterrani, M, 2015
)
0.62
" Randomized studies comparing eplerenone with placebo or other antihypertensive drugs for net reduction of systolic and diastolic blood pressures (SBP; DBP) from baseline and for incidence of adverse events were considered."( Efficacy and safety of eplerenone in the management of mild to moderate arterial hypertension: systematic review and meta-analysis.
Gaudio, C; Greco, C; Patti, G; Pelliccia, F; Rosano, G, 2014
)
1
" Also, spironolactone is safe and protective in arterial hypertension, particularly in patients with so-called resistant hypertension."( Safety profile of mineralocorticoid receptor antagonists: Spironolactone and eplerenone.
Gaudio, C; Greco, C; Lainscak, M; Pelliccia, F; Rosano, G; Schiariti, M; Speziale, G; Vitale, C, 2015
)
0.65
" Mineralocorticoid receptor antagonists could improve kidney survival but are not commonly used during renal impairment and in association with several immunosuppressive drugs due to a supposed higher risk of adverse events."( Safety of Eplerenone for Kidney-Transplant Recipients with Impaired Renal Function and Receiving Cyclosporine A.
Barbe, C; Bertocchio, JP; Jaisser, F; Lavaud, S; Nazeyrollas, P; Rieu, P; Toupance, O, 2016
)
0.84
" Serum potassium, renal function and expected adverse events were closely monitored."( Safety of Eplerenone for Kidney-Transplant Recipients with Impaired Renal Function and Receiving Cyclosporine A.
Barbe, C; Bertocchio, JP; Jaisser, F; Lavaud, S; Nazeyrollas, P; Rieu, P; Toupance, O, 2016
)
0.84
" Adverse events, including hyperkalemia, were similar between the groups."( Double-Blind, Randomized, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Eplerenone in Japanese Patients With Chronic Heart Failure (J-EMPHASIS-HF).
Ichikawa, Y; Ito, H; Izumi, T; Kanmuri, K; Kitakaze, M; Komuro, I; Matsuzaki, M; Murohara, T; Okayama, A; Sunagawa, K; Tsutamoto, T; Tsutsui, H; Yamamoto, K; Yano, M; Yasumura, Y; Yoshikawa, T; Zhang, J, 2017
)
0.68
"018), the discontinuation rates due to adverse events were similar in the two groups (p = 0."( Comparison of effects of aldosterone receptor antagonists spironolactone and eplerenone on cardiovascular outcomes and safety in patients with acute decompensated heart failure.
Aonuma, K; Baba, M; Hamada-Harimura, Y; Higuchi, H; Ishizu, T; Machino-Ohtsuka, T; Nakatsukasa, T; Nishi, I; Obara, K; Sai, S; Seo, Y; Sugano, A; Yamamoto, M, 2019
)
0.74
" Compared with spironolactone and eplerenone, finerenone 10 mg was associated with low risk in the occurrence of cardiovascular mortality, hospitalization, and adverse events (P < 0."( Comparative efficacy and safety of mineralocorticoid receptor antagonists in heart failure: a network meta-analysis of randomized controlled trials.
Chen, X; Shen, W; Wu, Q; Wu, T; Xu, G; Xu, X; Yang, P; Zhu, D, 2019
)
0.79
" In addition, no noticeable difference was identified in the adverse events of hyperkalemia and cough between them."( Efficacy and safety of eplerenone treatment for patients with diabetic nephropathy: A meta-analysis.
Cong, X; Hu, H; Jin, X; Liang, W; Wang, S; Zhao, X, 2022
)
1.03

Pharmacokinetics

A population pharmacokinetic model incorporating protein binding and the reversible relationship between eplerenone and SC-70303 was developed. A validated high-performance liquid chromatography-mass spectrometry (HPLC-MS) method was established.

ExcerptReferenceRelevance
" The method has been successfully applied in the pharmacokinetic study of the EP tablets."( Establishment of HPLC-ESI-MS method for the determination of eplerenone in human plasma and its pharmacokinetics.
Ding, L; Gong, B; Leng, Y; Qian, WJ; Wen, AD; Yang, L; Yun, CH, 2009
)
0.59
" A population pharmacokinetic model incorporating protein binding and the reversible relationship between eplerenone and SC-70303 was developed."( A population approach to eplerenone pharmacokinetics and saturable protein binding.
Chiba, K; Mori, Y; Ogata, H; Takahashi, H, 2010
)
0.88
" The method was successfully applied to the pharmacokinetic study after an intravenous administration of isoforskolin in beagle dogs."( A sensitive and specific HPLC-MS/MS analysis and preliminary pharmacokinetic characterization of isoforskolin in beagle dogs.
Chen, J; Huang, J; Ling, Y; Tian, L; Wang, Y; Yin, J, 2011
)
0.37
" The pharmacokinetic study of multiple-dose of eplerenone was also conducted."( Dose Proportionality and Pharmacokinetics of Eplerenone in Healthy Chinese Subjects.
Chen, J; Jiang, B; Lou, H; Ruan, Z; Shao, R; Xu, Y, 2016
)
0.95
" A validated high-performance liquid chromatography-mass spectrometry (HPLC-MS) method was established to determine the eplerenone in plasma, and the portal vein absorption model was applied to conduct the pharmacokinetic study."( Pharmacokinetic study of eplerenone in rats after long-term coadministration with buckwheat tea.
Chen, HJ; Jia, K; Li, R; Lin, JZ; Peng, LX; Wang, P; Zhao, G; Zou, L, 2016
)
0.95
"To characterize eplerenone pharmacokinetics (PK) in Japanese chronic heart failure (CHF) patients and to estimate the impact of factors that may affect eplerenone PK, population pharmacokinetic (PPK) analysis was conducted."( Population Pharmacokinetics of Eplerenone in Japanese Patients With Chronic Heart Failure.
Oishi, M; Sweeney, K; Tomono, Y; Zhao, Q, 2017
)
1.09

Compound-Compound Interactions

Short-term use of MRAs, either spironolactone or eplerenone, in combination with ACEI/ARBs, was not associated with lower risk of cardiovascular or kidney outcomes.

ExcerptReferenceRelevance
" Due to suspicion of a potential drug-drug interaction, both eplerenone and ARVs were interrupted."( Severe hyperkalaemia due to a potential drug-drug interaction between eplerenone and antiretrovirals in a HIV-positive patient after a myocardial infarction.
Bono, L; Cordova, E; Garibaldi, F; Rodriguez, C, 2021
)
1.1
"Mineralocorticoid receptor antagonist (MRA) when combined with either angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) may provide additional benefits of cardiovascular and kidney disease risk reduction in patients with diabetic kidney disease (DKD) and hypertension."( Cardiovascular and kidney outcomes of spironolactone or eplerenone in combination with ACEI/ARBs in patients with diabetic kidney disease.
An, J; Niu, F; Sim, JJ, 2021
)
0.87
"Among patients with DKD and hypertension, the short-term use of MRAs, either spironolactone or eplerenone, in combination with ACEI/ARBs, was not associated with lower risk of cardiovascular or kidney outcomes compared with ACEI/ARB monotherapy."( Cardiovascular and kidney outcomes of spironolactone or eplerenone in combination with ACEI/ARBs in patients with diabetic kidney disease.
An, J; Niu, F; Sim, JJ, 2021
)
1.09

Bioavailability

Eplerenone improves endothelial function by reducing superoxide formation and increasing NO bioavailability in diabetic rats. Increased nitric oxide bioavailability can only partially explain the reduced platelet activation by epleren one and ACE inhibition. Eplerenones is highly metabolized to inactive metabolites and excreted principally in the bile.

ExcerptReferenceRelevance
" Pharmacokinetic studies reveal that eplerenone has good bioavailability with low protein binding, good plasma exposure, and is highly metabolized to inactive metabolites and excreted principally in the bile."( Eplerenone: a selective aldosterone receptor antagonist (SARA).
Cook, CS; Delyani, JA; Levin, S; Rocha, R; Roniker, B; Sing, YL; Tobert, DS; Whelihan, B; Workman, DL, 2001
)
2.03
" Increased nitric oxide bioavailability can only partially explain the reduced platelet activation by eplerenone and ACE inhibition."( Inhibition of platelet activation in congestive heart failure by aldosterone receptor antagonism and ACE inhibition.
Bauersachs, J; Christ, M; Eigenthaler, M; Fraccarollo, D; Hildemann, S; Kobsar, A; Schäfer, A; Walter, U, 2003
)
0.53
" We investigated the effect of a combination of eplerenone, a selective aldosterone antagonist, and enalapril, an angiotensin-converting enzyme inhibitor, on NO bioavailability and spontaneous atherosclerotic changes."( Addition of eplerenone to an angiotensin-converting enzyme inhibitor effectively improves nitric oxide bioavailability.
Akasaka, T; Goto, M; Ikejima, H; Imanishi, T; Kobayashi, K; Kuroi, A; Mochizuki, S; Muragaki, Y; Tsujioka, H; Yoshida, K, 2008
)
0.98
" Eplerenone also increases nitric oxide bioavailability and improves impaired endothelial function by decreasing oxidative stress."( Effects of eplerenone, a selective mineralocorticoid receptor antagonist, on clinical and experimental salt-sensitive hypertension.
Takeda, Y, 2009
)
1.65
" Eplerenone improves endothelial function by reducing superoxide formation and increasing NO bioavailability in diabetic rats."( Eplerenone improves vascular function and reduces platelet activation in diabetic rats.
Bauersachs, J; Ertl, G; Flierl, U; Fraccarollo, D; Hildemann, SK; Schafer, A; Vogt, C; Widder, J, 2010
)
2.71
" Therefore, the mechanism of aldosterone prothrombotic action is multiple and involves primary haemostasis activation, procoagulative and antifibrinolytic action, NO bioavailability impairment and oxidative stress augmentation."( [Prothrombotic aldosterone action--a new side of the hormone].
Chabielska, E; Gromotowicz, A; Mantur, M; Osmólska, U; Szemraj, J; Szoka, P; Zakrzeska, A, 2010
)
0.36
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

The pharmacokinetics of eplerenone (EP) were examined in rats following single or repeated dosing with (14)C-labelled or unlabelled EP to characterize absorption, metabolism and excretion. Oral dosing of 3S,3aR-27d (PF-3882845) in the Dahl salt sensitive preclinical model of salt-induced hypertension and nephropathy showed blood pressure attenuation.

ExcerptRelevanceReference
", oral, and rectal dosing (15 mg/kg) and following intragastric, intraduodenal, intrajejunal, and intracolonic dosing (7."( Absorption and disposition of a selective aldosterone receptor antagonist, eplerenone, in the dog.
Cook, CS; Fischer, JS; Zhang, L, 2000
)
0.54
" For all measurements, the antihypertensive effect of eplerenone increased in a dose-response fashion."( Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension.
Krause, SL; Roniker, B; Weinberger, MH; Weiss, RJ, 2002
)
2.01
" The pharmacokinetics of eplerenone (EP) were examined in rats following single or repeated dosing with (14)C-labelled or unlabelled EP to characterize absorption, metabolism and excretion."( Single- and repeated-dose pharmacokinetics of eplerenone, a selective aldosterone receptor blocker, in rats.
Ames, GB; Cook, CS; Fischer, J; Levin, S; Zhang, J; Zhang, L, 2003
)
0.88
"The influence of renal impairment on the pharmacokinetics of eplerenone following single and multiple dosing was evaluated."( Pharmacokinetics of eplerenone after single and multiple dosing in subjects with and without renal impairment.
Ravis, WR; Reid, S; Sica, DA; Tolbert, DS, 2005
)
0.89
"5 mEq/l on appropriately dosed diuretics."( Predictors of hyperkalemia risk following hypertension control with aldosterone blockade.
Bakris, GL; Kalaitzidis, R; Khosla, N, 2009
)
0.35
"Aldosterone antagonism is effective and safe for achieving a BP goal among people with diabetic nephropathy when added to a triple antihypertensive regimen that includes a blocker of the renin-angiotensin system and an appropriately selected and dosed diuretic."( Predictors of hyperkalemia risk following hypertension control with aldosterone blockade.
Bakris, GL; Kalaitzidis, R; Khosla, N, 2009
)
0.35
"8 mm Hg; no dose-response relationship was demonstrated."( The efficacy and safety of the novel aldosterone antagonist eplerenone in children with hypertension: a randomized, double-blind, dose-response study.
Davis, I; Flynn, JT; Li, JS; Ogawa, M; Portman, R; Pressler, ML; Shi, H, 2010
)
0.6
" Oral dosing of 3S,3aR-27d (PF-3882845) in the Dahl salt sensitive preclinical model of salt-induced hypertension and nephropathy showed blood pressure attenuation significantly greater than that with eplerenone, reduction in urinary albumin, and renal protection."( Discovery of (3S,3aR)-2-(3-chloro-4-cyanophenyl)-3-cyclopentyl-3,3a,4,5-tetrahydro-2H-benzo[g]indazole-7-carboxylic acid (PF-3882845), an orally efficacious mineralocorticoid receptor (MR) antagonist for hypertension and nephropathy.
Arhancet, GB; Blinn, JR; Chen, X; Collins, JT; Dietz, JD; Garland, DJ; Heron, MI; Hockerman, SL; Homer, BL; Hu, X; Huang, HC; Long, SA; Mahoney, MW; McGee, KF; Meyers, MJ; Payne, MA; Reitz, DB; Rico, JR; Wendling, JM; Yang, S, 2010
)
0.55
" The effect of MR antagonism on urinary Na+/K+ was not sustained chronically; thus we studied the effect of the compounds on plasma aldosterone following chronic dosing in SHR."( The use of plasma aldosterone and urinary sodium to potassium ratio as translatable quantitative biomarkers of mineralocorticoid receptor antagonism.
Banker, ME; Boustany-Kari, CM; Eudy, RJ; King-Ahmad, A; Loria, P; Near, K; Piotrowski, DW; Sahasrabudhe, V; Sweeney, K; Tugnait, M, 2011
)
0.37
" The dose-response relationship for natriuresis with spironolactone has not been explored completely as to its combination therapy responses."( Aldosterone and volume management in hypertensive heart disease.
Sica, DA, 2014
)
0.4
"In a dosage of 50 mg bid, eplerenone does not augment extracellular adenosine formation in healthy human subjects."( The effect of eplerenone on adenosine formation in humans in vivo: a double-blinded randomised controlled study.
Bilos, A; Deinum, J; Donders, AR; Riksen, NP; Rongen, GA; van den Berg, TN, 2014
)
1.06
" The main difficulty in choosing the proper therapeutic regimen consists in the lack of suitable dosing guidelines with adapted therapeutic targets for the older multimorbid population, usually not represented in the large controlled trials forming the basis of general recommendations."( [Cardiovascular drugs in aged and multimorbid patients].
Follath, F, 2015
)
0.42
" Treatment with eplerenone should be initiated at a dosage of 25mg once daily and titrated to a target dosage of 50mg once daily preferably within 4 weeks."( Safety profile of mineralocorticoid receptor antagonists: Spironolactone and eplerenone.
Gaudio, C; Greco, C; Lainscak, M; Pelliccia, F; Rosano, G; Schiariti, M; Speziale, G; Vitale, C, 2015
)
0.99
" According to the results, the dosage of eplerenone should be adjusted in hypertension treatment trials when administered with Tartary buckwheat or Tartary buckwheat-containing dietary supplements to avoid potential drug interactions."( Pharmacokinetic study of eplerenone in rats after long-term coadministration with buckwheat tea.
Chen, HJ; Jia, K; Li, R; Lin, JZ; Peng, LX; Wang, P; Zhao, G; Zou, L, 2016
)
1
" The patients were dosed with eplerenone according to the scheme: first 25 mg/day for a week, then 50 mg/day for 3 months."( The use of mineralocorticoid receptor antagonists in chronic central serous chorioretinopathy.
Filemonowicz-Skoczek, A; Karska-Basta, I; Kubicka-Trzaska, A; Ozog-Baran, J; Pociej-Marciak, W; Romanowska-Dixon, B, 2016
)
0.72
" Treatment was more frequently withdrawn, and daily drug dosage was lower among patients treated with spironolactone."( Initiation of eplerenone or spironolactone, treatment adherence, and associated outcomes in patients with new-onset heart failure with reduced ejection fraction: a nationwide cohort study.
Denholt, CS; Fosbøl, E; Gustafsson, F; Kristensen, SL; Køber, L; Larsson, JE; Nielsen, OW; Raja, AA; Schou, M; Thune, JJ, 2023
)
1.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
aldosterone antagonistnull
antihypertensive agentAny drug used in the treatment of acute or chronic vascular hypertension regardless of pharmacological mechanism.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (7)

ClassDescription
steroid acid ester
methyl esterAny carboxylic ester resulting from the formal condensation of a carboxy group with methanol.
oxaspiro compoundA spiro compound in which at least one of the cyclic components is an oxygen heterocyle.
gamma-lactoneA lactone having a five-membered lactone ring.
organic heteropentacyclic compound
3-oxo-Delta(4) steroidA 3-oxo steroid conjugated to a C=C double bond at the alpha,beta position.
epoxy steroidAny steroid whose structure includes an epoxy group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Eplerenone Action Pathway319

Protein Targets (22)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
GALC proteinHomo sapiens (human)Potency0.707928.183828.183828.1838AID1159614
AR proteinHomo sapiens (human)Potency12.32940.000221.22318,912.5098AID1259243; AID1259247; AID743035; AID743042; AID743063
progesterone receptorHomo sapiens (human)Potency13.33320.000417.946075.1148AID1346795
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency9.61750.000214.376460.0339AID720691; AID720692
estrogen nuclear receptor alphaHomo sapiens (human)Potency0.06010.000229.305416,493.5996AID743075
cytochrome P450 2D6Homo sapiens (human)Potency38.90180.00108.379861.1304AID1645840
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency0.66820.001723.839378.1014AID743083
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)133.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)133.00000.20005.677410.0000AID1473741
Bile salt export pumpHomo sapiens (human)IC50 (µMol)133.00000.11007.190310.0000AID1473738
Estrogen receptorHomo sapiens (human)IC50 (µMol)15.00000.00000.723732.7000AID499928; AID761378
Glucocorticoid receptorHomo sapiens (human)IC50 (µMol)22.68500.00000.495310.0000AID1880431; AID499933; AID635463; AID761383
Glucocorticoid receptorHomo sapiens (human)Ki3.16230.00010.38637.0010AID1623468
Progesterone receptorHomo sapiens (human)IC50 (µMol)12.00000.00000.580710.0000AID1162566; AID1162567; AID499927; AID635465; AID761374
Progesterone receptorHomo sapiens (human)Ki19.95260.00030.03160.3997AID1623469
Mineralocorticoid receptor Homo sapiens (human)IC50 (µMol)0.66800.00030.748410.0000AID1130076; AID1140664; AID1162564; AID1162568; AID1623470; AID1623475; AID1623479; AID1711869; AID1880426; AID1880440; AID478704; AID499835; AID499924; AID635462; AID635470; AID761384
Mineralocorticoid receptor Homo sapiens (human)Ki0.12590.00030.17380.8510AID1623467
Androgen receptorHomo sapiens (human)IC50 (µMol)13.40000.00000.875310.0000AID1162565; AID1880429; AID499926; AID635464; AID761381
Voltage-dependent L-type calcium channel subunit alpha-1CRattus norvegicus (Norway rat)IC50 (µMol)5.00000.00132.24956.9000AID478705
Mineralocorticoid receptorRattus norvegicus (Norway rat)IC50 (µMol)0.03980.03980.86522.1000AID1623477
Mineralocorticoid receptorRattus norvegicus (Norway rat)Ki0.04440.04440.04440.0444AID1880425
Voltage-dependent L-type calcium channel subunit alpha-1DRattus norvegicus (Norway rat)IC50 (µMol)5.00000.00131.991510.0000AID478705
Sodium-dependent serotonin transporterRattus norvegicus (Norway rat)IC50 (µMol)8.94000.00030.81978.4900AID499933
Voltage-dependent L-type calcium channel subunit alpha-1SRattus norvegicus (Norway rat)IC50 (µMol)5.00000.00131.60206.9000AID478705
Estrogen receptor betaHomo sapiens (human)IC50 (µMol)60.00000.00010.529432.7000AID1880423; AID761375
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)133.00002.41006.343310.0000AID1473739
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Estrogen receptorHomo sapiens (human)EC50 (µMol)20.00000.00000.53054.4000AID761379
Glucocorticoid receptorHomo sapiens (human)EC50 (µMol)20.00000.00040.05401.0000AID761382
Progesterone receptorHomo sapiens (human)EC50 (µMol)20.00000.00010.40478.2000AID761376
Mineralocorticoid receptor Homo sapiens (human)EC50 (µMol)0.10000.00000.01260.1000AID1623464
Androgen receptorHomo sapiens (human)EC50 (µMol)20.00000.00000.20794.3000AID761380
Estrogen receptor betaHomo sapiens (human)EC50 (µMol)20.00000.00000.47954.8900AID761377
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (161)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIEstrogen receptorHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIEstrogen receptorHomo sapiens (human)
antral ovarian follicle growthEstrogen receptorHomo sapiens (human)
epithelial cell developmentEstrogen receptorHomo sapiens (human)
chromatin remodelingEstrogen receptorHomo sapiens (human)
regulation of DNA-templated transcriptionEstrogen receptorHomo sapiens (human)
signal transductionEstrogen receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayEstrogen receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationEstrogen receptorHomo sapiens (human)
androgen metabolic processEstrogen receptorHomo sapiens (human)
male gonad developmentEstrogen receptorHomo sapiens (human)
negative regulation of gene expressionEstrogen receptorHomo sapiens (human)
positive regulation of phospholipase C activityEstrogen receptorHomo sapiens (human)
intracellular steroid hormone receptor signaling pathwayEstrogen receptorHomo sapiens (human)
intracellular estrogen receptor signaling pathwayEstrogen receptorHomo sapiens (human)
response to estradiolEstrogen receptorHomo sapiens (human)
regulation of toll-like receptor signaling pathwayEstrogen receptorHomo sapiens (human)
negative regulation of smooth muscle cell apoptotic processEstrogen receptorHomo sapiens (human)
negative regulation of canonical NF-kappaB signal transductionEstrogen receptorHomo sapiens (human)
negative regulation of DNA-binding transcription factor activityEstrogen receptorHomo sapiens (human)
response to estrogenEstrogen receptorHomo sapiens (human)
positive regulation of DNA-templated transcriptionEstrogen receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIEstrogen receptorHomo sapiens (human)
fibroblast proliferationEstrogen receptorHomo sapiens (human)
positive regulation of fibroblast proliferationEstrogen receptorHomo sapiens (human)
stem cell differentiationEstrogen receptorHomo sapiens (human)
regulation of inflammatory responseEstrogen receptorHomo sapiens (human)
positive regulation of DNA-binding transcription factor activityEstrogen receptorHomo sapiens (human)
RNA polymerase II preinitiation complex assemblyEstrogen receptorHomo sapiens (human)
uterus developmentEstrogen receptorHomo sapiens (human)
vagina developmentEstrogen receptorHomo sapiens (human)
prostate epithelial cord elongationEstrogen receptorHomo sapiens (human)
prostate epithelial cord arborization involved in prostate glandular acinus morphogenesisEstrogen receptorHomo sapiens (human)
regulation of branching involved in prostate gland morphogenesisEstrogen receptorHomo sapiens (human)
mammary gland branching involved in pregnancyEstrogen receptorHomo sapiens (human)
mammary gland alveolus developmentEstrogen receptorHomo sapiens (human)
epithelial cell proliferation involved in mammary gland duct elongationEstrogen receptorHomo sapiens (human)
protein localization to chromatinEstrogen receptorHomo sapiens (human)
cellular response to estradiol stimulusEstrogen receptorHomo sapiens (human)
negative regulation of miRNA transcriptionEstrogen receptorHomo sapiens (human)
regulation of epithelial cell apoptotic processEstrogen receptorHomo sapiens (human)
regulation of transcription by RNA polymerase IIEstrogen receptorHomo sapiens (human)
cellular response to estrogen stimulusEstrogen receptorHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIGlucocorticoid receptorHomo sapiens (human)
regulation of gluconeogenesisGlucocorticoid receptorHomo sapiens (human)
chromatin organizationGlucocorticoid receptorHomo sapiens (human)
regulation of DNA-templated transcriptionGlucocorticoid receptorHomo sapiens (human)
apoptotic processGlucocorticoid receptorHomo sapiens (human)
chromosome segregationGlucocorticoid receptorHomo sapiens (human)
signal transductionGlucocorticoid receptorHomo sapiens (human)
glucocorticoid metabolic processGlucocorticoid receptorHomo sapiens (human)
gene expressionGlucocorticoid receptorHomo sapiens (human)
microglia differentiationGlucocorticoid receptorHomo sapiens (human)
adrenal gland developmentGlucocorticoid receptorHomo sapiens (human)
regulation of glucocorticoid biosynthetic processGlucocorticoid receptorHomo sapiens (human)
synaptic transmission, glutamatergicGlucocorticoid receptorHomo sapiens (human)
maternal behaviorGlucocorticoid receptorHomo sapiens (human)
intracellular glucocorticoid receptor signaling pathwayGlucocorticoid receptorHomo sapiens (human)
glucocorticoid mediated signaling pathwayGlucocorticoid receptorHomo sapiens (human)
positive regulation of neuron apoptotic processGlucocorticoid receptorHomo sapiens (human)
negative regulation of DNA-templated transcriptionGlucocorticoid receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIGlucocorticoid receptorHomo sapiens (human)
astrocyte differentiationGlucocorticoid receptorHomo sapiens (human)
cell divisionGlucocorticoid receptorHomo sapiens (human)
mammary gland duct morphogenesisGlucocorticoid receptorHomo sapiens (human)
motor behaviorGlucocorticoid receptorHomo sapiens (human)
cellular response to steroid hormone stimulusGlucocorticoid receptorHomo sapiens (human)
cellular response to glucocorticoid stimulusGlucocorticoid receptorHomo sapiens (human)
cellular response to dexamethasone stimulusGlucocorticoid receptorHomo sapiens (human)
cellular response to transforming growth factor beta stimulusGlucocorticoid receptorHomo sapiens (human)
neuroinflammatory responseGlucocorticoid receptorHomo sapiens (human)
positive regulation of miRNA transcriptionGlucocorticoid receptorHomo sapiens (human)
intracellular steroid hormone receptor signaling pathwayGlucocorticoid receptorHomo sapiens (human)
regulation of transcription by RNA polymerase IIGlucocorticoid receptorHomo sapiens (human)
ovulation from ovarian follicleProgesterone receptorHomo sapiens (human)
glandular epithelial cell maturationProgesterone receptorHomo sapiens (human)
regulation of DNA-templated transcriptionProgesterone receptorHomo sapiens (human)
signal transductionProgesterone receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayProgesterone receptorHomo sapiens (human)
cell-cell signalingProgesterone receptorHomo sapiens (human)
positive regulation of gene expressionProgesterone receptorHomo sapiens (human)
negative regulation of gene expressionProgesterone receptorHomo sapiens (human)
paracrine signalingProgesterone receptorHomo sapiens (human)
negative regulation of phosphorylationProgesterone receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIProgesterone receptorHomo sapiens (human)
lung alveolus developmentProgesterone receptorHomo sapiens (human)
regulation of epithelial cell proliferationProgesterone receptorHomo sapiens (human)
progesterone receptor signaling pathwayProgesterone receptorHomo sapiens (human)
maintenance of protein location in nucleusProgesterone receptorHomo sapiens (human)
tertiary branching involved in mammary gland duct morphogenesisProgesterone receptorHomo sapiens (human)
regulation of transcription by RNA polymerase IIProgesterone receptorHomo sapiens (human)
intracellular steroid hormone receptor signaling pathwayProgesterone receptorHomo sapiens (human)
signal transductionMineralocorticoid receptor Homo sapiens (human)
positive regulation of non-canonical NF-kappaB signal transductionMineralocorticoid receptor Homo sapiens (human)
regulation of transcription by RNA polymerase IIMineralocorticoid receptor Homo sapiens (human)
intracellular steroid hormone receptor signaling pathwayMineralocorticoid receptor Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIAndrogen receptorHomo sapiens (human)
MAPK cascadeAndrogen receptorHomo sapiens (human)
in utero embryonic developmentAndrogen receptorHomo sapiens (human)
regulation of systemic arterial blood pressureAndrogen receptorHomo sapiens (human)
epithelial cell morphogenesisAndrogen receptorHomo sapiens (human)
transcription by RNA polymerase IIAndrogen receptorHomo sapiens (human)
signal transductionAndrogen receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAndrogen receptorHomo sapiens (human)
cell-cell signalingAndrogen receptorHomo sapiens (human)
spermatogenesisAndrogen receptorHomo sapiens (human)
single fertilizationAndrogen receptorHomo sapiens (human)
positive regulation of cell population proliferationAndrogen receptorHomo sapiens (human)
negative regulation of cell population proliferationAndrogen receptorHomo sapiens (human)
positive regulation of gene expressionAndrogen receptorHomo sapiens (human)
male somatic sex determinationAndrogen receptorHomo sapiens (human)
intracellular estrogen receptor signaling pathwayAndrogen receptorHomo sapiens (human)
androgen receptor signaling pathwayAndrogen receptorHomo sapiens (human)
intracellular receptor signaling pathwayAndrogen receptorHomo sapiens (human)
positive regulation of intracellular estrogen receptor signaling pathwayAndrogen receptorHomo sapiens (human)
Leydig cell differentiationAndrogen receptorHomo sapiens (human)
multicellular organism growthAndrogen receptorHomo sapiens (human)
positive regulation of phosphorylationAndrogen receptorHomo sapiens (human)
positive regulation of MAPK cascadeAndrogen receptorHomo sapiens (human)
positive regulation of insulin-like growth factor receptor signaling pathwayAndrogen receptorHomo sapiens (human)
positive regulation of cell differentiationAndrogen receptorHomo sapiens (human)
negative regulation of integrin biosynthetic processAndrogen receptorHomo sapiens (human)
positive regulation of integrin biosynthetic processAndrogen receptorHomo sapiens (human)
positive regulation of DNA-templated transcriptionAndrogen receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIAndrogen receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIIAndrogen receptorHomo sapiens (human)
insulin-like growth factor receptor signaling pathwayAndrogen receptorHomo sapiens (human)
regulation of developmental growthAndrogen receptorHomo sapiens (human)
animal organ formationAndrogen receptorHomo sapiens (human)
male genitalia morphogenesisAndrogen receptorHomo sapiens (human)
epithelial cell proliferationAndrogen receptorHomo sapiens (human)
negative regulation of epithelial cell proliferationAndrogen receptorHomo sapiens (human)
positive regulation of NF-kappaB transcription factor activityAndrogen receptorHomo sapiens (human)
activation of prostate induction by androgen receptor signaling pathwayAndrogen receptorHomo sapiens (human)
morphogenesis of an epithelial foldAndrogen receptorHomo sapiens (human)
lateral sprouting involved in mammary gland duct morphogenesisAndrogen receptorHomo sapiens (human)
prostate gland growthAndrogen receptorHomo sapiens (human)
prostate gland epithelium morphogenesisAndrogen receptorHomo sapiens (human)
epithelial cell differentiation involved in prostate gland developmentAndrogen receptorHomo sapiens (human)
tertiary branching involved in mammary gland duct morphogenesisAndrogen receptorHomo sapiens (human)
mammary gland alveolus developmentAndrogen receptorHomo sapiens (human)
positive regulation of epithelial cell proliferation involved in prostate gland developmentAndrogen receptorHomo sapiens (human)
cellular response to steroid hormone stimulusAndrogen receptorHomo sapiens (human)
cellular response to estrogen stimulusAndrogen receptorHomo sapiens (human)
cellular response to testosterone stimulusAndrogen receptorHomo sapiens (human)
seminiferous tubule developmentAndrogen receptorHomo sapiens (human)
non-membrane-bounded organelle assemblyAndrogen receptorHomo sapiens (human)
positive regulation of miRNA transcriptionAndrogen receptorHomo sapiens (human)
regulation of protein localization to plasma membraneAndrogen receptorHomo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathwayAndrogen receptorHomo sapiens (human)
male gonad developmentAndrogen receptorHomo sapiens (human)
intracellular steroid hormone receptor signaling pathwayAndrogen receptorHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIEstrogen receptor betaHomo sapiens (human)
regulation of DNA-templated transcriptionEstrogen receptor betaHomo sapiens (human)
signal transductionEstrogen receptor betaHomo sapiens (human)
cell-cell signalingEstrogen receptor betaHomo sapiens (human)
negative regulation of cell growthEstrogen receptor betaHomo sapiens (human)
intracellular estrogen receptor signaling pathwayEstrogen receptor betaHomo sapiens (human)
positive regulation of DNA-templated transcriptionEstrogen receptor betaHomo sapiens (human)
positive regulation of DNA-binding transcription factor activityEstrogen receptor betaHomo sapiens (human)
cellular response to estradiol stimulusEstrogen receptor betaHomo sapiens (human)
regulation of transcription by RNA polymerase IIEstrogen receptor betaHomo sapiens (human)
cellular response to estrogen stimulusEstrogen receptor betaHomo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (68)

Processvia Protein(s)Taxonomy
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingEstrogen receptorHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificEstrogen receptorHomo sapiens (human)
TFIIB-class transcription factor bindingEstrogen receptorHomo sapiens (human)
transcription coregulator bindingEstrogen receptorHomo sapiens (human)
transcription corepressor bindingEstrogen receptorHomo sapiens (human)
transcription coactivator bindingEstrogen receptorHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificEstrogen receptorHomo sapiens (human)
chromatin bindingEstrogen receptorHomo sapiens (human)
DNA-binding transcription factor activityEstrogen receptorHomo sapiens (human)
nuclear receptor activityEstrogen receptorHomo sapiens (human)
steroid bindingEstrogen receptorHomo sapiens (human)
protein bindingEstrogen receptorHomo sapiens (human)
calmodulin bindingEstrogen receptorHomo sapiens (human)
beta-catenin bindingEstrogen receptorHomo sapiens (human)
zinc ion bindingEstrogen receptorHomo sapiens (human)
TBP-class protein bindingEstrogen receptorHomo sapiens (human)
enzyme bindingEstrogen receptorHomo sapiens (human)
protein kinase bindingEstrogen receptorHomo sapiens (human)
nitric-oxide synthase regulator activityEstrogen receptorHomo sapiens (human)
nuclear estrogen receptor activityEstrogen receptorHomo sapiens (human)
nuclear estrogen receptor bindingEstrogen receptorHomo sapiens (human)
estrogen response element bindingEstrogen receptorHomo sapiens (human)
identical protein bindingEstrogen receptorHomo sapiens (human)
ATPase bindingEstrogen receptorHomo sapiens (human)
14-3-3 protein bindingEstrogen receptorHomo sapiens (human)
sequence-specific double-stranded DNA bindingEstrogen receptorHomo sapiens (human)
RNA polymerase II transcription regulatory region sequence-specific DNA bindingGlucocorticoid receptorHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingGlucocorticoid receptorHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificGlucocorticoid receptorHomo sapiens (human)
core promoter sequence-specific DNA bindingGlucocorticoid receptorHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificGlucocorticoid receptorHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificGlucocorticoid receptorHomo sapiens (human)
DNA-binding transcription factor activityGlucocorticoid receptorHomo sapiens (human)
RNA bindingGlucocorticoid receptorHomo sapiens (human)
nuclear receptor activityGlucocorticoid receptorHomo sapiens (human)
nuclear glucocorticoid receptor activityGlucocorticoid receptorHomo sapiens (human)
steroid bindingGlucocorticoid receptorHomo sapiens (human)
protein bindingGlucocorticoid receptorHomo sapiens (human)
zinc ion bindingGlucocorticoid receptorHomo sapiens (human)
TBP-class protein bindingGlucocorticoid receptorHomo sapiens (human)
protein kinase bindingGlucocorticoid receptorHomo sapiens (human)
identical protein bindingGlucocorticoid receptorHomo sapiens (human)
Hsp90 protein bindingGlucocorticoid receptorHomo sapiens (human)
steroid hormone bindingGlucocorticoid receptorHomo sapiens (human)
sequence-specific double-stranded DNA bindingGlucocorticoid receptorHomo sapiens (human)
estrogen response element bindingGlucocorticoid receptorHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingProgesterone receptorHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificProgesterone receptorHomo sapiens (human)
transcription coactivator bindingProgesterone receptorHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificProgesterone receptorHomo sapiens (human)
DNA bindingProgesterone receptorHomo sapiens (human)
nuclear steroid receptor activityProgesterone receptorHomo sapiens (human)
G protein-coupled receptor activityProgesterone receptorHomo sapiens (human)
steroid bindingProgesterone receptorHomo sapiens (human)
protein bindingProgesterone receptorHomo sapiens (human)
zinc ion bindingProgesterone receptorHomo sapiens (human)
enzyme bindingProgesterone receptorHomo sapiens (human)
identical protein bindingProgesterone receptorHomo sapiens (human)
ATPase bindingProgesterone receptorHomo sapiens (human)
estrogen response element bindingProgesterone receptorHomo sapiens (human)
nuclear receptor activityProgesterone receptorHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificMineralocorticoid receptor Homo sapiens (human)
DNA-binding transcription factor activityMineralocorticoid receptor Homo sapiens (human)
nuclear steroid receptor activityMineralocorticoid receptor Homo sapiens (human)
steroid bindingMineralocorticoid receptor Homo sapiens (human)
protein bindingMineralocorticoid receptor Homo sapiens (human)
zinc ion bindingMineralocorticoid receptor Homo sapiens (human)
TBP-class protein bindingMineralocorticoid receptor Homo sapiens (human)
sequence-specific double-stranded DNA bindingMineralocorticoid receptor Homo sapiens (human)
nuclear receptor activityMineralocorticoid receptor Homo sapiens (human)
estrogen response element bindingMineralocorticoid receptor Homo sapiens (human)
transcription cis-regulatory region bindingAndrogen receptorHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingAndrogen receptorHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificAndrogen receptorHomo sapiens (human)
RNA polymerase II general transcription initiation factor bindingAndrogen receptorHomo sapiens (human)
transcription coactivator bindingAndrogen receptorHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificAndrogen receptorHomo sapiens (human)
chromatin bindingAndrogen receptorHomo sapiens (human)
DNA-binding transcription factor activityAndrogen receptorHomo sapiens (human)
nuclear receptor activityAndrogen receptorHomo sapiens (human)
G protein-coupled receptor activityAndrogen receptorHomo sapiens (human)
signaling receptor bindingAndrogen receptorHomo sapiens (human)
steroid bindingAndrogen receptorHomo sapiens (human)
androgen bindingAndrogen receptorHomo sapiens (human)
protein bindingAndrogen receptorHomo sapiens (human)
beta-catenin bindingAndrogen receptorHomo sapiens (human)
zinc ion bindingAndrogen receptorHomo sapiens (human)
enzyme bindingAndrogen receptorHomo sapiens (human)
ATPase bindingAndrogen receptorHomo sapiens (human)
molecular adaptor activityAndrogen receptorHomo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingAndrogen receptorHomo sapiens (human)
POU domain bindingAndrogen receptorHomo sapiens (human)
molecular condensate scaffold activityAndrogen receptorHomo sapiens (human)
estrogen response element bindingAndrogen receptorHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingEstrogen receptor betaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificEstrogen receptor betaHomo sapiens (human)
DNA bindingEstrogen receptor betaHomo sapiens (human)
nuclear steroid receptor activityEstrogen receptor betaHomo sapiens (human)
nuclear receptor activityEstrogen receptor betaHomo sapiens (human)
steroid bindingEstrogen receptor betaHomo sapiens (human)
protein bindingEstrogen receptor betaHomo sapiens (human)
zinc ion bindingEstrogen receptor betaHomo sapiens (human)
enzyme bindingEstrogen receptor betaHomo sapiens (human)
nuclear estrogen receptor activityEstrogen receptor betaHomo sapiens (human)
estrogen response element bindingEstrogen receptor betaHomo sapiens (human)
receptor antagonist activityEstrogen receptor betaHomo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (35)

Processvia Protein(s)Taxonomy
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
nucleusEstrogen receptorHomo sapiens (human)
nucleoplasmEstrogen receptorHomo sapiens (human)
transcription regulator complexEstrogen receptorHomo sapiens (human)
cytoplasmEstrogen receptorHomo sapiens (human)
Golgi apparatusEstrogen receptorHomo sapiens (human)
cytosolEstrogen receptorHomo sapiens (human)
plasma membraneEstrogen receptorHomo sapiens (human)
membraneEstrogen receptorHomo sapiens (human)
chromatinEstrogen receptorHomo sapiens (human)
euchromatinEstrogen receptorHomo sapiens (human)
protein-containing complexEstrogen receptorHomo sapiens (human)
nucleusEstrogen receptorHomo sapiens (human)
nucleusGlucocorticoid receptorHomo sapiens (human)
nucleusGlucocorticoid receptorHomo sapiens (human)
nucleoplasmGlucocorticoid receptorHomo sapiens (human)
cytoplasmGlucocorticoid receptorHomo sapiens (human)
mitochondrial matrixGlucocorticoid receptorHomo sapiens (human)
centrosomeGlucocorticoid receptorHomo sapiens (human)
spindleGlucocorticoid receptorHomo sapiens (human)
cytosolGlucocorticoid receptorHomo sapiens (human)
membraneGlucocorticoid receptorHomo sapiens (human)
nuclear speckGlucocorticoid receptorHomo sapiens (human)
synapseGlucocorticoid receptorHomo sapiens (human)
chromatinGlucocorticoid receptorHomo sapiens (human)
protein-containing complexGlucocorticoid receptorHomo sapiens (human)
plasma membraneProgesterone receptorHomo sapiens (human)
nucleoplasmProgesterone receptorHomo sapiens (human)
mitochondrial outer membraneProgesterone receptorHomo sapiens (human)
cytosolProgesterone receptorHomo sapiens (human)
chromatinProgesterone receptorHomo sapiens (human)
nucleusProgesterone receptorHomo sapiens (human)
nucleoplasmMineralocorticoid receptor Homo sapiens (human)
endoplasmic reticulum membraneMineralocorticoid receptor Homo sapiens (human)
cytosolMineralocorticoid receptor Homo sapiens (human)
chromatinMineralocorticoid receptor Homo sapiens (human)
receptor complexMineralocorticoid receptor Homo sapiens (human)
nucleusMineralocorticoid receptor Homo sapiens (human)
plasma membraneAndrogen receptorHomo sapiens (human)
nucleusAndrogen receptorHomo sapiens (human)
nucleoplasmAndrogen receptorHomo sapiens (human)
cytoplasmAndrogen receptorHomo sapiens (human)
cytosolAndrogen receptorHomo sapiens (human)
nuclear speckAndrogen receptorHomo sapiens (human)
chromatinAndrogen receptorHomo sapiens (human)
protein-containing complexAndrogen receptorHomo sapiens (human)
nucleusAndrogen receptorHomo sapiens (human)
nucleusEstrogen receptor betaHomo sapiens (human)
nucleoplasmEstrogen receptor betaHomo sapiens (human)
mitochondrionEstrogen receptor betaHomo sapiens (human)
intracellular membrane-bounded organelleEstrogen receptor betaHomo sapiens (human)
chromatinEstrogen receptor betaHomo sapiens (human)
nucleusEstrogen receptor betaHomo sapiens (human)
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (169)

Assay IDTitleYearJournalArticle
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1623472Intrinsic clearance in human liver microsomes at 1 uM measured up to 30 mins in presence of NADPH by LC-MS/MS analysis
AID1130076Antagonist activity at mineralocorticoid receptor (unknown origin) by PathHunter assay2014Bioorganic & medicinal chemistry letters, Apr-01, Volume: 24, Issue:7
Mineralocorticoid receptor antagonists: identification of heterocyclic amide replacements in the oxazolidinedione series.
AID1162565Displacement of [3H]testosterone from androgen receptor (unknown origin) expressed in 293 cells after 16 hrs by scintillation counting2014Bioorganic & medicinal chemistry, Oct-01, Volume: 22, Issue:19
Discovery of 6-[5-(4-fluorophenyl)-3-methyl-pyrazol-4-yl]-benzoxazin-3-one derivatives as novel selective nonsteroidal mineralocorticoid receptor antagonists.
AID1880466Organ protective activity in aldosterone-induced uninephrectomized Sprague-Dawley rat model assessed as glomerular mesangial proliferation in kidney by measuring pathological lesion score at 100 mg/kg/day by PAS and H and E staining based histological ana2022Journal of medicinal chemistry, 06-23, Volume: 65, Issue:12
Discovery of Apararenone (MT-3995) as a Highly Selective, Potent, and Novel Nonsteroidal Mineralocorticoid Receptor Antagonist.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID499932Selectivity ratio of IC50 glucocorticoid receptor IC50 for mineralocorticoid receptor2010Journal of medicinal chemistry, Aug-26, Volume: 53, Issue:16
Discovery of (3S,3aR)-2-(3-chloro-4-cyanophenyl)-3-cyclopentyl-3,3a,4,5-tetrahydro-2H-benzo[g]indazole-7-carboxylic acid (PF-3882845), an orally efficacious mineralocorticoid receptor (MR) antagonist for hypertension and nephropathy.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1623476Antagonist activity at full length human mineralocorticoid receptor in expressed in human U2OS cells by luciferase reporter gene assay relative to control
AID761378Antagonist activity at estrogen receptor alpha (unknown origin) by NH Pro assay2013Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15
Discovery of novel oxazolidinedione derivatives as potent and selective mineralocorticoid receptor antagonists.
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1440418In vivo antagonist activity at MR in rat assessed as inhibition aldosterone-induced decrease in urinary sodium/potassium ratio at 30 mg/kg, po after 8 hrs2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
Modulating Mineralocorticoid Receptor with Non-steroidal Antagonists. New Opportunities for the Development of Potent and Selective Ligands without Off-Target Side Effects.
AID1623477Antagonist activity at gal4-fused rat mineralocorticoid receptor LBD in expressed in human U2OS cells by luciferase reporter gene assay
AID635470Antagonist activity at human MR transfected in human COS1 cells after 1 day by luciferase reporter gene assay2011Journal of medicinal chemistry, Dec-22, Volume: 54, Issue:24
Identification of benzoxazin-3-one derivatives as novel, potent, and selective nonsteroidal mineralocorticoid receptor antagonists.
AID1623482Induction of hyperkalemia in Sprague-Dawley rat fed on low salt diet for 72 hrs assessed as increase in Na+/K+ ratio in urine administered via oral gavage after 8 hrs
AID1880482Organ protective activity in aldosterone-induced uninephrectomized Sprague-Dawley rat model assessed as interstitial cellular infiltration in kidney by measuring pathological lesion score at 100 mg/kg/day by PAS and H and E staining based histological ana2022Journal of medicinal chemistry, 06-23, Volume: 65, Issue:12
Discovery of Apararenone (MT-3995) as a Highly Selective, Potent, and Novel Nonsteroidal Mineralocorticoid Receptor Antagonist.
AID1623504Organ protective activity in Sprague-Dawley rat assessed as reduction in UACR in urine at 30 mg/kg, po administered via gavage administered for 2 to 4 weeks measured at 24 hrs post dose by LC-MS/MS analysis
AID1880431Displacement of [3H]-dexamethasone from recombinant full length human glucocorticoid receptor expressed in baculovirus infected insect cells incubated overnight by liquid scintillation counting analysis2022Journal of medicinal chemistry, 06-23, Volume: 65, Issue:12
Discovery of Apararenone (MT-3995) as a Highly Selective, Potent, and Novel Nonsteroidal Mineralocorticoid Receptor Antagonist.
AID1880448Antihypertensive activity against aldosterone induced uninephrectomized Sprague-Dawley rat assessed as inhibition of area under the curve changes in systolic blood pressure at 50 mg/kg, po bid administered for 4 weeks (Rvb = 294.5 +/-48.5 mmHg.day)2022Journal of medicinal chemistry, 06-23, Volume: 65, Issue:12
Discovery of Apararenone (MT-3995) as a Highly Selective, Potent, and Novel Nonsteroidal Mineralocorticoid Receptor Antagonist.
AID1623489Clearance in Han Wistar rat at 1.2 mg/kg, iv by LC-MS/MS analysis
AID761380Agonist activity at androgen receptor (unknown origin) by NH Pro assay2013Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15
Discovery of novel oxazolidinedione derivatives as potent and selective mineralocorticoid receptor antagonists.
AID1162567Displacement of [3H]-Dexamethasone from glucocorticoid receptor (unknown origin) expressed in 293 cells after 16 hrs by scintillation counting2014Bioorganic & medicinal chemistry, Oct-01, Volume: 22, Issue:19
Discovery of 6-[5-(4-fluorophenyl)-3-methyl-pyrazol-4-yl]-benzoxazin-3-one derivatives as novel selective nonsteroidal mineralocorticoid receptor antagonists.
AID1140660Ratio of IC50 for mineralocorticoid receptor in human HuH7 cells to EC50 for Sprague-Dawley rat2014Journal of medicinal chemistry, May-22, Volume: 57, Issue:10
Identification of (R)-6-(1-(4-cyano-3-methylphenyl)-5-cyclopentyl-4,5-dihydro-1H-pyrazol-3-yl)-2-methoxynicotinic acid, a highly potent and selective nonsteroidal mineralocorticoid receptor antagonist.
AID1226698Agonist activity at human estrogen receptor beta by cell-based assay2015ACS medicinal chemistry letters, Apr-09, Volume: 6, Issue:4
Discovery of benzimidazole oxazolidinediones as novel and selective nonsteroidal mineralocorticoid receptor antagonists.
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID761383Antagonist activity at glucocorticoid receptor (unknown origin) by NH Pro assay2013Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15
Discovery of novel oxazolidinedione derivatives as potent and selective mineralocorticoid receptor antagonists.
AID1880429Displacement of [3H]-methyltrienolene from human androgen receptor incubated overnight by liquid scintillation counting analysis2022Journal of medicinal chemistry, 06-23, Volume: 65, Issue:12
Discovery of Apararenone (MT-3995) as a Highly Selective, Potent, and Novel Nonsteroidal Mineralocorticoid Receptor Antagonist.
AID1880462Organ protective activity in aldosterone-induced uninephrectomized Sprague-Dawley rat model assessed as degeneration of arteries and perivascular fibrosis in heart by measuring pathological lesion score at 100 mg/kg/day by sirius red and H and E staining 2022Journal of medicinal chemistry, 06-23, Volume: 65, Issue:12
Discovery of Apararenone (MT-3995) as a Highly Selective, Potent, and Novel Nonsteroidal Mineralocorticoid Receptor Antagonist.
AID1162569Agonist activity at human mineralocorticoid receptor expressed in COS1 cells at 10 uM after 1 day by luciferase reporter gene assay2014Bioorganic & medicinal chemistry, Oct-01, Volume: 22, Issue:19
Discovery of 6-[5-(4-fluorophenyl)-3-methyl-pyrazol-4-yl]-benzoxazin-3-one derivatives as novel selective nonsteroidal mineralocorticoid receptor antagonists.
AID499930Selectivity ratio of IC50 estrogen receptor IC50 for mineralocorticoid receptor2010Journal of medicinal chemistry, Aug-26, Volume: 53, Issue:16
Discovery of (3S,3aR)-2-(3-chloro-4-cyanophenyl)-3-cyclopentyl-3,3a,4,5-tetrahydro-2H-benzo[g]indazole-7-carboxylic acid (PF-3882845), an orally efficacious mineralocorticoid receptor (MR) antagonist for hypertension and nephropathy.
AID1623484Fraction unbound in Han Wistar rat plasma at 1 uM after 4 hrs by LC/MS/MS analysis
AID499835Antagonist activity at mineralocorticoid receptor LBD expressed in human HUH7 cells coexpressing GAL4 by luciferase reporter gene assay2010Journal of medicinal chemistry, Aug-26, Volume: 53, Issue:16
Discovery of novel cyanodihydropyridines as potent mineralocorticoid receptor antagonists.
AID1880423Displacement of [3H]-estradiol from recombinant full-length human estrogen beta receptor expressed in baculovirus infected insect cells incubated overnight by liquid scintillation counting analysis2022Journal of medicinal chemistry, 06-23, Volume: 65, Issue:12
Discovery of Apararenone (MT-3995) as a Highly Selective, Potent, and Novel Nonsteroidal Mineralocorticoid Receptor Antagonist.
AID1623467Displacement of [3H]-aldosterone to human mineralocorticoid receptor LBD by radiometric binding assay
AID1880441Antagonist activity at human mineralocorticoid receptor S810L mutant expressed in CHO-K1 cells assessed as inhibition of aldosterone-induced transcriptional activity incubated for 24 hrs in presence of 0.5 nM aldosterone by Steady-Glo reagent based report2022Journal of medicinal chemistry, 06-23, Volume: 65, Issue:12
Discovery of Apararenone (MT-3995) as a Highly Selective, Potent, and Novel Nonsteroidal Mineralocorticoid Receptor Antagonist.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID499849Antihypertensive activity in Dahl salt-sensitive rat model assessed as decrease of systolic blood pressure at 100 mg/kg administered with chow diet for 21 days2010Journal of medicinal chemistry, Aug-26, Volume: 53, Issue:16
Discovery of novel cyanodihydropyridines as potent mineralocorticoid receptor antagonists.
AID499926Antagonist activity at androgen receptor2010Journal of medicinal chemistry, Aug-26, Volume: 53, Issue:16
Discovery of (3S,3aR)-2-(3-chloro-4-cyanophenyl)-3-cyclopentyl-3,3a,4,5-tetrahydro-2H-benzo[g]indazole-7-carboxylic acid (PF-3882845), an orally efficacious mineralocorticoid receptor (MR) antagonist for hypertension and nephropathy.
AID1611700Toxicity in DOCA salt-induced hypertensive FSGS Sprague-Dawley rat model assessed as change in body weight at 50 mg/kg, po administered twice daily for 3 weeks2019ACS medicinal chemistry letters, Nov-14, Volume: 10, Issue:11
Discovery of a Potent and Selective TRPC5 Inhibitor, Efficacious in a Focal Segmental Glomerulosclerosis Model.
AID1623468Binding affinity to recombinant human GR LBD by fluormone GS red-fluorescence polarization assay
AID761382Agonist activity at glucocorticoid receptor (unknown origin) by NH Pro assay2013Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15
Discovery of novel oxazolidinedione derivatives as potent and selective mineralocorticoid receptor antagonists.
AID1226695Agonist activity at human glucocorticoid receptor by cell-based assay2015ACS medicinal chemistry letters, Apr-09, Volume: 6, Issue:4
Discovery of benzimidazole oxazolidinediones as novel and selective nonsteroidal mineralocorticoid receptor antagonists.
AID1140687Ratio of EC50 in healthy human assessed as increase in urinary Na+/K+ ratio to EC50 in rat assessed as increase in urinary Na+/K+ ratio2014Journal of medicinal chemistry, May-22, Volume: 57, Issue:10
Identification of (R)-6-(1-(4-cyano-3-methylphenyl)-5-cyclopentyl-4,5-dihydro-1H-pyrazol-3-yl)-2-methoxynicotinic acid, a highly potent and selective nonsteroidal mineralocorticoid receptor antagonist.
AID1473139In vivo antagonist activity at MR in Wistar rat assessed as increase in urinary Na+ /K+ ratio at 100 mg/kg, po administered as single dose measured after 2 to 6 hrs post dose
AID499933Antagonist activity at glucocorticoid receptor2010Journal of medicinal chemistry, Aug-26, Volume: 53, Issue:16
Discovery of (3S,3aR)-2-(3-chloro-4-cyanophenyl)-3-cyclopentyl-3,3a,4,5-tetrahydro-2H-benzo[g]indazole-7-carboxylic acid (PF-3882845), an orally efficacious mineralocorticoid receptor (MR) antagonist for hypertension and nephropathy.
AID1623492Terminal half life in Han Wistar rat at 1.2 mg/kg, iv by LC-MS/MS analysis
AID1880470Organ protective activity in aldosterone-induced uninephrectomized Sprague-Dawley rat model assessed as renal tubular ectasia in kidney by measuring pathological lesion score at 100 mg/kg/day by PAS and H and E staining based histological analysis (Rvb = 2022Journal of medicinal chemistry, 06-23, Volume: 65, Issue:12
Discovery of Apararenone (MT-3995) as a Highly Selective, Potent, and Novel Nonsteroidal Mineralocorticoid Receptor Antagonist.
AID1226697Agonist activity at human estrogen receptor alpha by cell-based assay2015ACS medicinal chemistry letters, Apr-09, Volume: 6, Issue:4
Discovery of benzimidazole oxazolidinediones as novel and selective nonsteroidal mineralocorticoid receptor antagonists.
AID1251762Reduction of aldosterone level in angiotension-2 ZSF1 rat infusion model2015Journal of medicinal chemistry, Oct-22, Volume: 58, Issue:20
Discovery of 4-Aryl-5,6,7,8-tetrahydroisoquinolines as Potent, Selective, and Orally Active Aldosterone Synthase (CYP11B2) Inhibitors: In Vivo Evaluation in Rodents and Cynomolgus Monkeys.
AID499929Selectivity ratio of IC50 progesteron receptor IC50 for mineralocorticoid receptor2010Journal of medicinal chemistry, Aug-26, Volume: 53, Issue:16
Discovery of (3S,3aR)-2-(3-chloro-4-cyanophenyl)-3-cyclopentyl-3,3a,4,5-tetrahydro-2H-benzo[g]indazole-7-carboxylic acid (PF-3882845), an orally efficacious mineralocorticoid receptor (MR) antagonist for hypertension and nephropathy.
AID1623485Intrinsic clearance in Han Wistar rat hepatocytes assessed per million cells at 1 uM after 4 hrs by LC/MS/MS analysis
AID1880438Antagonist activity at human wild-type mineralocorticoid receptor expressed in CHO-K1 cells assessed as inhibition of aldosterone-induced transcriptional activity incubated for 24 hrs in presence of 1 nM aldosterone by Steady-Glo reagent based reporter ge2022Journal of medicinal chemistry, 06-23, Volume: 65, Issue:12
Discovery of Apararenone (MT-3995) as a Highly Selective, Potent, and Novel Nonsteroidal Mineralocorticoid Receptor Antagonist.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID761377Agonist activity at estrogen receptor beta (unknown origin) by NH Pro assay2013Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15
Discovery of novel oxazolidinedione derivatives as potent and selective mineralocorticoid receptor antagonists.
AID1880474Organ protective activity in aldosterone-induced uninephrectomized Sprague-Dawley rat model assessed as renal tubular regeneration in kidney by measuring pathological lesion score at 100 mg/kg/day by PAS and H and E staining based histological analysis (R2022Journal of medicinal chemistry, 06-23, Volume: 65, Issue:12
Discovery of Apararenone (MT-3995) as a Highly Selective, Potent, and Novel Nonsteroidal Mineralocorticoid Receptor Antagonist.
AID761376Agonist activity at progesterone receptor beta (unknown origin) by NH Pro assay2013Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15
Discovery of novel oxazolidinedione derivatives as potent and selective mineralocorticoid receptor antagonists.
AID1623470Antagonist activity at gal4-fused human mineralocorticoid receptor LBD expressed in UAS-MR-bla HEK293 cells by luciferase reporter gene assay
AID1162568Antagonist activity at human mineralocorticoid receptor expressed in COS1 cells after 1 day by luciferase reporter gene assay2014Bioorganic & medicinal chemistry, Oct-01, Volume: 22, Issue:19
Discovery of 6-[5-(4-fluorophenyl)-3-methyl-pyrazol-4-yl]-benzoxazin-3-one derivatives as novel selective nonsteroidal mineralocorticoid receptor antagonists.
AID499850Antihypertensive activity in Dahl salt-sensitive rat model assessed as decrease of systolic blood pressure at 60 mg/kg, po bid for 21 days2010Journal of medicinal chemistry, Aug-26, Volume: 53, Issue:16
Discovery of novel cyanodihydropyridines as potent mineralocorticoid receptor antagonists.
AID761384Antagonist activity at human mineralocorticoid receptor assessed as inhibition of binding to coactivator peptide by NH Pro assay2013Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15
Discovery of novel oxazolidinedione derivatives as potent and selective mineralocorticoid receptor antagonists.
AID1140691In vivo inhibition of mineralocorticoid receptor in Sprague-Dawley rat assessed as reduction in urinary K+ at 30 mg/kg, po after 1 to 7 hrs relative to creatinine2014Journal of medicinal chemistry, May-22, Volume: 57, Issue:10
Identification of (R)-6-(1-(4-cyano-3-methylphenyl)-5-cyclopentyl-4,5-dihydro-1H-pyrazol-3-yl)-2-methoxynicotinic acid, a highly potent and selective nonsteroidal mineralocorticoid receptor antagonist.
AID635463Displacement of [3H]dexomethasone from GR2011Journal of medicinal chemistry, Dec-22, Volume: 54, Issue:24
Identification of benzoxazin-3-one derivatives as novel, potent, and selective nonsteroidal mineralocorticoid receptor antagonists.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1140664Antagonist activity at mineralocorticoid receptor (unknown origin) by Gal4-based cellular assay2014Journal of medicinal chemistry, May-22, Volume: 57, Issue:10
Identification of (R)-6-(1-(4-cyano-3-methylphenyl)-5-cyclopentyl-4,5-dihydro-1H-pyrazol-3-yl)-2-methoxynicotinic acid, a highly potent and selective nonsteroidal mineralocorticoid receptor antagonist.
AID1880458Organ protective activity in aldosterone-induced uninephrectomized Sprague-Dawley rat model assessed as myocardial fibrosis in heart by measuring pathological lesion score at 100 mg/kg/day by sirius red and H and E staining based histological analysis (Rv2022Journal of medicinal chemistry, 06-23, Volume: 65, Issue:12
Discovery of Apararenone (MT-3995) as a Highly Selective, Potent, and Novel Nonsteroidal Mineralocorticoid Receptor Antagonist.
AID499924Antagonist activity at Gal4-tagged mineralocorticoid receptor expressed in human Huh7 cells by luciferase reporter gene assay2010Journal of medicinal chemistry, Aug-26, Volume: 53, Issue:16
Discovery of (3S,3aR)-2-(3-chloro-4-cyanophenyl)-3-cyclopentyl-3,3a,4,5-tetrahydro-2H-benzo[g]indazole-7-carboxylic acid (PF-3882845), an orally efficacious mineralocorticoid receptor (MR) antagonist for hypertension and nephropathy.
AID635462Displacement of [3H]aldosterone from cytosolic human MR expressed in HEK293 cells after 16 hrs by scintillation counting2011Journal of medicinal chemistry, Dec-22, Volume: 54, Issue:24
Identification of benzoxazin-3-one derivatives as novel, potent, and selective nonsteroidal mineralocorticoid receptor antagonists.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1623479Modulation activity at human mineralocorticoid receptor in human EA.hy926 cells assessed as blocking of nuclear translocation of mineralocorticoid receptor in presence of aldosterone by receptor translocation assay
AID1623506Organ protective activity in Sprague-Dawley rat assessed as reduction in renal pathology score at 30 mg/kg, po administered via gavage administered for 4 weeks measured at 24 hrs post treatment by LC-MS/MS analysis
AID1623475Antagonist activity at full length human mineralocorticoid receptor expressed in human U2OS cells by luciferase reporter gene assay
AID499923Protection of renal injury in Dahl salt-sensitive rat model assessed as reduction of urinal albumin excretion at 60 mg/kg, po bid for 21 days2010Journal of medicinal chemistry, Aug-26, Volume: 53, Issue:16
Discovery of novel cyanodihydropyridines as potent mineralocorticoid receptor antagonists.
AID1162564Displacement of [3H]aldosterone from human mineralocorticoid receptor expressed in 293 cells after 16 hrs by scintillation counting2014Bioorganic & medicinal chemistry, Oct-01, Volume: 22, Issue:19
Discovery of 6-[5-(4-fluorophenyl)-3-methyl-pyrazol-4-yl]-benzoxazin-3-one derivatives as novel selective nonsteroidal mineralocorticoid receptor antagonists.
AID499931Selectivity ratio of IC50 androgen receptor IC50 for mineralocorticoid receptor2010Journal of medicinal chemistry, Aug-26, Volume: 53, Issue:16
Discovery of (3S,3aR)-2-(3-chloro-4-cyanophenyl)-3-cyclopentyl-3,3a,4,5-tetrahydro-2H-benzo[g]indazole-7-carboxylic acid (PF-3882845), an orally efficacious mineralocorticoid receptor (MR) antagonist for hypertension and nephropathy.
AID1226700Agonist activity at human mineralocorticoid receptor by cell-based assay2015ACS medicinal chemistry letters, Apr-09, Volume: 6, Issue:4
Discovery of benzimidazole oxazolidinediones as novel and selective nonsteroidal mineralocorticoid receptor antagonists.
AID1162566Displacement of [[3H]-Progesterone from progesterone receptor (unknown origin) expressed in 293 cells after 16 hrs by scintillation counting2014Bioorganic & medicinal chemistry, Oct-01, Volume: 22, Issue:19
Discovery of 6-[5-(4-fluorophenyl)-3-methyl-pyrazol-4-yl]-benzoxazin-3-one derivatives as novel selective nonsteroidal mineralocorticoid receptor antagonists.
AID1623505Organ protective activity in Sprague-Dawley rat assessed as reduction in cardiac pathology score at 30 mg/kg, po administered via gavage administered for 4 weeks measured at 24 hrs post treatment by LC-MS/MS analysis
AID1226696Agonist activity at human androgen receptor by cell-based assay2015ACS medicinal chemistry letters, Apr-09, Volume: 6, Issue:4
Discovery of benzimidazole oxazolidinediones as novel and selective nonsteroidal mineralocorticoid receptor antagonists.
AID1880422Displacement of [3H]-estradiol from recombinant full-length human estrogen alpha receptor expressed in insect cells incubated overnight by liquid scintillation counting analysis2022Journal of medicinal chemistry, 06-23, Volume: 65, Issue:12
Discovery of Apararenone (MT-3995) as a Highly Selective, Potent, and Novel Nonsteroidal Mineralocorticoid Receptor Antagonist.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1711869Antagonist activity at human full-length MCR assessed as inhibition of receptor binding to co-activator peptide by PathHunter assay2016Bioorganic & medicinal chemistry letters, 06-15, Volume: 26, Issue:12
Discovery of novel non-steroidal reverse indole mineralocorticoid receptor antagonists.
AID1880443Invivo antagonist activity at MR in po dosed Sprague-Dawley rat assessed as reversal of aldosterone induced decrease in urinary Na+/K+ ratio preincubated for 0.5 hrs followed by aldosterone stimulation and measured over 5 hrs by automated electrolyte anal2022Journal of medicinal chemistry, 06-23, Volume: 65, Issue:12
Discovery of Apararenone (MT-3995) as a Highly Selective, Potent, and Novel Nonsteroidal Mineralocorticoid Receptor Antagonist.
AID1623469Binding affinity to recombinant human progesterone receptor LBD by fluormone PL red-fluorescence polarization assay
AID1623471Antagonist activity at human gal4-fused mineralocorticoid receptor LBD expressed in UAS-MR-bla HEK293 by luciferase reporter gene assay relative to control
AID1226699Agonist activity at human progesterone receptor beta by cell-based assay2015ACS medicinal chemistry letters, Apr-09, Volume: 6, Issue:4
Discovery of benzimidazole oxazolidinediones as novel and selective nonsteroidal mineralocorticoid receptor antagonists.
AID761381Antagonist activity at androgen receptor (unknown origin) by NH Pro assay2013Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15
Discovery of novel oxazolidinedione derivatives as potent and selective mineralocorticoid receptor antagonists.
AID1623495Oral bioavailability in Han Wistar rat at 2.1 mg/kg by LC-MS/MS analysis
AID1880478Organ protective activity in aldosterone-induced uninephrectomized Sprague-Dawley rat model assessed as urinary cast in kidney by measuring pathological lesion score at 100 mg/kg/day by PAS and H and E staining based histological analysis (Rvb = 1.4 +/- 02022Journal of medicinal chemistry, 06-23, Volume: 65, Issue:12
Discovery of Apararenone (MT-3995) as a Highly Selective, Potent, and Novel Nonsteroidal Mineralocorticoid Receptor Antagonist.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1880440Antagonist activity at human wild-type mineralocorticoid receptor expressed in CHO-K1 cells assessed as inhibition of aldosterone-induced transcriptional activity incubated for 24 hrs in presence of 1 nM aldosterone by Steady-Glo reagent based reporter ge2022Journal of medicinal chemistry, 06-23, Volume: 65, Issue:12
Discovery of Apararenone (MT-3995) as a Highly Selective, Potent, and Novel Nonsteroidal Mineralocorticoid Receptor Antagonist.
AID705904Protein binding in plasma2012Journal of medicinal chemistry, Sep-27, Volume: 55, Issue:18
Mineralocorticoid receptor antagonists for the treatment of hypertension and diabetic nephropathy.
AID1623466Kinetic solubility of compound at pH 7.4 after 24 hrs by shake-flask assay
AID1177639Decrease in diastolic blood pressure in hypertension patient at 50 mg, bid for 8 weeks2014Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12
Aldosterone synthase inhibitors as promising treatments for mineralocorticoid dependent cardiovascular and renal diseases.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1177665Increase in aldosterone level in primary aldosteronism patient plasma at 50 mg, bid for 31 days2014Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12
Aldosterone synthase inhibitors as promising treatments for mineralocorticoid dependent cardiovascular and renal diseases.
AID635465Displacement of [3H]progesterone from PR2011Journal of medicinal chemistry, Dec-22, Volume: 54, Issue:24
Identification of benzoxazin-3-one derivatives as novel, potent, and selective nonsteroidal mineralocorticoid receptor antagonists.
AID1611698Toxicity in DOCA salt-induced hypertensive FSGS Sprague-Dawley rat model assessed as change in urinary creatinine clearance at 50 mg/kg, po administered twice daily for 3 weeks2019ACS medicinal chemistry letters, Nov-14, Volume: 10, Issue:11
Discovery of a Potent and Selective TRPC5 Inhibitor, Efficacious in a Focal Segmental Glomerulosclerosis Model.
AID1251764Induction of improvement in renal histology in angiotension-2 ZSF1 rat infusion model2015Journal of medicinal chemistry, Oct-22, Volume: 58, Issue:20
Discovery of 4-Aryl-5,6,7,8-tetrahydroisoquinolines as Potent, Selective, and Orally Active Aldosterone Synthase (CYP11B2) Inhibitors: In Vivo Evaluation in Rodents and Cynomolgus Monkeys.
AID640615Clearance in human liver microsomes at 1 uM measured after 60 mins by HPLC analysis2012Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2
Capture hydrolysis signals in the microsomal stability assay: molecular mechanisms of the alkyl ester drug and prodrug metabolism.
AID1623464Modulation activity at human mineralocorticoid receptor in human EA.hy926 cells assessed as induction of nuclear translocation of mineralocorticoid receptor in absence of aldosterone by receptor translocation assay
AID1140689In vivo inhibition of mineralocorticoid receptor in Sprague-Dawley rat assessed as increase in urinary Na+ at 30 mg/kg, po after 1 to 7 hrs relative to creatinine2014Journal of medicinal chemistry, May-22, Volume: 57, Issue:10
Identification of (R)-6-(1-(4-cyano-3-methylphenyl)-5-cyclopentyl-4,5-dihydro-1H-pyrazol-3-yl)-2-methoxynicotinic acid, a highly potent and selective nonsteroidal mineralocorticoid receptor antagonist.
AID478704Antagonist activity at Gal4-fused mineralocorticoid receptor expressed in human HuH7 cells assessed as inhibition of aldosterone-induced receptor activation by luciferase reporter gene assay2010Journal of medicinal chemistry, May-27, Volume: 53, Issue:10
Stereochemical requirements for the mineralocorticoid receptor antagonist activity of dihydropyridines.
AID635464Displacement of [3H]testosterone from AR2011Journal of medicinal chemistry, Dec-22, Volume: 54, Issue:24
Identification of benzoxazin-3-one derivatives as novel, potent, and selective nonsteroidal mineralocorticoid receptor antagonists.
AID1177657Increase in aldosterone level in sodium depleted healthy human urine2014Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12
Aldosterone synthase inhibitors as promising treatments for mineralocorticoid dependent cardiovascular and renal diseases.
AID1623465Octanol-water partitioning co-efficient, log D of the compound at pH 7.4 by LC/MS/MS analysis
AID1623481Modulation activity at human mineralocorticoid receptor in human EA.hy926 cells assessed as induction of nuclear translocation of mineralocorticoid receptor in absence of aldosterone by receptor translocation assay relative to control
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1623478Antagonist activity at gal4-fused rat mineralocorticoid receptor LBD in expressed in human U2OS cells by luciferase reporter gene assay relative to control
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1623486Volume of distribution at steady state in Han Wistar rat at 1.2 mg/kg, iv by LC-MS/MS analysis
AID499928Antagonist activity at estrogen receptor2010Journal of medicinal chemistry, Aug-26, Volume: 53, Issue:16
Discovery of (3S,3aR)-2-(3-chloro-4-cyanophenyl)-3-cyclopentyl-3,3a,4,5-tetrahydro-2H-benzo[g]indazole-7-carboxylic acid (PF-3882845), an orally efficacious mineralocorticoid receptor (MR) antagonist for hypertension and nephropathy.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID761375Antagonist activity at estrogen receptor beta (unknown origin) by NH Pro assay2013Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15
Discovery of novel oxazolidinedione derivatives as potent and selective mineralocorticoid receptor antagonists.
AID1177658Increase in aldosterone level in sodium depleted healthy human plasma2014Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12
Aldosterone synthase inhibitors as promising treatments for mineralocorticoid dependent cardiovascular and renal diseases.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1880425Displacement of [3H]-aldosterone from rat mineralocorticoid receptor incubated overnight by liquid scintillation counting analysis2022Journal of medicinal chemistry, 06-23, Volume: 65, Issue:12
Discovery of Apararenone (MT-3995) as a Highly Selective, Potent, and Novel Nonsteroidal Mineralocorticoid Receptor Antagonist.
AID1611697Toxicity in DOCA salt-induced hypertensive FSGS Sprague-Dawley rat model assessed as reduction in blood pressure at 50 mg/kg, po administered twice daily for 3 weeks measured on week 2 to 32019ACS medicinal chemistry letters, Nov-14, Volume: 10, Issue:11
Discovery of a Potent and Selective TRPC5 Inhibitor, Efficacious in a Focal Segmental Glomerulosclerosis Model.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1880424Displacement of [3H]-progesteron from human recombinant progesterone receptor incubated overnight by liquid scintillation counting analysis2022Journal of medicinal chemistry, 06-23, Volume: 65, Issue:12
Discovery of Apararenone (MT-3995) as a Highly Selective, Potent, and Novel Nonsteroidal Mineralocorticoid Receptor Antagonist.
AID499927Antagonist activity at progesterone receptor2010Journal of medicinal chemistry, Aug-26, Volume: 53, Issue:16
Discovery of (3S,3aR)-2-(3-chloro-4-cyanophenyl)-3-cyclopentyl-3,3a,4,5-tetrahydro-2H-benzo[g]indazole-7-carboxylic acid (PF-3882845), an orally efficacious mineralocorticoid receptor (MR) antagonist for hypertension and nephropathy.
AID1880444Antagonist activity at human mineralocorticoid receptor S810L mutant expressed in CHO-K1 cells assessed as inhibition of aldosterone-induced transcriptional activity at 300 nM incubated for 24 hrs in presence of aldosterone at 0.5 nM by reporter gene assa2022Journal of medicinal chemistry, 06-23, Volume: 65, Issue:12
Discovery of Apararenone (MT-3995) as a Highly Selective, Potent, and Novel Nonsteroidal Mineralocorticoid Receptor Antagonist.
AID1251763Induction of improvement in glomerular filtration rate in angiotension-2 ZSF1 rat infusion model2015Journal of medicinal chemistry, Oct-22, Volume: 58, Issue:20
Discovery of 4-Aryl-5,6,7,8-tetrahydroisoquinolines as Potent, Selective, and Orally Active Aldosterone Synthase (CYP11B2) Inhibitors: In Vivo Evaluation in Rodents and Cynomolgus Monkeys.
AID1880454Organ protective activity in aldosterone-induced uninephrectomized Sprague-Dawley rat model assessed as myocardial necrosis and interstitial cellular infiltration in heart by measuring pathological lesion score at 100 mg/kg/day by sirius red and H and E s2022Journal of medicinal chemistry, 06-23, Volume: 65, Issue:12
Discovery of Apararenone (MT-3995) as a Highly Selective, Potent, and Novel Nonsteroidal Mineralocorticoid Receptor Antagonist.
AID1880426Displacement of [3H]-aldosterone from recombinant human mineralocorticoid receptor expressed in baculovirus infected insect cells incubated overnight by liquid scintillation counting analysis2022Journal of medicinal chemistry, 06-23, Volume: 65, Issue:12
Discovery of Apararenone (MT-3995) as a Highly Selective, Potent, and Novel Nonsteroidal Mineralocorticoid Receptor Antagonist.
AID1880450Antihypertensive activity against aldosterone induced uninephrectomized Sprague-Dawley rat assessed as reduction in urinary albumin excretion at 50 mg/kg, po bid administered for 4 weeks2022Journal of medicinal chemistry, 06-23, Volume: 65, Issue:12
Discovery of Apararenone (MT-3995) as a Highly Selective, Potent, and Novel Nonsteroidal Mineralocorticoid Receptor Antagonist.
AID478705Inhibition of L-type calcium channel in rat A10 cells assessed as inhibition of depolarization-induced increase in calcium flux after 48 hrs by FLIPR assay2010Journal of medicinal chemistry, May-27, Volume: 53, Issue:10
Stereochemical requirements for the mineralocorticoid receptor antagonist activity of dihydropyridines.
AID761374Antagonist activity at progesterone receptor beta (unknown origin) by NH Pro assay2013Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15
Discovery of novel oxazolidinedione derivatives as potent and selective mineralocorticoid receptor antagonists.
AID761379Agonist activity at estrogen receptor alpha (unknown origin) by NH Pro assay2013Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15
Discovery of novel oxazolidinedione derivatives as potent and selective mineralocorticoid receptor antagonists.
AID1611692Protection against renal dysfunction in DOCA salt-induced hypertensive FSGS Sprague-Dawley rat model assessed as reduction in urine albumin level at 50 mg/kg, po administered twice daily for 3 weeks and measured on week 2 to 32019ACS medicinal chemistry letters, Nov-14, Volume: 10, Issue:11
Discovery of a Potent and Selective TRPC5 Inhibitor, Efficacious in a Focal Segmental Glomerulosclerosis Model.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1623480Modulation activity at human mineralocorticoid receptor in human EA.hy926 cells assessed as blocking of nuclear translocation of mineralocorticoid receptor in presence of aldosterone by receptor translocation assay relative to control
AID1346902Human Mineralocorticoid receptor (3C. 3-Ketosteroid receptors)2007Journal of medicinal chemistry, Dec-27, Volume: 50, Issue:26
(S)-N-{3-[1-cyclopropyl-1-(2,4-difluoro-phenyl)-ethyl]-1H-indol-7-yl}-methanesulfonamide: a potent, nonsteroidal, functional antagonist of the mineralocorticoid receptor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (996)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (0.10)18.7374
1990's1 (0.10)18.2507
2000's356 (35.74)29.6817
2010's494 (49.60)24.3611
2020's144 (14.46)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 102.47

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index102.47 (24.57)
Research Supply Index7.10 (2.92)
Research Growth Index6.91 (4.65)
Search Engine Demand Index184.12 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (102.47)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials172 (16.60%)5.53%
Reviews210 (20.27%)6.00%
Case Studies33 (3.19%)4.05%
Observational7 (0.68%)0.25%
Other614 (59.27%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (110)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Effects of Eplerenone on Blood Pressure, Heart and Kidney in Elderly Hypertensive Early Stage Chronic Kidney Disease Patients [NCT01302236]Phase 40 participants (Actual)Interventional2011-03-31Withdrawn(stopped due to We could not find patients who agreed to enrolled this clinical study.)
Prospective and Open Label Study With Blind End Point Evaluation on the Effect of Mineralocorticoid Receptor Inhibition on Endothelial Function of the Micro- and Macrovasculature in Patients With Metabolic Syndrome [NCT01319344]Phase 342 participants (Actual)Interventional2010-09-30Completed
A Comparison of the Effects of Selective and Non Selective Mineralocorticoid Antagonism on Glucose Homeostasis and Lipid Profile of Heart Failure Patients With Glucose Intolerance or Type 2 Diabetes. [NCT01586442]Phase 362 participants (Actual)Interventional2012-03-31Completed
Role of Eplerenone in Reducing Recurrence of Atrial Fibrillation in Patient With Structural Heart Disease [NCT06168994]Phase 4100 participants (Anticipated)Interventional2024-02-01Not yet recruiting
Effects of Eplerenone on Left Ventricular Hypertrophy in Patients With Resistant Hypertension and Obstructive Sleep Apnoea [NCT03186742]Phase 4125 participants (Actual)Interventional2014-07-01Completed
Eplerenone in the Management of Abdominal Aortic Aneurysms: A Proof-Of-Concept Randomised Controlled Trial [NCT02345590]Phase 4172 participants (Anticipated)Interventional2015-05-31Recruiting
A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate Efficacy and Safety of CS-3150 in Japanese Subjects With Hypertension [NCT02345044]Phase 2426 participants (Actual)Interventional2015-01-31Completed
A Double-Blind, Multicenter, Placebo Controlled Study of Aldosterone Blockade (Eplerenone) in Women With Chest Pain, Coronary Vascular Dysfunction and Evidence of Myocardial Ischemia in the Absence of Significant Epicardial Coronary Artery Disease [NCT00187889]Phase 470 participants (Actual)Interventional2004-08-31Completed
A Phase 1, Double-Blind (Sponsor Open), Randomized, Placebo-Controlled Trial To Evaluate The Effects Of 100 MG Once Daily Of Eplerenone On Serum Aldesterone And Plasma Renin Activity During 10 Days Of Dosing In Healthy Volunteers [NCT00990223]Phase 120 participants (Actual)Interventional2009-10-31Completed
HYpertension Therapy With Valsartan Versus EpleRenone for Obese Patients: A Randomized Clinical Trial [NCT03476616]Phase 4330 participants (Anticipated)Interventional2018-09-01Not yet recruiting
Cluster and Registry Trials Of the Working Group of Heart Failure in Denmark: Are SPironolactone and Eplerenone Comparable Treatments? [NCT03984591]Phase 47,200 participants (Anticipated)Interventional2020-11-01Enrolling by invitation
A Randomised Trial Examining Therapy to Maintain Remission in Dilated Cardiomyopathy [NCT06091475]50 participants (Anticipated)Interventional2023-10-20Not yet recruiting
OCTA in Central Serous Chorioratinopathy Treated With Oral Eplerenone or Hal-fluence Photodynamic Therapy: a Comparative Study [NCT05104138]30 participants (Actual)Observational2015-10-01Completed
Comparative Bioavailability Study of Eplerenone 50 mg Tablets (Sandoz Inc., USA) and Inspra 50 mg Tablets (GD Searle LLC, USA) in Healthy Male and/or Female Volunteers Under Fasting Conditions. [NCT00865176]Phase 160 participants (Actual)Interventional2006-06-30Completed
Aldosterone Blockade to Prevent Myocardial Remodeling In Patients With Controlled Essential Hypertension [NCT00980031]20 participants (Actual)Interventional2007-04-30Terminated(stopped due to Funding ended prior to study completion)
Mineralocorticoid Receptor Antagonism for Cardiovascular Health in HIV--The MIRACLE HIV Study [NCT02740179]40 participants (Actual)Interventional2017-01-31Completed
Salt Sensitive Hypertension and Striatin [NCT03683069]Phase 4400 participants (Actual)Interventional2019-01-15Active, not recruiting
The Effect of Eplerenone on Ischemia Reperfusion Injury in Human Myocardium (EPLICARD Study) [NCT02118753]24 participants (Actual)Interventional2014-03-31Completed
Study of the Safety, Tolerability, Pharmacokinetics and Effect on Renal Potassium Clearance After Multiple Oral Dosing of LY2623091 in Healthy Volunteers [NCT01237899]Phase 132 participants (Actual)Interventional2010-10-31Completed
A Multi-center, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group, Proof-of-concept Study to Evaluate the Efficacy and Safety of LFF269 Compared to Placebo After Treatment in Subjects With Essential Hypertension [NCT01373086]Phase 219 participants (Actual)Interventional2011-05-31Terminated
Aldosterone Blockade in Chronic Kidney Disease. Influence on Arterial Stiffness and Kidney Function [NCT01100203]Phase 354 participants (Actual)Interventional2010-04-30Terminated(stopped due to It was not possible within the time frame to recruit the planned no. of patients.)
Comparative Bioavailability Study of Eplerenone 50 mg Tablets (Sandoz Inc., USA) and Inspra 50 mg Tablets (GD Searle LLC, USA) in Healthy Male and/or Female Volunteers Under Fed Conditions. [NCT00865618]Phase 160 participants (Actual)Interventional2006-06-30Completed
A Double Blind Study of CS-3150 to Evaluate Efficacy and Safety Compared to Eplerenone in Patients With Essential Hypertension (ESAX-HTN Study) [NCT02890173]Phase 31,001 participants (Actual)Interventional2016-09-30Completed
A Multi-center, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group, Dose Finding Study to Evaluate the Efficacy and Safety of LCI699 Compared to Placebo After 8 Weeks Treatment in Patients With Essential Hypertension [NCT00758524]Phase 2628 participants (Actual)Interventional2008-09-11Completed
The Effect Of Eplerenone Versus Placebo On Cardiovascular Mortality And Heart Failure Hospitalization In Subjects With NYHA Class II Chronic Systolic Heart Failure [NCT00232180]Phase 32,743 participants (Actual)Interventional2006-03-31Completed
A Phase II, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group, Multi-center, Dose Ranging Study to Evaluate the Efficacy and Safety of LCI699 Compared to Placebo After 8 Weeks Treatment in Patients With Resistant Hypertension [NCT00817635]Phase 2155 participants (Actual)Interventional2008-12-22Completed
Eplerenone Treatment for Chronic Central Serous Chorioretinopathy in Hungarian Population [NCT02462499]Phase 428 participants (Actual)Interventional2014-06-30Completed
Aldosterone, the Mineralocorticoid Receptor, and Cardiovascular Disease in Obesity [NCT04519164]Phase 480 participants (Anticipated)Interventional2020-12-01Recruiting
[NCT02153125]Phase 230 participants (Anticipated)Interventional2014-04-30Recruiting
Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension [NCT05593055]Phase 475 participants (Anticipated)Interventional2023-08-25Recruiting
A Randomised, Single Blind, Multicentre, 9-month, Phase IV Study, Comparing Treatment Guided by Clinical Symptoms and Signs and NT-proBNP vs Treatment Guided by Clinical Symptoms and Signs Alone, in Patients With Heart Failure (HF) and Left Ventricular Sy [NCT00391846]Phase 4252 participants (Actual)Interventional2006-10-31Completed
Association Between Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use and COVID-19 Severity and Mortality Among US Veterans [NCT04467931]22,213 participants (Actual)Observational2020-01-19Completed
A Randomized, Double-blind, Double-dummy, Multi-center Study to Assess Safety and Efficacy of BAY94-8862 in Japanese Subjects With Emergency Presentation at the Hospital Because of Worsening Chronic Heart Failure With Left Ventricular Systolic Dysfunction [NCT01955694]Phase 272 participants (Actual)Interventional2013-11-11Completed
Clinical Protocol For A Double-Blind, Randomized, Active- Controlled Comparison Study Of The Antihypertensive Effect Of Eplerenone Versus Losartan In Patients With Mild To Moderate Hypertension [NCT00649311]Phase 2248 participants (Actual)Interventional2003-04-30Terminated(stopped due to Poor enrollment; termination not due to safety reasons.)
Randomized, Two-way, Two-period, Single Oral Dose, Open-label, Crossover, Bioequivalence Study to Compare Efez 50 mg Eplerenone Film-coated Tablets Versus INSPRA® 50 mg Eplerenone Film-coated Tablets, in Healthy Adult Male and Female Subjects Under Fastin [NCT05663372]Phase 136 participants (Actual)Interventional2021-12-07Completed
EPLERAF-Study: Eplerenone in the Prevention of Atrial Fibrillation Recurrences After Cardioversion [NCT00647192]Phase 238 participants (Actual)Interventional2008-03-31Terminated(stopped due to Inclusion rate too low. Recruitment of further study centers too costly.)
Phase I Trial Comparing Eplerenone Pharmacokinetics (Tablet) in Different Dosages: 25mg, 50mg,100 mg Per Day and 100 mg (One 50 mg Tablet Every 12 Hours). [NCT02607657]Phase 10 participants (Actual)Interventional2016-05-31Withdrawn
Aldosterone Antagonists in Systemic Right Ventricle: a Randomized Clinical Trial. [NCT00703352]Phase 426 participants (Actual)Interventional2008-07-31Completed
Treatment of Post-Ocriplasmin Therapy Vitreolysis Induced Subretinal Fluid With Eplerenone (Mineralocorticoid Antagonists): The TOTEM Study [NCT04300881]Phase 22 participants (Actual)Interventional2019-10-04Terminated(stopped due to Enrollment)
A Double-blind, Randomized, Placebo-controlled Trial Evaluating The Safety And Efficacy Of Early Treatment With Eplerenone In Patients With Acute Myocardial Infarction [NCT01176968]Phase 41,012 participants (Actual)Interventional2010-09-30Completed
Pressure Assessment to Improve Outcomes After TAVR: a Registry [NCT03923530]Early Phase 112 participants (Actual)Interventional2019-06-03Completed
Effects of Aldosterone Antagonism on Insulin-mediated Microvascular Function in Subjects With the Metabolic Syndrome [NCT01887119]Phase 425 participants (Actual)Interventional2013-10-31Terminated(stopped due to Failure to recruit sufficient participants)
A Double-Blind, Parallel Design Study to Compare the Effectiveness of Eplerenone Versus Atenolol in Reversing the Remodeling of Resistance Arteries in Subjects With Mild to Moderate Primary Hypertension [NCT00147563]Phase 434 participants Interventional2003-10-31Completed
Aldosterone-Renin Ratio to Diagnose Primary Aldosteronism in a Population of Patients With Therapy-Resistant Hypertension: Test Characteristics, Diagnostic Value and Predictive Value for Antihypertensive Treatment. The Dutch ARRAT Study. [NCT00407784]500 participants Observational2007-01-31Recruiting
Polydiuretic Therapy for Heart Failure With Preserved Ejection Fraction: A Pilot Trial [NCT05129722]Phase 430 participants (Anticipated)Interventional2022-10-01Recruiting
Role of LSD1 in Hypertension in Blacks [NCT04840342]Phase 4300 participants (Anticipated)Interventional2022-02-03Recruiting
A Randomized, Double-blind, Placebo-controlled Study of the Effect of Mineralocorticoid Receptor Antagonists in Type 2 Diabetes Patients on Myocardial Function, Glucose and Fat Metabolism (The MIRAD-study) [NCT02809963]Phase 4140 participants (Actual)Interventional2015-11-30Completed
Phase I, Open-label, Three Periods Study in Health Male and Female Subjects, Under Fasting Condition for Evaluation of Pharmacokinetics Profile of Single Dose of Eplerenone in Coated Tablets Formulation on Concentrations of 25mg, 50mg and 100mg, Produced [NCT02957435]Phase 10 participants (Actual)Interventional2017-07-31Withdrawn(stopped due to Study has been cancelled and it has not been initiated.)
Epidural Steroid Injection With Supplemental Oral Eplerenone for Low Back Pain: A Prospective, Double Blind Randomized Trial [NCT03418649]Phase 40 participants (Actual)Interventional2023-06-30Withdrawn(stopped due to Unable to recruit subjects)
Investigation of Reduction of Blood Pressure and Metabolic Rate in Obese Hypertensive Patients Using Eplerenone: Implications for Treatment of Hypertension and Heart Failure [NCT00825188]10 participants (Actual)Interventional2009-01-31Terminated(stopped due to funding to complete was inadequate)
The Effect of Mineralocorticoid Receptor Antagonist Therapy in Patients With Acute Myocardial Infection or Injury and Cardiovascular Risk Factors: a Registry-based, Stratified-medicine, Randomised, Controlled Trial [NCT05198791]Phase 2350 participants (Anticipated)Interventional2022-02-04Recruiting
The Effect Of Eplerenone Versus Placebo On Cardiovascular Mortality And Heart Failure Hospitalization In Japanese Subjects With Chronic Heart Failure [NCT01115855]Phase 3221 participants (Actual)Interventional2010-07-31Completed
The Role of Minerelocorticoid Receptor on Modulating Aldosterone Production [NCT02871648]Phase 123 participants (Actual)Interventional2016-01-31Completed
Polydiuretic Therapy for Heart Failure With Preserved Ejection Fraction and Diabetes Mellitus: A Pilot Trial [NCT04697485]Phase 40 participants (Actual)Interventional2021-01-08Withdrawn(stopped due to Enrollment and funding challenges)
PHOspholamban RElated CArdiomyopathy STudy - Intervention (Efficacy Study of Eplerenone in Presymptomaticphospholamban R14del Carriers) [NCT01857856]Phase 384 participants (Actual)Interventional2013-05-31Completed
Does Aldosterone Cause Hypertension by a Non-Renal Mechanism? [NCT00553722]Phase 427 participants (Anticipated)Interventional2007-11-30Not yet recruiting
Influence of Combined Eplerenone , Intravitreal Aflibercept and Topical Nepafenac Therapy on Serous Foveal Detachment in Central Serous Chorioretinopathy (CSCR) [NCT05847049]16 participants (Actual)Observational2023-02-28Completed
Hypoglycemia and the Mineralocorticoid Receptor [NCT01394627]21 participants (Actual)Interventional2011-01-31Completed
The Role of Aldosterone in Diabetes Related Vascular Disease, a New Therapeutic Target? [NCT03017703]27 participants (Actual)Interventional2016-12-01Completed
Effect of Eplerenone on Novel Biomarkers of Mineralocorticoid Receptor Activation (ENOVA) [NCT04746495]Phase 40 participants (Actual)Interventional2023-02-28Withdrawn(stopped due to Issues relate to COVID-19 and staffing challenges, as well as very tight finances.)
A Randomized, Double-Blind, Multi-Center,Study Evaluating the Effects of Eplerenone Versus Placebo on Ventricular Remodeling in Patient's With Left Ventricular Systolic Dysfunction (EF Less Than or Equal to 35%) and Mild to Moderate Heart Failure [NCT00082589]Phase 4250 participants Interventional2004-04-30Completed
Eplerenone, ACE Inhibition and Albuminuria [NCT00315016]Phase 230 participants (Actual)Interventional2007-01-31Completed
The Effect of Aldosterone Inhibition on Proteinuria in Patients With Progressive Renal Disease [NCT00430924]Phase 442 participants (Actual)Interventional2007-03-31Completed
The Effects of Eplerenone on Left Ventricular Remodelling Post-Acute Myocardial Infarction: a Double-Blind Placebo-Controlled Cardiac MR-Based Study [NCT00132093]Phase 4100 participants Interventional2005-04-30Completed
Aldosterone Antagonism in Diastolic Heart Failure [NCT00108251]Phase 448 participants (Actual)Interventional2004-08-31Completed
A Randomised, Double-blinded, Placebo-controlled Trial Using Cardiovascular Magnetic Resonance (CMR) Scanning to Assess Remodelling and Regression of Fibrosis in Cardiomyopathy With Eplerenone [NCT00401856]Phase 442 participants (Actual)Interventional2007-12-31Completed
Peds II (Pediatric Eplerenone Development Study II)--An Open Label, Long-Term Study To Evaluate The Safety Of Eplerenone In The Treatment Of Hypertension In Children [NCT00147615]Phase 3140 participants Interventional2004-10-31Completed
Effectiveness of Eplerenone to Improve Target Organ Damage in Patients With Resistant Arterial Hypertension [NCT00138944]Phase 385 participants (Actual)Interventional2007-01-31Completed
The Effect of Eplerenone and Atorvastatin on Markers of Collagen Turnover in Diastolic Heart Failure [NCT00505336]43 participants (Actual)Interventional2006-04-30Completed
Early Treatment With Aldosterone Antagonism Attenuates Cardiomyopathy in Duchenne Muscular Dystrophy [NCT01521546]42 participants (Actual)Interventional2012-02-29Completed
DRUG USE INVESTIGATION OF SELARA(REGISTERED). TABLETS(AN INVESTIGATION FOR CHRONIC HEART FAILURE) [NCT03342690]1,165 participants (Actual)Observational2017-07-05Completed
Effects of the Selective Mineralocorticoid Receptor Antagonist Eplerenone on Extracellular Adenosine Formation in Humans in Vivo [NCT01837108]Phase 414 participants (Actual)Interventional2013-04-30Completed
Eplerenone for the Treatment of Central Serous Chorioretinopathy [NCT01990677]108 participants (Actual)Interventional2013-10-31Completed
Study of the Safety of Eplerenone in Cyclosporine A-treated Transplant Recipients [NCT01834768]Phase 231 participants (Anticipated)Interventional2013-02-28Recruiting
Aldosterone and Vascular Disease in Diabetes Mellitus [NCT00214825]46 participants (Actual)Interventional2003-08-31Completed
Peds I (Pediatric Eplerenone Development Study I): A Randomized, Double-Blind, Placebo Withdrawal, Parallel Group, Dose-Response Study To Evaluate The Efficacy And Safety Of Eplerenone In The Treatment Of Hypertension In Children [NCT00147589]Phase 3320 participants Interventional2004-09-30Completed
The Pathophysiology and Treatment of Supine Hypertension in Patients With Autonomic Failure [NCT00223717]Phase 1152 participants (Actual)Interventional2001-01-31Completed
Comprehensive Stress-Perfusion Cardiac MRI Assessment of Diabetic Cardiomyopathy: Prognostic Role of the Fibrotic Index [NCT01794091]Phase 150 participants (Anticipated)Interventional2013-08-31Not yet recruiting
Study of the Safety and Efficacy of LY2623091 in Chronic Kidney Disease Patients [NCT01427972]Phase 242 participants (Actual)Interventional2011-09-30Completed
The Effects of Night-time Versus Morning Administration of Eplerenone on the Diurnal Variation of Plasminogen Activator Inhibitor-1 [NCT00515021]Phase 421 participants (Actual)Interventional2007-04-30Completed
Therapeutic Potential for Aldosterone Inhibition in Duchenne Muscular Dystrophy [NCT02354352]Phase 352 participants (Actual)Interventional2015-03-20Completed
A Randomized, Double-masked, Placebo Controlled Study of the Beneficial Effects of Eplerenone on Central Serous Chorioretinopathy [NCT02215330]Phase 2/Phase 360 participants (Anticipated)Interventional2014-10-31Not yet recruiting
Determine the Effectiveness of Eplerenone in Reversing Diastolic Dysfunction, Improving Endothelial Function, and Suppressing Natriuretic Peptides and Collagen Turnover in Patients With Diastolic Heart Failure ( PREDICT Study) [NCT00293150]Phase 411 participants (Actual)Interventional2003-09-30Terminated(stopped due to Lack of eligible patients)
Study on Half-dose Photodynamic Therapy Versus Eplerenone in Chronic CenTRAl Serous Chorioretinopathy (SPECTRA Trial) [NCT03079141]Phase 4107 participants (Anticipated)Interventional2017-02-20Active, not recruiting
Pilot Trial of Hemodialysis Patient Aldosterone antagoniSm With Eplerenone Trial [NCT01650012]158 participants (Actual)Interventional2013-03-31Completed
The Role of Aldosterone on Augmented Exercise Pressor Reflex in Hypertension [NCT01996449]Phase 214 participants (Actual)Interventional2013-07-31Completed
Unilateral Primary Aldosteronism, Mineralocorticoid Antagonists Versus Surgical Treatment - A Randomized Controlled Trial [NCT05797558]80 participants (Anticipated)Interventional2023-04-28Recruiting
A Prospective Randomized Placebo-controlled Study of the Effect of Eplerenone on Left Ventricular Diastolic Function in Women Receiving Anthracycline Therapy for Breast Cancer [NCT01708798]Phase 2/Phase 344 participants (Actual)Interventional2014-05-31Terminated(stopped due to Futility)
Swedish, Multicentered, Randomized Study of Eplerenone Versus Spironolactone as Treatment of Ascites Due to Liver Cirrhosis Regarding Efficacy and Side Effects [NCT01801228]Phase 20 participants (Actual)Interventional2013-02-28Withdrawn(stopped due to difficulties to include patients)
Eplerenone to Prevent Myocardial Fibrosis in Congenital Heart Disease [NCT01971593]Phase 426 participants (Actual)Interventional2013-08-31Terminated(stopped due to Investigator left institution)
[NCT01893788]Phase 4100 participants (Anticipated)Interventional2013-04-30Recruiting
Evaluating Alternative Medical Therapies in Primary Hyperparathyroidism [NCT02525796]Phase 2/Phase 369 participants (Actual)Interventional2016-01-31Completed
Randomized Placebo-controlled Trial to Investigate the Effects of Eplerenone in Patients With HIV-associated Abdominal Fat Accumulation [NCT01405456]46 participants (Actual)Interventional2012-01-31Completed
Defining Strategies for Improving Endothelial and Fibrinolytic Dysfunction in Obesity [NCT00608465]Phase 44 participants (Actual)Interventional2006-05-31Terminated(stopped due to Lack of enrollment)
A Phase I, Randomized, Single-Blind, Crossover Study to Assess the Pharmacodynamics of AZD9977 Following Single-Dose Administration to Healthy Male Subjects [NCT02532998]Phase 140 participants (Actual)Interventional2015-09-30Completed
Cardiometabolic Effects of Eplerenone in HIV Infection [NCT02629094]Phase 25 participants (Actual)Interventional2015-12-02Terminated
Glucose Metabolism in Subjects With Aldosterone-Producing Adenomas [NCT02362308]10 participants (Actual)Observational2015-01-31Completed
A Randomized Crossover Clinical Trial Regarding the Blockage of the Mineralocorticoid Receptor Using Eplerenone on the Evolution of Arterial Stiffness in Kidney Patients One Year After Transplant [NCT04450953]Phase 336 participants (Anticipated)Interventional2021-10-12Recruiting
Cardiovascular Manifestations of MR Activation in Primary Aldosteronism: Pilot Clinical Study [NCT05030545]Phase 440 participants (Anticipated)Interventional2022-12-15Recruiting
[NCT01832558]24 participants (Anticipated)Interventional2012-11-30Recruiting
Effect of Eplerenone on Postprandial Inflammatory Response in Healthy Adults [NCT01786551]16 participants (Actual)Interventional2010-03-31Completed
Antiproteinuric Efficacy of ACE Inhibitors, Selective MRAs and ACE Inhibitor/Selective MRA Combination Therapy in Diabetic Hypertensives With Microalbuminuria [NCT04143412]Phase 275 participants (Anticipated)Interventional2019-02-04Recruiting
Double-blind Placebo-Controlled Randomized Clinical Trial of Mineralocorticoid Receptor Blockade With Eplerenone After Renal Transplantation : Effect on Graft Function at 3 Months. [NCT02490904]Phase 3132 participants (Anticipated)Interventional2016-10-19Active, not recruiting
Eplerenone for Central Serous Chorioretinopathy: A Pilot Study [NCT01822561]Phase 217 participants (Actual)Interventional2013-05-31Completed
A Randomized, Double Blind Pilot Study Evaluating CLCNKA (Ka Renal Chloride Channel[ClC-Ka]) Polymorphism Effects on Hypertrophy Regression in Caucasian Hypertensive Patients Treated With Eplerenone [NCT01275352]Phase 40 participants (Actual)Interventional2011-12-31Withdrawn(stopped due to Lack of funding)
Study to Investigate the Effectiveness of Different Single Oral Doses of BAY94-8862 on Natriuresis After Administration of 0.5 mg Fludrocortisone (Astonin H®) With 50 mg Eplerenone (Inspra®) as Active Control in Healthy Male Subjects in a Randomized, Sing [NCT01473108]Phase 167 participants (Actual)Interventional2010-03-29Completed
ESTIA: TorasEmide Induced Effect on Quality of Life and Clinical parameterS in paTients With chronIc heArt Failure Receiving Eplerenone. Multicenter, Non-interventional, Prospective, Observational Clinical Study. [NCT06117722]210 participants (Anticipated)Observational2024-01-01Not yet recruiting
A Randomized, Double-blind, Double-dummy, Multi-center Study to Assess Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Emergency Presentation at the Hospital Because of Worsening Chronic Heart Failure With Left Ventricular Systo [NCT01807221]Phase 21,066 participants (Actual)Interventional2013-06-17Completed
Prospective Study Assessing Blood Pressure, Cardiovascular, Endothelial and Other Outcomes poSt-surgical and Medical Treatment in Patients With Primary Aldosteronism [NCT03174847]57 participants (Actual)Observational2017-02-20Completed
Randomised, Double-blind, Placebo-controlled (Within Dose Groups) and Active Controlled (Eplerenone Group) Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of 3 Oral Doses of BI 690517 Over 28 Days in Female and Male Pa [NCT03165240]Phase 162 participants (Actual)Interventional2017-10-05Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00187889 (2) [back to overview]Epicardial Coronary Artery Endothelial Function (Adjusted) at Week 16 Comparing the Eplerenone Group to the Placebo Group
NCT00187889 (2) [back to overview]Microvascular Coronary Flow Reserve(Adjusted) at Week 16 Adjusted for Baseline Coronary Flow Reserve Comparing the Eplerenone Group to the Placebo Group
NCT00232180 (18) [back to overview]Number of Participants With First Occurrence of Fatal or Non-fatal Myocardial Infarction (Adjudicated)
NCT00232180 (18) [back to overview]Number of Participants With First Occurrence of Cardiovascular (CV) Mortality (Adjudicated)
NCT00232180 (18) [back to overview]Number of Participants With First Occurrence of Cardiovascular (CV) Hospitalization (Adjudicated)
NCT00232180 (18) [back to overview]Number of Participants With First Occurrence of Implantation of Cardiac Defibrillator (ICD) (Adjudicated)
NCT00232180 (18) [back to overview]Number of Participants With New Onset Diabetes Mellitus (DM)
NCT00232180 (18) [back to overview]Number of Participants With New Onset Atrial Fibrillation or Flutter
NCT00232180 (18) [back to overview]Number of Participants With First Occurrence of Cardiovascular (CV) Mortality or Hospitalization Due to Heart Failure (HF) (Adjudicated)
NCT00232180 (18) [back to overview]Number of Participants With First Occurrence of All-Cause Hospitalization (Adjudicated)
NCT00232180 (18) [back to overview]Number of Participants With First Occurrence of All-Cause Mortality or Heart Failure (HF) Hospitalization (Adjudicated)
NCT00232180 (18) [back to overview]Number of Participants With First Occurrence of Hospitalization Due to Worsening Renal Function (Adjudicated)
NCT00232180 (18) [back to overview]Number of Participants With First Occurrence of All-Cause Mortality or All-Cause Hospitalization (Adjudicated)
NCT00232180 (18) [back to overview]Number of Participants With First Occurrence of Implantation of Resynchronization Device (Cardiac Resynchronization Therapy [CRT]) (Adjudicated)
NCT00232180 (18) [back to overview]Number of Participants With First Occurrence of Hospitalization Due to Hyperkalemia (Adjudicated)
NCT00232180 (18) [back to overview]Number of Participants With First Occurrence Of Heart Failure (HF) Mortality or Heart Failure (HF) Hospitalization (Adjudicated)
NCT00232180 (18) [back to overview]Number of Participants With First Occurrence of Heart Failure (HF) Hospitalization (Adjudicated)
NCT00232180 (18) [back to overview]Number of Participants With First Occurrence of Fatal or Non-fatal Stroke (Adjudicated)
NCT00232180 (18) [back to overview]Number of Participants With First Occurrence of Cardiovascular (CV) Mortality or Hospitalization Due to Heart Failure (HF) (Adjudicated): Up to Cut-off Date
NCT00232180 (18) [back to overview]Number of Participants With First Occurrence of All-Cause Mortality (Adjudicated)
NCT00391846 (8) [back to overview]Changes in Health-related Quality of Life
NCT00391846 (8) [back to overview]Changes in Heart Failure Symptoms
NCT00391846 (8) [back to overview]Total Number of Titration Steps in Prescribed Heart Failure Treatment
NCT00391846 (8) [back to overview]Composite Value of 3 Variables After 9 Months: Cardiovascular Death (Days Alive), Cardiovascular Hospitalization (Days Out of Hospital), Heart Failure Symptoms (Symptom Score Subset of the Kansas City Cardiomyopathy Questionnaire - Questions 3,5,7,9)
NCT00391846 (8) [back to overview]Changes in NT-proBNP Values Over Time in All Patients
NCT00391846 (8) [back to overview]Discontinuations
NCT00391846 (8) [back to overview]Number of CV Deaths
NCT00391846 (8) [back to overview]Number of Days in Hospital for CV Reason
NCT00515021 (2) [back to overview]Plasminogen Activator Inhibitor-1 (PAI-1) Levels
NCT00515021 (2) [back to overview]Plasminogen Activator Inhibitor-1 (PAI-1) Levels
NCT00758524 (15) [back to overview]Core Period: Dose Response Relationship of LCI699 as Measured by Change From Baseline in MSDBP at Week 8
NCT00758524 (15) [back to overview]Core Period: Dose Response Relationship of LCI699 as Measured by Change From Baseline in MSSBP at Week 8
NCT00758524 (15) [back to overview]Withdrawal Period: Change From Week 8 to Week 9 in MSDBP at Week 9, as Measured by OBP
NCT00758524 (15) [back to overview]Core Period: Number of Participants With Adverse Event (AEs), Serious Adverse Events (SAEs), and Deaths
NCT00758524 (15) [back to overview]Core Period: Percentage of Participants With a MSDBP Response and MSDBP Control at Week 8 LOCF
NCT00758524 (15) [back to overview]Withdrawal Period: Change From Week 8 to Week 9 in MSSBP at Week 9 as Measured by OBP
NCT00758524 (15) [back to overview]Core Period: Trough to Hour Ratio for Change From Baseline in 24-hour Mean Ambulatory DBP at Week 8
NCT00758524 (15) [back to overview]Core Period: Trough to Hour Ratio for Change From Baseline in 24-hour Mean Ambulatory SBP at Week 8
NCT00758524 (15) [back to overview]Core Period: Change From Baseline in Plasma Aldosterone Levels at Week 8
NCT00758524 (15) [back to overview]Core Period: Change From Baseline in Mean 24 Hour Ambulatory SBP at Week 8 as Measured by Ambulatory Blood Pressure Monitoring (ABPM)
NCT00758524 (15) [back to overview]Core Period: Change From Baseline in Mean 24 Hour Ambulatory DBP at Week 8, as Measured by ABPM
NCT00758524 (15) [back to overview]Core Period: Change From Baseline in Mean Sitting Diastolic Blood Pressure (MSDBP) at Week 8 Last Observation Carried Forward (LOCF), as Measured by Office Blood Pressure (OBP)
NCT00758524 (15) [back to overview]Core Period: Change From Baseline in Mean Sitting Systolic Blood Pressure (MSSBP) at Week 8 LOCF, as Measured by OBP
NCT00758524 (15) [back to overview]Core Period: Change From Baseline in Plasma Cortisol Levels by Adrenocorticotropic Hormone (ACTH) Stimulation Test
NCT00758524 (15) [back to overview]Core Period: Percentage of Participants With a MSSBP Response and MSSBP Control at Week 8 LOCF
NCT00817635 (16) [back to overview]Dose/Exposure BP Response Relationship of LCI699, as Measured by Change From Baseline in MSSBP at Week 8
NCT00817635 (16) [back to overview]Number of Participants With Cortisol Levels Below 500 Nmol/L at 1 Hour After Adrenocorticotropic Hormone (ACTH) Injection at Week 8
NCT00817635 (16) [back to overview]Percent Change From Baseline in RAAS Biomarker: Active Renin (ARC) in LCI699 Compared to Eplerenone 50mg at Week 8 LOCF
NCT00817635 (16) [back to overview]Percent Change From Baseline in RAAS Biomarker: Plasma Renin Activity (PRA) in LCI699 Compared to Eplerenone 50mg at Week 8 LOCF
NCT00817635 (16) [back to overview]Percent Change From Baseline in Renin-Angiotensin-Aldosterone-System (RAAS) Biomarker: Plasma Aldosterone (PA) in LCI699 Compared to Eplerenone 50 mg at Week 8 LOCF
NCT00817635 (16) [back to overview]Change From Baseline in Mean 24 Hours, Mean Daytime and Mean Nighttime DBP in LCI699 1mg QD Versus LCI699 0.5mg BID Arm at Week 4, as Measured by ABPM
NCT00817635 (16) [back to overview]Change From Baseline in Mean 24 Hours, Mean Daytime and Mean Nighttime Diastolic Blood Pressure (DBP) at Week 8 LOCF, as Measured by ABPM
NCT00817635 (16) [back to overview]Change From Baseline in Mean 24 Hours, Mean Daytime and Mean Nighttime SBP in LCI699 1mg QD Versus LCI699 0.5mg BID Arm at Week 4, as Measured by ABPM
NCT00817635 (16) [back to overview]Change From Baseline in Mean 24 Hours, Mean Daytime and Mean Nighttime Systolic Blood Pressure (SBP) at Week 8 LOCF, as Measured by Ambulatory Blood Pressure Measurement (ABPM)
NCT00817635 (16) [back to overview]Number of Participants With Adverse Event (AEs), Serious Adverse Events (SAEs), Hyperkalemia, and Hyponatremia
NCT00817635 (16) [back to overview]Percentage of Participants With a MSDBP Response and MSDBP Control at Week 8, as Measured by OBP
NCT00817635 (16) [back to overview]Percentage of Participants With a MSSBP Response and MSSBP Control at Week 8, as Measured by Office Blood Pressure (OBP)
NCT00817635 (16) [back to overview]Percent Change From Baseline in RAAS Biomarker: Ratio of PA to PRA in LCI699 Compared to Eplerenone 50mg at Week 8 LOCF
NCT00817635 (16) [back to overview]Change From Baseline in MSDBP at Week 8 LOCF
NCT00817635 (16) [back to overview]Change From Baseline in MSSBP at Week 8 Last Observation Carried Forward (LOCF)
NCT00817635 (16) [back to overview]Dose/Exposure BP Response Relationship of LCI699, as Measured by Change From Baseline in MSDBP at Week 8
NCT01115855 (22) [back to overview]Number of Participants With Change From Baseline in New York Heart Association (NYHA) Classification at Weeks 1, 4, Months 2, 3, 4, 5, 9, 13, 17 21, 25, 29, 33, 37, 42, 48 and Final Visit
NCT01115855 (22) [back to overview]Number of Participants With First Occurrence of Fatal/Non-Fatal Stroke
NCT01115855 (22) [back to overview]Number of Participants With With First Occurrence of All-Cause Mortality
NCT01115855 (22) [back to overview]Number of Participants With First Occurrence of Cardiovascular (CV) Mortality, Hospitalization Due to Heart Failure (HF), or Addition/Increase of Heart Failure (HF) Medication
NCT01115855 (22) [back to overview]Number of Participants With First Occurrence of Cardiovascular (CV) Hospitalization
NCT01115855 (22) [back to overview]Number of Participants With First Occurrence of All-cause Mortality or All-cause Hospitalization
NCT01115855 (22) [back to overview]Number of Participants With First Occurrence of All-cause Hospitalization
NCT01115855 (22) [back to overview]Number of Participants With First Occurrence of Addition/Increase of Heart Failure (HF) Medication Due to Heart Failure (HF) Worsening
NCT01115855 (22) [back to overview]Number of Participants With With First Occurrence of Cardiovascular Mortality
NCT01115855 (22) [back to overview]Change From Baseline in Left Ventricular Ejection Fraction (LVEF) at Months 5, 9, 13, 17, 21, 25, 29, 33, 37, 42, 48 and Final Visit
NCT01115855 (22) [back to overview]Number of Participants With First Occurrence of Heart Failure (HF) Mortality or Heart Failure (HF) Hospitalization
NCT01115855 (22) [back to overview]Number of Participants With First Occurrence of Cardiovascular (CV) Mortality or Hospitalization Due to Heart Failure (HF)
NCT01115855 (22) [back to overview]Number of Participants With First Occurrence of Hospitalisation Due to Worsening Renal Function
NCT01115855 (22) [back to overview]Number of Participants With First Occurrence of Hospitalization Due to Heart Failure (HF)
NCT01115855 (22) [back to overview]Change From Baseline in Plasma Concentration of Brain Natriuretic Peptide at Months 5, 9, 13, 17, 21, 25, 29, 33, 37, 42, 48 and Final Visit
NCT01115855 (22) [back to overview]Change From Baseline in Plasma Concentration of Serum N-terminal Pro-Brain Natriuretic Peptide (NT-proBNP) at Months 5, 9, 13, 17, 21, 25, 29, 33, 37, 42, 48 and Final Visit
NCT01115855 (22) [back to overview]Change From Baseline in Specific Activity Scale (SAS) Score at Week 4, Months 2, 3, 4, 5, 9, 13, 17 21, 25, 29, 33, 37, 42, 48 and Final Visit
NCT01115855 (22) [back to overview]Change From Baseline in Urine Albumin-to-Creatinine Ratio at Months 5, 9, 13, 17, 21, 25, 29, 33, 37, 42, 48 and Final Visit
NCT01115855 (22) [back to overview]Number of Participants With First Occurrence of New Onset Diabetes Mellitus
NCT01115855 (22) [back to overview]Number of Participants With First Occurrence of Fatal/Non-Fatal Myocardial Infarction (MI)
NCT01115855 (22) [back to overview]Number of Participants With First Occurrence of New Onset Atrial Fibrillation/Flutter
NCT01115855 (22) [back to overview]Number of Participants With First Occurrence of Hospitalization for Hyperkalemia
NCT01176968 (14) [back to overview]Diagnosis of Heart Failure
NCT01176968 (14) [back to overview]Electrocardiogram Q Wave to the End of the S Wave Corresponding to Ventricle Depolarization (QRS) Duration at 6 Months Post-randomization.
NCT01176968 (14) [back to overview]First and Each Subsequent Episode (After an Event Free Interval of ≥ 48 Hours) of Sustained Ventricular Tachycardia or Ventricular Fibrillation.
NCT01176968 (14) [back to overview]First Event of Cardiovascular Mortality, Re-hospitalization or Extended Initial Hospital Stay Due to Diagnosis of Heart Failure, Sustained Ventricular Tachycardia or Fibrillation, Ejection Fraction ≤40% or BNP Above Age Adjusted Cut Off
NCT01176968 (14) [back to overview]First Recorded Ejection Fraction (EF) of ≤40% (Recorded 1 Month or Later Post-randomization).
NCT01176968 (14) [back to overview]Second or Subsequent Non-fatal Myocardial Infarction (MI).
NCT01176968 (14) [back to overview]Change in Serum Levels of Biomarkers (Aldosterone and Cortisol) at 6 Months Post-randomization.
NCT01176968 (14) [back to overview]Change in Serum Levels of Biomarkers (PIIINP, Galectin 3, and PINP) at 6 Months Post-randomization.
NCT01176968 (14) [back to overview]Left Atrial Diameter (LAD) (Recorded on Each Occasion an Echocardiogram is Conducted).
NCT01176968 (14) [back to overview]Cardiovascular Mortality
NCT01176968 (14) [back to overview]Brain (B-type) Natriuretic Peptide (BNP) >200 pg/mL or NT-proBNP >450, >900 or >1800 pg/mL for Ages <50 Years, 50-75 Years and >75 Years, Respectively (Recorded 1 Month or Later Post-randomization).
NCT01176968 (14) [back to overview]Change in Serum Level of Biomarker (ICTP) at 6 Months Post-randomization.
NCT01176968 (14) [back to overview]Change in Serum Level of Biomarker (Interleukin-6) at 6 Months Post-randomization.
NCT01176968 (14) [back to overview]Decision to Provide an Implantable Cardioverter Defibrillator (ICD) or Cardiac Resynchronization Therapy (CRT).
NCT01237899 (4) [back to overview]Number of Participants With Clinically Significant Effects (Adverse Events)
NCT01237899 (4) [back to overview]Pharmacokinetics of LY2623091: Maximal Concentration (Cmax) at Day 6
NCT01237899 (4) [back to overview]Pharmacokinetics LY2623091: Area Under the Concentration-Time Curve (AUC) at Day 6
NCT01237899 (4) [back to overview]Pharmacodynamics: Serum to Urine Potassium Area Under the Concentration-Time Curve (AUC) Standardized for Urinary Excretion at Day 7
NCT01394627 (2) [back to overview]Change From Baseline in Cardiovascular Autonomic Function
NCT01394627 (2) [back to overview]Change From Baseline in Inflammation
NCT01405456 (12) [back to overview]Plasminogen Activator Inhibitor 1
NCT01405456 (12) [back to overview]C-Reactive Protein
NCT01405456 (12) [back to overview]Adiponectin
NCT01405456 (12) [back to overview]Hemoglobin A1c
NCT01405456 (12) [back to overview]Insulin Stimulated Glucose Uptake
NCT01405456 (12) [back to overview]Flow Mediated Vasodilation
NCT01405456 (12) [back to overview]Intramyocellular Lipid
NCT01405456 (12) [back to overview]Liver Fat
NCT01405456 (12) [back to overview]Markers of Immune Activation
NCT01405456 (12) [back to overview]Visceral Adipose Tissue
NCT01405456 (12) [back to overview]Potassium
NCT01405456 (12) [back to overview]Markers of Systemic Inflammation
NCT01427972 (5) [back to overview]The Number of Participants Who Died While on Study
NCT01427972 (5) [back to overview]PK: Maximum Plasma Concentration (Cmax) of LY2623091
NCT01427972 (5) [back to overview]Pharmacokinetics (PK): Area Under the Plasma Concentration Time Curve During the Dosing Period of LY2623091 (AUC0-τ)
NCT01427972 (5) [back to overview]Change From Baseline to Day 21 in Proteinuria Based on 24-hours Pooled Urine
NCT01427972 (5) [back to overview]Change From Baseline to Day 21 in Potassium Clearance Following an Oral Potassium Challenge
NCT01521546 (1) [back to overview]12-month Change in Myocardial Strain
NCT01786551 (3) [back to overview]Vascular and Systemic Inflammation as Measured by Interleukin-6 (IL-6) Serum Levels
NCT01786551 (3) [back to overview]Post-prandial Insulin Serum Levels
NCT01786551 (3) [back to overview]Post-prandial Glucose Serum Levels
NCT01807221 (12) [back to overview]Ratio of BNP at Specified Visits to BNP at Baseline
NCT01807221 (12) [back to overview]Number of Participants With Emergency Presentations for Worsening Chronic Heart Failure (WCHF)
NCT01807221 (12) [back to overview]Number of Participants With Death Due to Any Cause
NCT01807221 (12) [back to overview]Ratio of NT-proBNP at Specified Visits to NT-proBNP at Baseline
NCT01807221 (12) [back to overview]Percentage of Participants With a Relative Decrease in NT-proBNP of More Than 30% From Baseline to Day 90
NCT01807221 (12) [back to overview]Change From Baseline in Diastolic Blood Pressure at Specified Visits
NCT01807221 (12) [back to overview]Change From Baseline in EQ-5D-3L Questionnaire Scores at Specified Visits
NCT01807221 (12) [back to overview]Change From Baseline in KCCQ Questionnaire Scores at Specified Visits
NCT01807221 (12) [back to overview]Change From Baseline in Serum Potassium at Specified Visits
NCT01807221 (12) [back to overview]Change From Baseline in Heart Rate at Specified Visits
NCT01807221 (12) [back to overview]Change From Baseline in Systolic Blood Pressure at Specified Visits
NCT01807221 (12) [back to overview]Number of Participants With Cardiovascular Hospitalization
NCT01822561 (5) [back to overview]Change in Serum Potassium
NCT01822561 (5) [back to overview]Change in Best Corrected Visual Acuity
NCT01822561 (5) [back to overview]Change in Macular Thickness
NCT01822561 (5) [back to overview]Change in Subfoveal Choroidal Thickness, Study Eye
NCT01822561 (5) [back to overview]Complete Resolution of Subretinal Fluid
NCT01971593 (6) [back to overview]6 Minute Walk
NCT01971593 (6) [back to overview]Galectin 3
NCT01971593 (6) [back to overview]Procollagen III N-Terminal Peptide
NCT01971593 (6) [back to overview]Quality of Life
NCT01971593 (6) [back to overview]Serum Creatinine
NCT01971593 (6) [back to overview]Procollagen N-terminal Peptide 1
NCT01990677 (3) [back to overview]Proportion of Eyes Demonstrating a Reduction in Subretinal Fluid on OCT
NCT01990677 (3) [back to overview]Mean Change in Maximal Subretinal Fluid Height Based on Spectral Domain Optical Coherence Tomography (OCT) Measurement.
NCT01990677 (3) [back to overview]Mean Change in Subfoveal Fluid Height Based on OCT Measurement
NCT01996449 (2) [back to overview]Muscle Sympathetic Nerve Activity at Rest
NCT01996449 (2) [back to overview]Muscle Sympathetic Nerve Activity During Exercise
NCT02354352 (1) [back to overview]Left Ventricular Strain
NCT02525796 (2) [back to overview]Change in Calcium Levels
NCT02525796 (2) [back to overview]Change in Parathyroid Hormone Levels
NCT02532998 (27) [back to overview]Time to Reach Maximum Concentration (Tmax) of Eplerenone.
NCT02532998 (27) [back to overview]Apparent Clearance (CL/F) of AZD9977.
NCT02532998 (27) [back to overview]Apparent Clearance (CL/F) of Eplerenone.
NCT02532998 (27) [back to overview]Apparent Volume of Distribution at Terminal Phase (Vz/F) of AZD9977.
NCT02532998 (27) [back to overview]Apparent Volume of Distribution at Terminal Phase (Vz/F) of Eplerenone.
NCT02532998 (27) [back to overview]Area Under Plasma Concentration-time Curve From Zero Extrapolated to Infinity (AUC) of AZD9977.
NCT02532998 (27) [back to overview]Area Under Plasma Concentration-time Curve From Zero Extrapolated to Infinity (AUC) of Eplerenone.
NCT02532998 (27) [back to overview]Area Under the Plasma Concentration-time Curve From Time Zero to t Hours After Dosing (AUC(0-t)) of Eplerenone.
NCT02532998 (27) [back to overview]Area Under the Plasma Concentration-time Curve From Time Zero to t Hours After Dosing (AUC[0-t]) of AZD9977.
NCT02532998 (27) [back to overview]Number of Participants With Clinically Significant Blood Pressure Values.
NCT02532998 (27) [back to overview]Number of Participants With Clinically Significant Electrocardiogram.
NCT02532998 (27) [back to overview]Number of Participants With Clinically Significant Physical Examination Values.
NCT02532998 (27) [back to overview]Number of Participants With Clinically Significant Pulse Rate.
NCT02532998 (27) [back to overview]Number of Participants With Clinically Significant Safety Laboratory Tests Values.
NCT02532998 (27) [back to overview]Observed Maximum Concentration (Cmax) of AZD9977
NCT02532998 (27) [back to overview]Observed Maximum Concentration (Cmax) of Eplerenone.
NCT02532998 (27) [back to overview]Pharmacodynamics of AZD9977 Assessed Per Sodium/Potassium Ratio in Urine in AZD9977 Treatment With Placebo Versus Treatment With AZD9977.
NCT02532998 (27) [back to overview]Pharmacodynamics of AZD9977 Assessed Per Sodium/Potassium Ratio in Urine in Eplerenone Treatment Versus a Combination Treatment of Eplerenone and AZD9977.
NCT02532998 (27) [back to overview]Terminal Half-life (t½λz) of AZD9977.
NCT02532998 (27) [back to overview]Terminal Half-life (t½λz) of Eplerenone.
NCT02532998 (27) [back to overview]Time to Reach Maximum Concentration (Tmax) of AZD9977.
NCT02532998 (27) [back to overview]Pharmacodynamics of AZD9977 Assessed by Estimating the Fractional Sodium Excretion in Urine for Each Urine Collection Time Interval.
NCT02532998 (27) [back to overview]Pharmacodynamics of AZD9977 Assessed Per Total Sodium Excreted Cumulatively and During Each of the Urine Collection Intervals.
NCT02532998 (27) [back to overview]Pharmacodynamics of AZD9977 Assessed Per Urine Production for Each Urine Collection Time Interval.
NCT02532998 (27) [back to overview]Pharmacodynamics of AZD9977 by Assessment of Total Potassium Excreted Cumulatively and During Each of the Urine Collection Intervals
NCT02532998 (27) [back to overview]Pharmacodynamics of AZD9977 by Assessment of Total Urine Volume Excreted Cumulatively and During Each of the Urine Collection Intervals
NCT02532998 (27) [back to overview]Pharmacodynamics of AZD9977 Assessed Per Fractional Potassium Excretion in Urine for Each Urine Collection Time Interval.
NCT02629094 (2) [back to overview]Improvement of Cardiac Steatosis: Mean Change in Intraventricular Septum Percentage of Lipid by MR Spectroscopy.
NCT02629094 (2) [back to overview]Improvement of Hepatic Steatosis: Mean Change in Hepatic Percentage of Lipid by MR Spectroscopy
NCT02740179 (16) [back to overview]Markers of Vascular Dysfunction
NCT02740179 (16) [back to overview]Myocardial Inflammation
NCT02740179 (16) [back to overview]Markers of Systemic Inflammation hsCRP
NCT02740179 (16) [back to overview]Myocardial Perfusion by MRI
NCT02740179 (16) [back to overview]Myocardial Perfusion by PET
NCT02740179 (16) [back to overview]Markers of Subclinical Injury
NCT02740179 (16) [back to overview]Markers of Immune Activation sCD163
NCT02740179 (16) [back to overview]Markers of Immune Activation MCP-1
NCT02740179 (16) [back to overview]Markers of Fibrosis
NCT02740179 (16) [back to overview]Markers of Arterial Inflammation
NCT02740179 (16) [back to overview]Coronary Plaque
NCT02740179 (16) [back to overview]Assessment of Cardiac Systolic Function Via Cardiac Imaging
NCT02740179 (16) [back to overview]Assessment of Cardiac Structure by Left Ventricular Mass on Cardiac Imaging
NCT02740179 (16) [back to overview]Assessment of Cardiac Diastolic Function Via Cardiac Imaging
NCT02740179 (16) [back to overview]Arterial Inflammation
NCT02740179 (16) [back to overview]Markers of Systemic Inflammation hsIL-6
NCT03342690 (6) [back to overview]Percentage of Participants With Adverse Drug Reactions in Chronic Heart Failure Participants With Moderate Renal Impairment
NCT03342690 (6) [back to overview]Percentage of Participants With Adverse Drug Reactions in Chronic Heart Failure Participants
NCT03342690 (6) [back to overview]The Overall Mortality Rate
NCT03342690 (6) [back to overview]The Number of Deaths (Overall Deaths)
NCT03342690 (6) [back to overview]The Number of Deaths (Cardiovascular Deaths)
NCT03342690 (6) [back to overview]The Cardiovascular-related Mortality Rate
NCT03923530 (7) [back to overview]Kansas City Cardiomyopathy Questionnaire (KCCQ-12)-Quality of Life Score
NCT03923530 (7) [back to overview]Diastolic Blood Pressure
NCT03923530 (7) [back to overview]Kansas City Cardiomyopathy Questionnaire (KCCQ-12)-Physical Limitation Score
NCT03923530 (7) [back to overview]Kansas City Cardiomyopathy Questionnaire (KCCQ-12)-Social Limitation Score
NCT03923530 (7) [back to overview]Kansas City Cardiomyopathy Questionnaire (KCCQ-12)-Summary Score
NCT03923530 (7) [back to overview]Kansas City Cardiomyopathy Questionnaire (KCCQ-12)-Symptom Frequency Score
NCT03923530 (7) [back to overview]Systolic Blood Pressure

Epicardial Coronary Artery Endothelial Function (Adjusted) at Week 16 Comparing the Eplerenone Group to the Placebo Group

The primary measure was the relative change in coronary diameter to acetylcholinem (ACH) at 16 weeks adjusted for baseline reactivity to acetylcholine. Change in coronary artery diameter after ACH was measured in mm at baseline and 16 weeks. Percent change at 16 weeks - percent change at baseline was the outcome. (NCT00187889)
Timeframe: 16 weeks

Intervention% change wk16-%change wk0- unitless (Mean)
EPLERINONE-1.2
PLACEBO-10.7

[back to top]

Microvascular Coronary Flow Reserve(Adjusted) at Week 16 Adjusted for Baseline Coronary Flow Reserve Comparing the Eplerenone Group to the Placebo Group

Coronary flow reserve is a ratio of coronary blood flow velocity before and after adenosine. The outcome measure is the difference between the coronary flow reserve at 16 weeks adjusted for coronary flow reserve at baseline. (NCT00187889)
Timeframe: 16 weeks

Interventiondifference of ratios (unitless) (Mean)
EPLERENONE-0.4
PLACEBO-0.4

[back to top]

Number of Participants With First Occurrence of Fatal or Non-fatal Myocardial Infarction (Adjudicated)

(NCT00232180)
Timeframe: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)

,
Interventionparticipants (Number)
Up to 50 months (cut-off) (n= 1364, 1373)Up to 59.5 months (complete DB) (n= 1367, 1376)
Eplerenone: Double-blind Phase4549
Placebo: Double-blind Phase3340

[back to top]

Number of Participants With First Occurrence of Cardiovascular (CV) Mortality (Adjudicated)

CV mortality is defined as death due to heart failure, myocardial infarction, cardiac arrhythmia, stroke or cerebral vascular accident (CVA), other CV cause (such as aneurysm or pulmonary embolism). (NCT00232180)
Timeframe: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)

,
Interventionparticipants (Number)
Up to 50 months (cut-off) (n= 1364, 1373)Up to 59.5 months (complete DB) (n= 1367, 1376)
Eplerenone: Double-blind Phase147178
Placebo: Double-blind Phase185215

[back to top]

Number of Participants With First Occurrence of Cardiovascular (CV) Hospitalization (Adjudicated)

First occurrence of CV hospitalization. CV hospitalization is defined as hospitalization due to HF (first or subsequent), acute myocardial infarction, angina pectoris (unstable), cardiac arrhythmia (atrial fibrillation [AF], atrial flutter, supraventricular arrhythmias, or ventricular arrhythmias), stroke/CVA, other CV reasons (such as hypotension or peripheral vascular disease), implantation of a cardioverter defibrillator (ICD), or cardiac resynchronization therapy (CRT) with CV event as the primary reason for hospitalization as determined by endpoint committee adjudicator. (NCT00232180)
Timeframe: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)

,
Interventionparticipants (Number)
Up to 50 months (cut-off) (n= 1364, 1373)Up to 59.5 months (complete DB) (n= 1367, 1376)
Eplerenone: Double-blind Phase304346
Placebo: Double-blind Phase399439

[back to top]

Number of Participants With First Occurrence of Implantation of Cardiac Defibrillator (ICD) (Adjudicated)

First occurrence of implantation of cardiac defibrillator (ICD). ICD is an electronic device capable of monitoring the heart rhythm. When the heart is beating normally, the device remains inactive. If the heart develops a life-threatening tachycardia, the ICD delivers electrical shocks to the heart to terminate the abnormal rhythm and return the heart rhythm to normal. (NCT00232180)
Timeframe: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)

,
Interventionparticipants (Number)
Up to 50 months (cut-off) (n= 1364, 1373)Up to 59.5 months (complete DB) (n= 1367, 1376)
Eplerenone: Double-blind Phase6176
Placebo: Double-blind Phase5978

[back to top]

Number of Participants With New Onset Diabetes Mellitus (DM)

The definition of new onset diabetes mellitus is the diagnosis of diabetes mellitus in a participant after randomization, when DM was not present before randomization. (NCT00232180)
Timeframe: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)

,
Interventionparticipants (Number)
Up to 50 months (cut-off) (n= 904, 973)Up to 59.5 months (complete DB) (n= 907, 975)
Eplerenone: Double-blind Phase3442
Placebo: Double-blind Phase4047

[back to top]

Number of Participants With New Onset Atrial Fibrillation or Flutter

New onset of atrial fibrillation or flutter is defined as the diagnosis of atrial fibrillation or flutter in a participant after randomization, where atrial fibrillation was not present before randomization. (NCT00232180)
Timeframe: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)

,
Interventionparticipants (Number)
Up to 50 months (cut-off) (n= 950, 937)Up to 59.5 months (complete DB) (n= 956, 940)
Eplerenone: Double-blind Phase3241
Placebo: Double-blind Phase5259

[back to top]

Number of Participants With First Occurrence of Cardiovascular (CV) Mortality or Hospitalization Due to Heart Failure (HF) (Adjudicated)

CV mortality is defined as death due to heart failure, myocardial infarction, cardiac arrhythmia, stroke or cerebral vascular accident (CVA), other CV cause (such as aneurysm or pulmonary embolism). Hospitalization due to HF is defined as an overnight stay, or longer, in a hospital environment (emergency room, observation unit or in-patient care, or similar facility including admission to a day care facility) due to HF as the primary reason for hospitalization as determined by the endpoint committee adjudicator. (NCT00232180)
Timeframe: Baseline (30 March 2006) up to 59.5 months (complete DB phase: 18 March 2011)

Interventionparticipants (Number)
Eplerenone: Double-blind Phase288
Placebo: Double-blind Phase392

[back to top]

Number of Participants With First Occurrence of All-Cause Hospitalization (Adjudicated)

Hospitalization due to any cause is defined as an overnight stay, or longer, in a hospital environment (emergency room, observation unit or in-patient care, or similar facility including admission to a day care facility). (NCT00232180)
Timeframe: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)

,
Interventionparticipants (Number)
Up to 50 months (cut-off) (n= 1364, 1373)Up to 59.5 months (complete DB) (n= 1367, 1376)
Eplerenone: Double-blind Phase408463
Placebo: Double-blind Phase491552

[back to top]

Number of Participants With First Occurrence of All-Cause Mortality or Heart Failure (HF) Hospitalization (Adjudicated)

Death due to any cause or first of occurrence HF hospitalization. HF hospitalization is defined as an overnight stay, or longer, in a hospital environment (emergency room, observation unit or in-patient care, or similar facility including admission to a day care facility) due to HF as the primary reason for hospitalization as determined by the endpoint committee adjudicator. (NCT00232180)
Timeframe: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)

,
Interventionparticipants (Number)
Up to 50 months (cut-off) (n= 1364, 1373)Up to 59.5 months (complete DB) (n= 1367, 1376)
Eplerenone: Double-blind Phase270311
Placebo: Double-blind Phase376418

[back to top]

Number of Participants With First Occurrence of Hospitalization Due to Worsening Renal Function (Adjudicated)

First occurrence of hospitalization due to worsening renal function. Hospitalization due to worsening renal function is defined as an overnight stay, or longer, in a hospital environment (emergency room, observation unit or in-patient care, or similar facility including admission to a day care facility) due to worsening renal function as the primary reason for hospitalization as determined by endpoint committee adjudicator. Worsening renal function is defined as doubling of serum creatinine level from baseline level. (NCT00232180)
Timeframe: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)

,
Interventionparticipants (Number)
Up to 50 months (cut-off) (n= 1364, 1373)Up to 59.5 months (complete DB) (n= 1367, 1376)
Eplerenone: Double-blind Phase910
Placebo: Double-blind Phase810

[back to top]

Number of Participants With First Occurrence of All-Cause Mortality or All-Cause Hospitalization (Adjudicated)

Death due to any cause or hospitalization due to any cause. Hospitalization due to any cause is defined as an overnight stay, or longer, in a hospital environment (emergency room, observation unit or in-patient care, or similar facility including admission to a day care facility). (NCT00232180)
Timeframe: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)

,
Interventionparticipants (Number)
Up to 50 months (cut-off) (n= 1364, 1373)Up to 59.5 months (complete DB) (n= 1367, 1376)
Eplerenone: Double-blind Phase462530
Placebo: Double-blind Phase569636

[back to top]

Number of Participants With First Occurrence of Implantation of Resynchronization Device (Cardiac Resynchronization Therapy [CRT]) (Adjudicated)

First occurrence of implantation of resynchronization device. CRT is use of a specialized pacemaker to re-coordinate the action of the right and left ventricles in heart failure. (NCT00232180)
Timeframe: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)

,
Interventionparticipants (Number)
Up to 50 months (cut-off) (n= 1364, 1373)Up to 59.5 months (complete DB) (n= 1367, 1376)
Eplerenone: Double-blind Phase3345
Placebo: Double-blind Phase4153

[back to top]

Number of Participants With First Occurrence of Hospitalization Due to Hyperkalemia (Adjudicated)

First occurrence of hospitalization due to hyperkalemia. Hospitalization due to hyperkalemia is defined as an overnight stay, or longer, in a hospital environment (emergency room, observation unit or in-patient care, or similar facility including admission to a day care facility) due to hyperkalemia as the primary reason for hospitalization as determined by endpoint committee adjudicator. Hyperkalemia is defined as serum potassium level greater than (>) 5.5 milliequivalents per liter (mEq/L). (NCT00232180)
Timeframe: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)

,
Interventionparticipants (Number)
Up to 50 months (cut-off) (n= 1364, 1373)Up to 59.5 months (complete DB) (n= 1367, 1376)
Eplerenone: Double-blind Phase44
Placebo: Double-blind Phase33

[back to top]

Number of Participants With First Occurrence Of Heart Failure (HF) Mortality or Heart Failure (HF) Hospitalization (Adjudicated)

Death due to HF or first occurrence of HF hospitalization. Hospitalization due to HF is defined as an overnight stay, or longer, in a hospital environment (emergency room, observation unit or in-patient care, or similar facility including admission to a day care facility) due to HF as the primary reason for hospitalization as determined by the endpoint committee adjudicator. (NCT00232180)
Timeframe: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)

,
Interventionparticipants (Number)
Up to 50 months (cut-off) (n= 1364, 1373)Up to 59.5 months (complete DB) (n= 1367, 1376)
Eplerenone: Double-blind Phase170194
Placebo: Double-blind Phase262287

[back to top]

Number of Participants With First Occurrence of Heart Failure (HF) Hospitalization (Adjudicated)

First occurrence of HF hospitalization. Hospitalization due to HF is defined as an overnight stay, or longer, in a hospital environment (emergency room, observation unit or in-patient care, or similar facility including admission to a day care facility) due to HF as the primary reason for hospitalization as determined by the endpoint committee adjudicator. (NCT00232180)
Timeframe: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)

,
Interventionparticipants (Number)
Up to 50 months (cut-off) (n= 1364, 1373)Up to 59.5 months (complete DB) (n= 1367, 1376)
Eplerenone: Double-blind Phase164186
Placebo: Double-blind Phase253277

[back to top]

Number of Participants With First Occurrence of Fatal or Non-fatal Stroke (Adjudicated)

(NCT00232180)
Timeframe: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)

,
Interventionparticipants (Number)
Up to 50 months (cut-off) (n= 1364, 1373)Up to 59.5 months (complete DB) (n= 1367, 1376)
Eplerenone: Double-blind Phase2124
Placebo: Double-blind Phase2631

[back to top]

Number of Participants With First Occurrence of Cardiovascular (CV) Mortality or Hospitalization Due to Heart Failure (HF) (Adjudicated): Up to Cut-off Date

CV mortality is defined as death due to heart failure, myocardial infarction, cardiac arrhythmia, stroke or cerebral vascular accident (CVA), other CV cause (such as aneurysm or pulmonary embolism). Hospitalization due to HF is defined as an overnight stay, or longer, in a hospital environment (emergency room, observation unit or in-patient care, or similar facility including admission to a day care facility) due to HF as the primary reason for hospitalization as determined by the endpoint committee adjudicator. (NCT00232180)
Timeframe: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010)

Interventionparticipants (Number)
Eplerenone: Double-blind Phase249
Placebo: Double-blind Phase356

[back to top]

Number of Participants With First Occurrence of All-Cause Mortality (Adjudicated)

Death due to any cause. (NCT00232180)
Timeframe: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)

,
Interventionparticipants (Number)
Up to 50 months (cut-off) (n= 1364, 1373)Up to 59.5 months (complete DB) (n= 1367, 1376)
Eplerenone: Double-blind Phase171205
Placebo: Double-blind Phase213253

[back to top] [back to top]

Changes in Heart Failure Symptoms

Changes from baseline in the symptom score subset (question 3, 5, 7 and 9) of KCCQ (swelling, fatigue, shortness of breath, shortness of breath night time). KCCQ is a self-administered by patient symptom score, where higher score reflect better health status. Scale scores are transformed to a 0 to 100 range by subtracting the lowest possible scale score, dividing by the range of the scale and multiplying by 100. This mean that the KCCQ scale is from 0 to 100 with the higher value showing a better health status. (NCT00391846)
Timeframe: 9 months and baseline

InterventionCategorial scale (Mean)
Guided by NT-proBNP3.67
Not Guided by NT-proBNP6.11

[back to top]

Total Number of Titration Steps in Prescribed Heart Failure Treatment

Each titration step in prescribed medication is counted as one step, either up or down. One step up indicates an increase of dose in prescribed medication and one step down indicates a decrease of dose in prescribed medication. The sum of steps is given as a score. Score is given for each arm as a total number of titration steps for all patients in arm. (NCT00391846)
Timeframe: 9 months

InterventionTitration steps (Number)
Guided by NT-proBNP517
Not Guided by NT-proBNP485

[back to top]

Composite Value of 3 Variables After 9 Months: Cardiovascular Death (Days Alive), Cardiovascular Hospitalization (Days Out of Hospital), Heart Failure Symptoms (Symptom Score Subset of the Kansas City Cardiomyopathy Questionnaire - Questions 3,5,7,9)

The non-parametric scale is constructed from 3 variables, modified after Cleland. Each patient receives a rank score from 1 to 246 (246-number of patients in the study). The lowest score receive patients who die (due to CV event), next patients still alive at end-of-study with the worst composite score, the best alive patients with 0 days in hospital and the largest improvement in the KCCQ (self-administered by patient symptom score, where the higher score reflect better health status). Scores will be summarized using non-parametric calculations. The mean of non-parametric scores is presented (NCT00391846)
Timeframe: 9 months

InterventionScores on a scale (Mean)
Guided by NT-proBNP118.6
Not Guided by NT-proBNP128.4

[back to top]

Changes in NT-proBNP Values Over Time in All Patients

The 95% confidential interval (CI) is given as measure of dispersion (NCT00391846)
Timeframe: 9 months and baseline

Interventionng/L (Geometric Mean)
Guided by NT-proBNP2332.1
Not Guided by NT-proBNP2063

[back to top]

Discontinuations

Number of patients discontinued due to adverse events' (NCT00391846)
Timeframe: 9 months

InterventionParticipants (Number)
Guided by NT-proBNP8
Not Guided by NT-proBNP6

[back to top]

Number of CV Deaths

Number of deaths (NCT00391846)
Timeframe: 9 months

InterventionParticipants (Number)
Guided by NT-proBNP4
Not Guided by NT-proBNP5

[back to top]

Number of Days in Hospital for CV Reason

Each overnight stay is counted as one day. The lower the better (NCT00391846)
Timeframe: 9 months

InterventionDays in hospital (Mean)
Guided by NT-proBNP5.79
Not Guided by NT-proBNP5.94

[back to top]

Plasminogen Activator Inhibitor-1 (PAI-1) Levels

PAI-1 levels after Eplerenone 50mg daily for 2 weeks then 100mg daily for 4 weeks. Time of administration varied in the arms, either morning or night time dosing. (NCT00515021)
Timeframe: after 6 weeks on Eplerenone

Interventionng/ml (Mean)
Eplerenone: Morning Administration39.9
Eplerenone: Night-time Administration40.4

[back to top]

Plasminogen Activator Inhibitor-1 (PAI-1) Levels

baseline PAI-1 levels prior to drug administration (NCT00515021)
Timeframe: Baseline

Interventionng/ml (Mean)
Eplerenone: Morning Administration Then Evening41.5
Eplerenone: Evening Administration Then Morning42.9

[back to top]

Core Period: Dose Response Relationship of LCI699 as Measured by Change From Baseline in MSDBP at Week 8

Automated arterial BP determinations were made after the participant was in the sitting position for 5 minutes according to the Guidelines for management of hypertension: report of the 4th working party of the British Hypertension Society, 2004-BHS IV, using an automated BP device (such as the Omron BP monitor). The change in the MSDBP was calculated comparing the Week 8 readings to the readings taken at Baseline. The change from baseline in MSDBP was analyzed using an analysis of covariance model (ANCOVA) with treatment and region as factors and baseline MSDBP level as a covariate. (NCT00758524)
Timeframe: Baseline, Week 8

Interventionmm Hg (Mean)
Core Period: LCI699 0.25 mg QD-4.47
Core Period: LCI699 0.5 mg QD-5.50
Core Period: LCI699 1.0 mg QD-7.11
Core Period: LCI699 0.5 mg BID-4.25

[back to top]

Core Period: Dose Response Relationship of LCI699 as Measured by Change From Baseline in MSSBP at Week 8

Automated arterial BP determinations were made after the participant was in the sitting position for 5 minutes according to the Guidelines for management of hypertension: report of the 4th working party of the British Hypertension Society, 2004-BHS IV, using an automated BP device (such as the Omron BP monitor). The change in the MSSBP was calculated comparing the Week 8 readings to the readings taken at Baseline. The change from baseline in MSSBP was analyzed using an ANCOVA with treatment and region as factors and baseline MSSBP levels as a covariate. (NCT00758524)
Timeframe: Baseline, Week 8

Interventionmm Hg (Mean)
Core Period: LCI699 0.25 mg QD-9.00
Core Period: LCI699 0.5 mg QD-10.69
Core Period: LCI699 1.0 mg QD-11.93
Core Period: LCI699 0.5 mg BID-9.10

[back to top]

Withdrawal Period: Change From Week 8 to Week 9 in MSDBP at Week 9, as Measured by OBP

Automated arterial BP determinations were made after the participant was in the sitting position for 5 minutes according to the Guidelines for management of hypertension: report of the 4th working party of the British Hypertension Society, 2004-BHS IV, using an automated BP device (such as the Omron BP monitor). The change in the MSDBP was calculated comparing the Week 9 readings to the readings taken at Week 8 (Baseline). The change from Week 8 to week 9 in MSDBP was analyzed using an ANCOVA with treatment and region as factors and Week 8 MSDBP level as a covariate. (NCT00758524)
Timeframe: From Week 8 to Week 9

Interventionmm Hg (Least Squares Mean)
Withdrawal Period: LCI699 0.25 mg QD0.5
Withdrawal Period: LCI699 0.25 mg QD Placebo0.5
Withdrawal Period: LCI699 0.5 mg QD1.6
Withdrawal Period: LCI699 0.5 mg QD Placebo-0.2
Withdrawal Period: LCI699 1.0 mg QD-0.5
Withdrawal Period: LCI699 1.0 mg QD Placebo2.5
Withdrawal Period: LCI699 0.5 mg BID1.3
Withdrawal Period: LCI699 0.5 mg BID Placebo1.3
Withdrawal Period: Eplerenone 50 mg BID-1.2
Withdrawal Period: Eplerenone 50 mg BID Placebo0.4
Withdrawal Period: Placebo1.6

[back to top]

Core Period: Number of Participants With Adverse Event (AEs), Serious Adverse Events (SAEs), and Deaths

An AE was an adverse medical event which occurs in a participant of the study and which is not necessarily in a causal relationship with the treatment the participant receives. SAEs were AEs leading to death, are life-threatening, require hospitalizations or prolongation of hospitalizations, represent an innate malformation or a congenital abnormality. (NCT00758524)
Timeframe: AEs: From start of the study drug treatment up to 8 weeks; SAE: From signing of the informed consent up to 8 weeks

,,,,,
InterventionParticipants (Count of Participants)
AEsSAEsDeaths
Core Period: Eplerenone 50 mg BID2600
Core Period: LCI699 0.25 mg QD2310
Core Period: LCI699 0.5 mg BID2700
Core Period: LCI699 0.5 mg QD2200
Core Period: LCI699 1.0 mg QD2400
Core Period: Placebo2310

[back to top]

Core Period: Percentage of Participants With a MSDBP Response and MSDBP Control at Week 8 LOCF

MSDBP response was defined as the percentage of participants with a MSDBP <90 mmHg or a >=10 mmHg reduction from Baseline. MSDBP control was defined as the percentage of participants with a MSDBP <90 mmHg. (NCT00758524)
Timeframe: Baseline, Week 8

,,,,,
Interventionpercentage of participants (Number)
MSDBP ResponseMSDBP Control
Core Period: Eplerenone 50 mg BID48.845.2
Core Period: LCI699 0.25 mg QD39.132.6
Core Period: LCI699 0.5 mg BID34.429.2
Core Period: LCI699 0.5 mg QD34.129.4
Core Period: LCI699 1.0 mg QD50.041.9
Core Period: Placebo27.618.4

[back to top]

Withdrawal Period: Change From Week 8 to Week 9 in MSSBP at Week 9 as Measured by OBP

Automated arterial BP determinations were made after the participant was in the sitting position for 5 minutes according to the Guidelines for management of hypertension: report of the 4th working party of the British Hypertension Society, 2004-BHS IV, using an automated BP device (such as the Omron BP monitor). The change in the MSSBP was calculated comparing the Week 9 readings to the readings taken at Week 8 (Baseline). The change from Week 8 to week 9 in MSSBP was analyzed using an ANCOVA with treatment and region as factors and Week 8 MSSBP level as a covariate. (NCT00758524)
Timeframe: From Week 8 to Week 9

Interventionmm Hg (Least Squares Mean)
Withdrawal Period: LCI699 0.25 mg QD0.3
Withdrawal Period: LCI699 0.25 mg QD Placebo3.3
Withdrawal Period: LCI699 0.5 mg QD0.5
Withdrawal Period: LCI699 0.5 mg QD Placebo2.5
Withdrawal Period: LCI699 1.0 mg QD0.4
Withdrawal Period: LCI699 1.0 mg QD Placebo5.3
Withdrawal Period: LCI699 0.5 mg BID1.6
Withdrawal Period: LCI699 0.5 mg BID Placebo4.4
Withdrawal Period: Eplerenone 50 mg BID-1.5
Withdrawal Period: Eplerenone 50 mg BID Placebo2.7
Withdrawal Period: Placebo1.8

[back to top]

Core Period: Trough to Hour Ratio for Change From Baseline in 24-hour Mean Ambulatory DBP at Week 8

Trough to peak ratios were derived from an ANCOVA model containing treatment, region, hour, treatment by hour interaction as factors with Baseline as a covariate. (NCT00758524)
Timeframe: Baseline, every hour up to 24 hours post-dose at Week 8

,,,,,
Interventionratio (Least Squares Mean)
Week 8, Hour 1Week 8, Hour 2Week 8, Hour 3Week 8, Hour 4Week 8, Hour 5Week 8, Hour 6Week 8, Hour 7Week 8, Hour 8Week 8, Hour 9Week 8, Hour 10Week 8, Hour 11Week 8, Hour 12Week 8, Hour 13Week 8, Hour 14Week 8, Hour 15Week 8, Hour 16Week 8, Hour 17Week 8, Hour 18Week 8, Hour 19Week 8, Hour 20Week 8, Hour 21Week 8, Hour 22Week 8, Hour 23Week 8, Hour 24
Core Period: Eplerenone 50 mg BID0.17-1.65-2.42-1.39-2.91-4.86-3.70-2.30-2.81-2.43-1.93-3.20-5.35-7.64-9.03-12.55-12.88-13.49-10.13-10.47-10.51-7.60-5.54-2.78
Core Period: LCI699 0.25 mg QD3.911.441.160.511.11-1.18-1.85-3.01-1.24-0.59-1.02-1.60-4.32-6.47-8.34-8.92-10.26-10.68-10.13-10.73-9.31-7.90-4.94-0.21
Core Period: LCI699 0.5 mg BID3.873.444.012.641.451.201.212.093.270.491.54-1.06-1.45-2.96-6.10-9.54-10.38-11.85-10.78-10.49-8.22-6.35-2.671.36
Core Period: LCI699 0.5 mg QD2.951.851.132.91-0.02-2.36-0.95-1.38-0.072.601.722.53-1.20-3.29-5.82-8.37-10.99-11.73-10.12-8.06-7.68-4.93-1.931.45
Core Period: LCI699 1.0 mg QD0.270.17-0.360.35-1.69-3.01-2.63-2.43-2.25-1.65-1.54-3.10-5.31-7.38-8.89-10.50-12.71-11.88-9.74-10.43-9.66-5.37-1.180.29
Core Period: Placebo7.116.284.997.024.311.823.622.653.303.862.383.241.52-0.90-1.01-1.61-4.20-6.89-5.84-5.21-4.12-1.091.821.98

[back to top]

Core Period: Trough to Hour Ratio for Change From Baseline in 24-hour Mean Ambulatory SBP at Week 8

Trough to peak ratios were derived from an ANCOVA model containing treatment, region, hour, treatment by hour interaction as factors with Baseline as a covariate. (NCT00758524)
Timeframe: Baseline, every hour up to 24 hours post-dose at Week 8

,,,,,
Interventionratio (Least Squares Mean)
Week 8, Hour 1Week 8, Hour 2Week 8, Hour 3Week 8, Hour 4Week 8, Hour 5Week 8, Hour 6Week 8, Hour 7Week 8, Hour 8Week 8, Hour 9Week 8, Hour 10Week 8, Hour 11Week 8, Hour 12Week 8, Hour 13Week 8, Hour 14Week 8, Hour 15Week 8, Hour 16Week 8, Hour 17Week 8, Hour 18Week 8, Hour 19Week 8, Hour 20Week 8, Hour 21Week 8, Hour 22Week 8, Hour 23Week 8, Hour 24
Core Period: Eplerenone 50 mg BID-5.33-5.90-5.89-5.12-7.22-7.91-8.70-8.06-7.46-7.35-5.75-6.25-8.81-10.91-12.04-16.68-19.59-18.55-15.49-16.09-15.34-12.47-9.02-8.90
Core Period: LCI699 0.25 mg QD-0.54-1.59-2.11-2.06-4.29-4.21-4.95-5.28-3.98-3.69-2.47-5.19-6.45-7.37-10.61-11.71-13.71-14.49-13.78-13.92-14.33-13.46-7.88-3.16
Core Period: LCI699 0.5 mg BID-1.42-0.570.911.50-1.70-1.02-0.76-3.02-1.87-1.73-1.74-3.92-4.05-6.12-9.78-13.03-13.72-15.60-15.93-15.47-13.63-10.55-6.73-3.76
Core Period: LCI699 0.5 mg QD0.090.15-1.53-1.18-3.09-3.12-2.10-4.69-1.59-0.30-0.430.73-2.30-5.68-8.28-10.01-11.96-14.37-13.08-13.22-10.06-8.35-6.23-0.64
Core Period: LCI699 1.0 mg QD-4.51-3.56-4.86-4.15-3.47-5.88-5.40-5.30-4.78-3.40-4.22-4.35-7.25-9.33-11.26-12.63-15.46-14.54-12.85-12.54-12.78-7.52-5.77-3.45
Core Period: Placebo8.236.484.604.682.781.422.253.762.392.543.514.693.200.750.02-0.33-3.03-6.35-6.98-6.53-3.89-0.942.180.70

[back to top]

Core Period: Change From Baseline in Plasma Aldosterone Levels at Week 8

Change from baseline was analyzed using plasma aldosterone values measured at Baseline and Week 8. (NCT00758524)
Timeframe: Baseline, Week 8

Interventionpicomoles per liter (pmol/L) (Mean)
Core Period: LCI699 0.25 mg QD-21.5
Core Period: LCI699 0.5 mg QD-20.0
Core Period: LCI699 1.0 mg QD-9.9
Core Period: LCI699 0.5 mg BID-47.5
Core Period: Eplerenone 50 mg BID277.1
Core Period: Placebo-28.8

[back to top]

Core Period: Change From Baseline in Mean 24 Hour Ambulatory SBP at Week 8 as Measured by Ambulatory Blood Pressure Monitoring (ABPM)

An ABPM measured a participant's BP over a 24-hour period readings using an automated validated monitoring device from Baseline to Week 8. The 24-hour SBP was calculated by taking the mean of all ambulatory SBP readings for the 24-hour period. (NCT00758524)
Timeframe: Baseline, Week 8

Interventionmm Hg (Least Squares Mean)
Core Period: LCI699 0.25 mg QD-7.15
Core Period: LCI699 0.5 mg QD-4.90
Core Period: LCI699 1.0 mg QD-7.73
Core Period: LCI699 0.5 mg BID-6.18
Core Period: Eplerenone 50 mg BID-10.52
Core Period: Placebo1.11

[back to top]

Core Period: Change From Baseline in Mean 24 Hour Ambulatory DBP at Week 8, as Measured by ABPM

An ABPM measured a participant's BP over a 24-hour period readings using an automated validated monitoring device from Baseline to Week 8. The 24-hour DBP was calculated by taking the mean of all ambulatory DBP readings for the 24-hour period. (NCT00758524)
Timeframe: Baseline, Week 8

Interventionmm Hg (Least Squares Mean)
Core Period: LCI699 0.25 mg QD-4.03
Core Period: LCI699 0.5 mg QD-2.44
Core Period: LCI699 1.0 mg QD-4.96
Core Period: LCI699 0.5 mg BID-2.75
Core Period: Eplerenone 50 mg BID-6.03
Core Period: Placebo1.03

[back to top]

Core Period: Change From Baseline in Mean Sitting Diastolic Blood Pressure (MSDBP) at Week 8 Last Observation Carried Forward (LOCF), as Measured by Office Blood Pressure (OBP)

Automated arterial BP determinations were made after the participant was in the sitting position for 5 minutes according to the Guidelines for management of hypertension: report of the 4th working party of the British Hypertension Society, 2004-BHS IV, using an automated BP device (such as the Omron BP monitor). The change in the MSDBP was calculated comparing the Week 8 readings to the readings taken at Baseline. The change from baseline in MSDBP was analyzed using an analysis of covariance model (ANCOVA) with treatment and region as factors and baseline MSDBP level as a covariate. (NCT00758524)
Timeframe: Baseline, Week 8

Interventionmm Hg (Mean)
Core Period: LCI699 0.25 mg QD-4.47
Core Period: LCI699 0.5 mg QD-5.50
Core Period: LCI699 1.0 mg QD-7.11
Core Period: LCI699 0.5 mg BID-4.25
Core Period: Eplerenone 50 mg BID-7.49
Core Period: Placebo-3.22

[back to top]

Core Period: Change From Baseline in Mean Sitting Systolic Blood Pressure (MSSBP) at Week 8 LOCF, as Measured by OBP

Automated arterial BP determinations were made after the participant was in the sitting position for 5 minutes according to the Guidelines for management of hypertension: report of the 4th working party of the British Hypertension Society, 2004-BHS IV, using an automated BP device (such as the Omron BP monitor). The change in the MSSBP was calculated comparing the Week 8 readings to the readings taken at Baseline. The change from baseline in MSSBP was analyzed using an ANCOVA with treatment and region as factors and baseline MSSBP levels as a covariate. (NCT00758524)
Timeframe: Baseline, Week 8

Interventionmm Hg (Mean)
Core Period: LCI699 0.25 mg QD-9.00
Core Period: LCI699 0.5 mg QD-10.69
Core Period: LCI699 1.0 mg QD-11.93
Core Period: LCI699 0.5 mg BID-9.10
Core Period: Eplerenone 50 mg BID-13.31
Core Period: Placebo-2.93

[back to top]

Core Period: Change From Baseline in Plasma Cortisol Levels by Adrenocorticotropic Hormone (ACTH) Stimulation Test

The ACTH stimulation cortisol test was a standard procedure to measure the ability of adrenal cortex to respond to exogenous ACTH and directly assess the adrenal reserve. Serum cortisol concentrations at 1 hour after injection were measured to assess the maximum stimulated cortisol level achieved. Potential adrenal suppression was indicated if the serum cortisol concentration was <500 nanomoles per liter (nmol/L) at 1 hour after the injection. (NCT00758524)
Timeframe: Baseline, 1 hour post-dose at Week 8

Interventionnanomoles per liter (nmol/L) (Mean)
Core Period: LCI699 0.25 mg QD729.20
Core Period: LCI699 0.5 mg QD692.74
Core Period: LCI699 1.0 mg QD604.46
Core Period: LCI699 0.5 mg BID609.21
Core Period: Eplerenone 50 mg BID802.32
Core Period: Placebo822.65

[back to top]

Core Period: Percentage of Participants With a MSSBP Response and MSSBP Control at Week 8 LOCF

MSSBP response was defined as the percentage of participants with a MSSBP <140 mmHg or a >=20 mmHg reduction from baseline reduction from baseline. MSSBP control was defined as the percentage of participants with a MSSBP <140 mmHg. (NCT00758524)
Timeframe: Baseline, Week 8

,,,,,
Interventionpercentage of participants (Number)
MSSBP ResponseMSSBP Control
Core Period: Eplerenone 50 mg BID52.444.0
Core Period: LCI699 0.25 mg QD39.131.5
Core Period: LCI699 0.5 mg BID34.425.0
Core Period: LCI699 0.5 mg QD37.627.1
Core Period: LCI699 1.0 mg QD48.840.7
Core Period: Placebo17.115.8

[back to top]

Dose/Exposure BP Response Relationship of LCI699, as Measured by Change From Baseline in MSSBP at Week 8

Arterial BP determinations were made after the participant was in the sitting position for 5 minutes according to the American Heart Association guidelines using a calibrated standard aneroid or mercury sphygmomanometer or a calibrated standard sphygmomanometer. The change in the MSSBP was calculated comparing the Week 8 readings to the readings taken at Baseline. The change from Baseline in MSSBP was analyzed using an ANCOVA with treatment and country as factors and Baseline MSSBP as a covariate. (NCT00817635)
Timeframe: Baseline, Week 8

InterventionmmHg (Mean)
LCI699 0.25 mg BID-11.4
LCI699 1 mg QD-13.1
LCI699 0.5 mg Followed by LCI699 1 mg BID-12.5

[back to top]

Number of Participants With Cortisol Levels Below 500 Nmol/L at 1 Hour After Adrenocorticotropic Hormone (ACTH) Injection at Week 8

Serum cortisol concentrations at 1 hour after injection were measured to assess the maximum stimulated cortisol level achieved. Potential adrenal suppression was indicated if the serum cortisol concentration was <500 nanomoles per liter (nmol/L) at 1 hour after the injection. (NCT00817635)
Timeframe: 1-hour post-dose at Week 8

InterventionParticipants (Count of Participants)
LCI699 0.25 mg BID0
LCI699 1 mg QD1
LCI699 0.5 mg Followed by LCI699 1 mg BID4
Eplerenone 50 mg BID0
Placebo0

[back to top]

Percent Change From Baseline in RAAS Biomarker: Active Renin (ARC) in LCI699 Compared to Eplerenone 50mg at Week 8 LOCF

Percent change from Baseline was analyzed by ANCOVA model using active renin values measured at Baseline and Week 8 LOCF, with treatment and country as factors and Baseline value as the covariate. Negative percent change from Baseline shows improvement. (NCT00817635)
Timeframe: Baseline, Week 8

Interventionpercent change in ARC (Geometric Least Squares Mean)
LCI699 0.25 mg BID73.1
LCI699 1 mg QD72.8
LCI699 0.5 mg Followed by LCI699 1 mg BID156.4
Eplerenone 50 mg BID430.6

[back to top]

Percent Change From Baseline in RAAS Biomarker: Plasma Renin Activity (PRA) in LCI699 Compared to Eplerenone 50mg at Week 8 LOCF

Percent change from Baseline was analyzed by ANCOVA model using plasma renin values measured at Baseline and Week 8 LOCF, with treatment and country as factors and Baseline value as the covariate. Negative percent change from Baseline shows improvement. (NCT00817635)
Timeframe: Baseline, Week 8

Interventionpercent change in PRA (Geometric Least Squares Mean)
LCI699 0.25 mg BID41.6
LCI699 1 mg QD74.3
LCI699 0.5 mg Followed by LCI699 1 mg BID107.7
Eplerenone 50 mg BID414.1

[back to top]

Percent Change From Baseline in Renin-Angiotensin-Aldosterone-System (RAAS) Biomarker: Plasma Aldosterone (PA) in LCI699 Compared to Eplerenone 50 mg at Week 8 LOCF

Percent change from Baseline was analyzed by ANCOVA model using PA values measured at Baseline and Week 8 LOCF, with treatment and country as factors and Baseline value as the covariate. Negative percent change from Baseline shows improvement. (NCT00817635)
Timeframe: Baseline, Week 8

Interventionpercent change in aldosterone (Geometric Least Squares Mean)
LCI699 0.25 mg BID-22.3
LCI699 1 mg QD-30.4
LCI699 0.5 mg Followed by LCI699 1 mg BID-53.1
Eplerenone 50 mg BID115.0

[back to top]

Change From Baseline in Mean 24 Hours, Mean Daytime and Mean Nighttime DBP in LCI699 1mg QD Versus LCI699 0.5mg BID Arm at Week 4, as Measured by ABPM

An ABPM measured a participant's blood pressure over a 24-hour period including daytime and nighttime readings using an automated validated monitoring device from Baseline to Week 4. The 24-hour DBP was calculated by taking the mean of all ambulatory diastolic blood pressure readings for the 24-hour period. The change from Baseline in DBP was analyzed using an ANCOVA with treatment and country as factors and Baseline MSDBP as a covariate. (NCT00817635)
Timeframe: Baseline, Week 4

,
InterventionmmHg (Mean)
24-hour Mean DBPDaytime Mean DBPNighttime Mean DBP
LCI699 0.5 mg BID-2.5-2.6-2.8
LCI699 1 mg QD-4.3-3.9-4.5

[back to top]

Change From Baseline in Mean 24 Hours, Mean Daytime and Mean Nighttime Diastolic Blood Pressure (DBP) at Week 8 LOCF, as Measured by ABPM

An ABPM measured a participant's blood pressure over a 24-hour period including daytime and nighttime readings, using an automated validated monitoring device from Baseline to Week 8. The 24-hour DBP was calculated by taking the mean of all ambulatory diastolic blood pressure readings for the 24-hour period. The change from Baseline in DBP was analyzed using an ANCOVA with treatment and country as factors and Baseline MSDBP as a covariate. (NCT00817635)
Timeframe: Baseline, Week 8

,,,,
InterventionmmHg (Mean)
24-hour Mean DBPDaytime Mean DBPNighttime Mean DBP
Eplerenone 50 mg BID-9.6-9.5-9.6
LCI699 0.25 mg BID1.00.61.9
LCI699 0.5 mg Followed by LCI699 1 mg BID-3.7-3.4-4.6
LCI699 1 mg QD-3.4-3.6-2.5
Placebo-0.2-0.81.2

[back to top]

Change From Baseline in Mean 24 Hours, Mean Daytime and Mean Nighttime SBP in LCI699 1mg QD Versus LCI699 0.5mg BID Arm at Week 4, as Measured by ABPM

An ABPM measured a participant's blood pressure over a 24-hour period including daytime and nighttime readings using an automated validated monitoring device from Baseline to Week 4. The 24-hour SBP was calculated by taking the mean of all ambulatory systolic blood pressure readings for the 24-hour period. The change from Baseline in SBP was analyzed using an ANCOVA with treatment and country as factors and Baseline MSDBP as a covariate. (NCT00817635)
Timeframe: Baseline, Week 4

,
InterventionmmHg (Mean)
24-hour Mean SBPDaytime Mean SBPNighttime Mean SBP
LCI699 0.5 mg BID-4.7-5.3-4.5
LCI699 1 mg QD-7.8-8.1-6.8

[back to top]

Change From Baseline in Mean 24 Hours, Mean Daytime and Mean Nighttime Systolic Blood Pressure (SBP) at Week 8 LOCF, as Measured by Ambulatory Blood Pressure Measurement (ABPM)

An ABPM measured a participant's blood pressure over a 24-hour period including daytime and nighttime readings, using an automated validated monitoring device from Baseline to Week 8. The 24-hour SBP was calculated by taking the mean of all ambulatory systolic blood pressure readings for the 24-hour period. The change from Baseline in SBP was analyzed using ANCOVA with treatment and country as factors and Baseline MSSBP as a covariate. (NCT00817635)
Timeframe: Baseline, Week 8

,,,,
InterventionmmHg (Mean)
24-hour Mean SBPDaytime Mean SBPNighttime Mean SBP
Eplerenone 50 mg BID-15.7-15.7-15.4
LCI699 0.25 mg BID-4.4-4.9-3.2
LCI699 0.5 mg Followed by LCI699 1 mg BID-6.3-6.3-7.0
LCI699 1 mg QD-5.7-6.0-4.8
Placebo-1.0-1.60.4

[back to top]

Number of Participants With Adverse Event (AEs), Serious Adverse Events (SAEs), Hyperkalemia, and Hyponatremia

An AE was an adverse medical event which occurs in a participant of the study and which is not necessarily in a causal relationship with the treatment the participant receives. SAEs were AEs leading to death, are life-threatening, require hospitalizations or prolongation of hospitalizations, represent an innate malformation or a congenital abnormality. Hyperkalemia was defined as potassium level >5.5 millimoles per liter (mmol/L). It is the medical term that describes a potassium level that's higher than normal. Hyponatremia was defined as sodium level <135 mmol/L. It is the medical term that describes a sodium level that's lesser than normal. (NCT00817635)
Timeframe: AEs, Hyperkalemia, and Hyponatremia: From start of the study drug treatment up to 10 weeks; SAE: From signing of the informed consent up to 10 weeks

,,,,
InterventionParticipants (Count of Participants)
AE(s)SAE(s)Hyperkalemia [potassium level >5.5 mmol/L]Hyperkalemia [potassium level ≥6.0 mmol/L]Hyponatremia [sodium level <130 and ≥125 mmol/L]Hyponatremia [sodium level <135 mmol/L and ≥130mmol/L]
Eplerenone 50 mg BID1310013
LCI699 0.25 mg BID1502203
LCI699 0.5 mg Followed by LCI699 1 mg BID800007
LCI699 1 mg QD1500002
Placebo1601002

[back to top]

Percentage of Participants With a MSDBP Response and MSDBP Control at Week 8, as Measured by OBP

MSDBP response was defined as the percentage of participants with a MSDBP <90 mmHg or a >=10 mmHg reduction from baseline. MSDBP control was defined as the percentage of participants with a MSDBP <90 mmHg for non-diabetic participants and <80mHg for diabetic participants. (NCT00817635)
Timeframe: Week 8

,,,,
Interventionpercentage of participants (Number)
MSDBP ResponseMSDBP Control
Eplerenone 50 mg BID71.956.3
LCI699 0.25 mg BID67.754.8
LCI699 0.5 mg Followed by LCI699 1 mg BID71.058.1
LCI699 1 mg QD73.165.4
Placebo57.654.5

[back to top]

Percentage of Participants With a MSSBP Response and MSSBP Control at Week 8, as Measured by Office Blood Pressure (OBP)

MSSBP response was defined as the percentage of participants with a MSSBP <140 mmHg or a >=20 mmHg reduction from baseline reduction from baseline. MSSBP control was defined as the percentage of participants with a MSSBP <140 mmHg for non-diabetic participants and <130mHg for diabetic participants. (NCT00817635)
Timeframe: Week 8

,,,,
Interventionpercentage of participants (Number)
MSSBP ResponseMSSBP Control
Eplerenone 50 mg BID65.653.1
LCI699 0.25 mg BID54.851.6
LCI699 0.5 mg Followed by LCI699 1 mg BID41.932.3
LCI699 1 mg QD57.750.0
Placebo42.436.4

[back to top]

Percent Change From Baseline in RAAS Biomarker: Ratio of PA to PRA in LCI699 Compared to Eplerenone 50mg at Week 8 LOCF

Percent change from Baseline was analyzed by ANCOVA model using percent ratio of PA to PRA values measured at Baseline and Week 8 LOCF, with treatment and country as factors and Baseline value as the covariate. Negative percent change from Baseline shows improvement. (NCT00817635)
Timeframe: Baseline, Week 8

Interventionpercent change in ratio of PA to PRA (Geometric Least Squares Mean)
LCI699 0.25 mg BID-46.7
LCI699 1 mg QD-50.0
LCI699 0.5 mg Followed by LCI699 1 mg BID-78.3
Eplerenone 50 mg BID-57.1

[back to top]

Change From Baseline in MSDBP at Week 8 LOCF

Arterial BP determinations were made after the participant was in the sitting position for 5 minutes according to the American Heart Association guidelines using a calibrated standard aneroid or mercury sphygmomanometer or a calibrated standard sphygmomanometer. The change in the MSDBP was calculated comparing the Week 8 readings to the readings taken at Baseline. The change from Baseline in MSDBP was analyzed using an ANCOVA with treatment and country as factors and Baseline MSDBP as a covariate. (NCT00817635)
Timeframe: Baseline, Week 8

InterventionmmHg (Mean)
LCI699 0.25 mg BID-4.5
LCI699 1 mg QD-6.0
LCI699 0.5 mg Followed by LCI699 1 mg BID-6.1
Eplerenone 50 mg BID-7.7
Placebo-4.8

[back to top]

Change From Baseline in MSSBP at Week 8 Last Observation Carried Forward (LOCF)

Arterial blood pressure (BP) determinations were made after the participant was in the sitting position for 5 minutes according to the American Heart Association guidelines using a calibrated standard aneroid or mercury sphygmomanometer or a calibrated standard sphygmomanometer. The change in the MSSBP was calculated comparing the Week 8 readings to the readings taken at Baseline. The change from Baseline in MSSBP was analyzed using an analysis of covariance model (ANCOVA) with treatment and country as factors and Baseline MSSBP as a covariate. (NCT00817635)
Timeframe: Baseline, Week 8

InterventionmmHg (Mean)
LCI699 0.25 mg BID-11.4
LCI699 1 mg QD-13.1
LCI699 0.5 mg Followed by LCI699 1 mg BID-12.5
Eplerenone 50 mg BID-18.7
Placebo-8.8

[back to top]

Dose/Exposure BP Response Relationship of LCI699, as Measured by Change From Baseline in MSDBP at Week 8

Arterial BP determinations were made after the participant was in the sitting position for 5 minutes according to the American Heart Association guidelines using a calibrated standard aneroid or mercury sphygmomanometer or a calibrated standard sphygmomanometer. The change in the MSDBP was calculated comparing the Week 8 readings to the readings taken at Baseline. The change from Baseline in MSDBP was analyzed using an ANCOVA with treatment and country as factors and Baseline MSDBP as a covariate. (NCT00817635)
Timeframe: Baseline, Week 8

InterventionmmHg (Mean)
LCI699 0.25 mg BID-4.5
LCI699 1 mg QD-6.0
LCI699 0.5 mg Followed by LCI699 1 mg BID-6.1

[back to top]

Number of Participants With Change From Baseline in New York Heart Association (NYHA) Classification at Weeks 1, 4, Months 2, 3, 4, 5, 9, 13, 17 21, 25, 29, 33, 37, 42, 48 and Final Visit

NYHA: classified as 'class I' (participants with cardiac disease but without resulting limitations of physical activity), 'class II' (participants with cardiac disease resulting in slight limitation of physical activity), 'class III' (participants with cardiac disease resulting in marked limitation of physical activity), 'class IV' (participants with cardiac disease resulting in inability to carry on any physical activity without discomfort). Participants with change from baseline were classified as 'improved' (positive change), 'no change' or 'worsened' (negative change). (NCT01115855)
Timeframe: Baseline, Weeks 1, 4, Months 2, 3, 4, 5, 9, 13, 17, 21, 25, 29, 33, 37, 42, 48 and Final Visit (up to Month 48)

,
Interventionparticipants (Number)
Week 1 (n=111, 110) : ImprovedWeek 1 (n=111, 110) : UnchangedWeek 1 (n=111, 110) : WorseWeek 4 (n=111, 108) : ImprovedWeek 4 (n=111, 108) : UnchangedWeek 4 (n=111, 108) : WorseMonth 2 (n=109, 109) : ImprovedMonth 2 (n=109, 109) : UnchangedMonth 2 (n=109, 109) : WorseMonth 3 (n=106, 107) : ImprovedMonth 3 (n=106, 107) : UnchangedMonth 3 (n=106, 107) : WorseMonth 4 (n=106, 106) : ImprovedMonth 4 (n=106, 106) : UnchangedMonth 4 (n=106, 106) : WorseMonth 5 (n=104, 106) : ImprovedMonth 5 (n=104, 106) : UnchangedMonth 5 (n=104, 106) : WorseMonth 9 (n=99, 105) : ImprovedMonth 9 (n=99, 105) : UnchangedMonth 9 (n=99, 105) : WorseMonth 13 (n=94, 102) : ImprovedMonth 13 (n=94, 102) : UnchangedMonth 13 (n=94, 102) : WorseMonth 17 (n=81, 82) : ImprovedMonth 17 (n=81, 82) : UnchangedMonth 17 (n=81, 82) : WorseMonth 21 (n=72, 73) : ImprovedMonth 21 (n=72, 73) : UnchangedMonth 21 (n=72, 73) : WorseMonth 25 (n=63, 64) : ImprovedMonth 25 (n=63, 64) : UnchangedMonth 25 (n=63, 64) : WorseMonth 29 (n=53, 48) : ImprovedMonth 29 (n=53, 48) : UnchangedMonth 29 (n=53, 48) : WorseMonth 33 (n=46, 39) : ImprovedMonth 33 (n=46, 39) : UnchangedMonth 33 (n=46, 39) : WorseMonth 37 (n=40, 33) : ImprovedMonth 37 (n=40, 33) : UnchangedMonth 37 (n=40, 33) : WorseMonth 42 (n=30, 26) : ImprovedMonth 42 (n=30, 26) : UnchangedMonth 42 (n=30, 26) : WorseMonth 48 (n=16, 16) : ImprovedMonth 48 (n=16, 16) : UnchangedMonth 48 (n=16, 16) : WorseFinal Visit (n=111, 110) : ImprovedFinal Visit (n=111, 110) : UnchangedFinal Visit (n=111, 110) : Worse
Eplerenone410701010101594018880228222476427711316212555121501233821736014311122807230214025806
Placebo2107114922149501691020860228312081419821186131951314482123511027210221718169126804

[back to top]

Number of Participants With First Occurrence of Fatal/Non-Fatal Stroke

Hazard ratio of Eplerenone versus placebo for first occurrence of the event was obtained from a Cox proportional hazards model. (NCT01115855)
Timeframe: Randomization up to the date when the last enrolled participant had been followed up for 1 year (up to 1744 days)

Interventionparticipants (Number)
Eplerenone3
Placebo4

[back to top]

Number of Participants With With First Occurrence of All-Cause Mortality

All-cause mortality was defined as any CV mortality, Non-CV mortality, including malignant tumor, pulmonary disease and trauma.CV mortality was defined as death due to HF, myocardial infarction, cardiac arrhythmia, stroke or cerebral vascular accident, other CV cause (such as aneurysm or pulmonary embolism). Mortality during treatment, within 30 days of treatment discontinuation and after 30 days of discontinuation was reported. Hazard ratio of Eplerenone versus placebo for first occurrence of the event was obtained from a Cox proportional hazards model. (NCT01115855)
Timeframe: Randomization up to the date when the last enrolled participant had been followed up for 1 year (up to 1744 days)

,
Interventionparticipants (Number)
During treatmentWithin 30 days of treatment discontinuationAfter 30 days of treatment discontinuation
Eplerenone6110
Placebo514

[back to top]

Number of Participants With First Occurrence of Cardiovascular (CV) Mortality, Hospitalization Due to Heart Failure (HF), or Addition/Increase of Heart Failure (HF) Medication

CV mortality was defined as any death due to HF, myocardial infarction, cardiac arrhythmia, stroke or cerebral vascular accident, other CV cause (such as aneurysm or pulmonary embolism). Hospitalization due to HF was defined as an overnight stay, or longer, in a hospital environment (emergency room, observation unit or in-patient care, or similar facility including admission to a day care facility) due to HF. Addition/ increase of HF medications was defined as administration of new HF medication or increase of 50 percentage (%) or more in dose of HF medication for >= 3 days. Hazard ratio of Eplerenone versus placebo for first occurrence of the event was obtained from a Cox proportional hazards model. (NCT01115855)
Timeframe: Randomization up to the date when the last enrolled participant had been followed up for 1 year (up to 1744 days)

Interventionparticipants (Number)
Eplerenone42
Placebo45

[back to top]

Number of Participants With First Occurrence of Cardiovascular (CV) Hospitalization

CV hospitalization, which was defined as any hospitalization due to CV events including HF, myocardial infarction, arrhythmia, angina pectoris. Hazard ratio of Eplerenone versus placebo for first occurrence of the event was obtained from a Cox proportional hazards model. (NCT01115855)
Timeframe: Randomization up to the date when the last enrolled participant had been followed up for 1 year (up to 1744 days)

Interventionparticipants (Number)
Eplerenone35
Placebo44

[back to top]

Number of Participants With First Occurrence of All-cause Mortality or All-cause Hospitalization

All cause hospitalization included all hospitalizations as CV hospitalization, which was defined as any hospitalization due to CV events including HF, myocardial infarction, arrhythmia, angina pectoris and non-CV hospitalizations which was defined as any hospitalization due to non-CV events including renal dysfunction, hyperkalaemia, malignant tumor and pulmonary disease. All-cause mortality was defined as any CV mortality, Non-CV mortality, including malignant tumor, pulmonary disease and trauma.CV mortality was defined as death due to HF, myocardial infarction, cardiac arrhythmia, stroke or cerebral vascular accident, other CV cause (such as aneurysm or pulmonary embolism). Hazard ratio of Eplerenone versus placebo for first occurrence of the event was obtained from a Cox proportional hazards model. (NCT01115855)
Timeframe: Randomization up to the date when the last enrolled participant had been followed up for 1 year (up to 1744 days)

Interventionparticipants (Number)
Eplerenone48
Placebo61

[back to top]

Number of Participants With First Occurrence of All-cause Hospitalization

All cause hospitalization included all hospitalizations as CV hospitalization, which was defined as any hospitalization due to CV events including HF, myocardial infarction, arrhythmia, angina pectoris and non-CV hospitalizations which was defined as any hospitalization due to non-CV events including renal dysfunction, hyperkalaemia, malignant tumor and pulmonary disease. Hazard ratio of Eplerenone versus placebo for first occurrence of the event was obtained from a Cox proportional hazards model. (NCT01115855)
Timeframe: Randomization up to the date when the last enrolled participant had been followed up for 1 year (up to 1744 days)

Interventionparticipants (Number)
Eplerenone45
Placebo58

[back to top]

Number of Participants With First Occurrence of Addition/Increase of Heart Failure (HF) Medication Due to Heart Failure (HF) Worsening

Addition/ increase of HF medications was defined as administration of new HF medication or increase of 50 percent or more in dose of HF medication for >= 3 days. Hazard ratio of Eplerenone versus placebo for first occurrence of the event was obtained from a Cox proportional hazards model. (NCT01115855)
Timeframe: Randomization up to the date when the last enrolled participant had been followed up for 1 year (up to 1744 days)

Interventionparticipants (Number)
Eplerenone38
Placebo43

[back to top]

Number of Participants With With First Occurrence of Cardiovascular Mortality

CV mortality was defined as death due to HF, myocardial infarction, cardiac arrhythmia, stroke or cerebral vascular accident, other CV cause (such as aneurysm or pulmonary embolism). Hazard ratio of Eplerenone versus placebo for first occurrence of the event was obtained from a Cox proportional hazards model. (NCT01115855)
Timeframe: Randomization up to the date when the last enrolled participant had been followed up for 1 year (up to 1744 days)

Interventionparticipants (Number)
Eplerenone14
Placebo6

[back to top]

Change From Baseline in Left Ventricular Ejection Fraction (LVEF) at Months 5, 9, 13, 17, 21, 25, 29, 33, 37, 42, 48 and Final Visit

LVEF was calculated based on end-diastolic volume measured by two-dimensional echocardiography. (NCT01115855)
Timeframe: Baseline, Months 5, 9, 13, 17, 21, 25, 29, 33, 37, 42, 48, Final Visit (up to Month 48)

,
Interventionpercentage of LVEF (Mean)
Baseline (n=111,110)Change at Month 5 (n=105,106)Change at Month 9 (n=99,104)Change at Month 13 (n=94,101)Change at Month 17 (n=81,82)Change at Month 21 (n=72,73)Change at Month 25 (n=63,64)Change at Month 29 (n=53,48)Change at Month 33 (n=45,39)Change at Month 37 (n=40,33)Change at Month 42 (n=30,26)Change at Month 48 (n=16,16)Change at Final Visit (n=109,110)
Eplerenone25.645.9833.899.6211.3612.7312.1811.9513.6713.3412.1510.189.50
Placebo26.644.0131.374.865.506.376.606.455.207.185.138.415.99

[back to top]

Number of Participants With First Occurrence of Heart Failure (HF) Mortality or Heart Failure (HF) Hospitalization

HF mortality was defined as any death due to HF. Hospitalization due to HF was defined as an overnight stay, or longer, in a hospital environment (emergency room, observation unit or in-patient care, or similar facility including admission to a day care facility) due to HF. Hazard ratio of Eplerenone versus placebo for first occurrence of the event was obtained from a Cox proportional hazards model. (NCT01115855)
Timeframe: Randomization up to the date when the last enrolled participant had been followed up for 1 year (up to 1744 days)

Interventionparticipants (Number)
Eplerenone29
Placebo33

[back to top]

Number of Participants With First Occurrence of Cardiovascular (CV) Mortality or Hospitalization Due to Heart Failure (HF)

CV mortality was defined as any death due to HF, myocardial infarction, cardiac arrhythmia, stroke or cerebral vascular accident, other CV cause (such as aneurysm or pulmonary embolism). Hospitalization due to HF was defined as an overnight stay, or longer, in a hospital environment (emergency room, observation unit or in-patient care, or similar facility including admission to a day care facility) due to HF. Hazard ratio of Eplerenone versus placebo for first occurrence of the event was obtained from a Cox proportional hazards model. (NCT01115855)
Timeframe: Randomization up to the date when the last enrolled participant had been followed up for 1 year (up to 1744 days)

Interventionparticipants (Number)
Eplerenone33
Placebo36

[back to top]

Number of Participants With First Occurrence of Hospitalisation Due to Worsening Renal Function

Hospitalization due to worsening renal function (as per physician's decision) was defined as an overnight stay, or longer, in a hospital environment (emergency room, observation unit or in-patient care, or similar facility including admission to a day care facility) due to worsening renal function as the primary reason for hospitalization. Hazard ratio of Eplerenone versus placebo for first occurrence of the event was obtained from a Cox proportional hazards model. (NCT01115855)
Timeframe: Randomization up to the date when the last enrolled participant had been followed up for 1 year (up to 1744 days)

Interventionparticipants (Number)
Eplerenone2
Placebo2

[back to top]

Number of Participants With First Occurrence of Hospitalization Due to Heart Failure (HF)

Hospitalization due to HF was defined as an overnight stay, or longer, in a hospital environment (emergency room, observation unit or in-patient care, or similar facility including admission to a day care facility) due to HF. Hazard ratio of Eplerenone versus placebo for first occurrence of the event was obtained from a Cox proportional hazards model. (NCT01115855)
Timeframe: Randomization up to the date when the last enrolled participant had been followed up for 1 year (up to 1744 days)

Interventionparticipants (Number)
Eplerenone27
Placebo33

[back to top]

Change From Baseline in Plasma Concentration of Brain Natriuretic Peptide at Months 5, 9, 13, 17, 21, 25, 29, 33, 37, 42, 48 and Final Visit

(NCT01115855)
Timeframe: Baseline, Months 5,9,13,17,21,25,29,33,37,42,48, Final Visit (up to Month 48)

,
Interventionpicogram/milliliter (pg/ml) (Mean)
Baseline (n=111,110)Change at Month 5 (n=105,106)Change at Month 9 (n=99,104)Change at Month 13 (n=95,101)Change at Month 17 (n=81,82)Change at Month 21 (n=72,73)Change at Month 25 (n=63,63)Change at Month 29 (n=53,48)Change at Month 33 (n=45,40)Change at Month 37 (n=40,33)Change at Month 42 (n=30,26)Change at Month 48 (n=16,16)Change at Final Visit (n=109,110)
Eplerenone469.29-169.75-208.54-258.66-242.92-241.33-249.76-269.07-228.84-211.86-155.65-200.85-149.75
Placebo435.61-36.36-76.23-93.99-69.74-57.31-83.99-95.33-43.98-73.73-22.31-122.33-57.45

[back to top]

Change From Baseline in Plasma Concentration of Serum N-terminal Pro-Brain Natriuretic Peptide (NT-proBNP) at Months 5, 9, 13, 17, 21, 25, 29, 33, 37, 42, 48 and Final Visit

(NCT01115855)
Timeframe: Baseline, Months 5, 9, 13, 17, 21 ,25, 29, 33, 37, 42, 48 and Final Visit (up to Month 48)

,
Interventionpg/mL (Mean)
Baseline (n=111,110)Change at Month 5 (n=105,106)Change at Month 9 (n=99,104)Change at Month 13 (n=95,101)Change at Month 17 (n=81,82)Change at Month 21 (n=72,73)Change at Month 25 (n=63,63)Change at Month 29 (n=53,48)Change at Month 33 (n=45,40)Change at Month 37 (n=40,33)Change at Month 42 (n=30,26)Change at Month 48 (n=16,16)Change at Final Visit (n=109,110)
Eplerenone2635.78-770.51-884.76-1066.86-1126.96-957.86-453.57-1013.83-168.36-9.64-246.77-970.71-177.00
Placebo2354.31-205.18-425.47-452.02-109.59-250.85-128.02-187.08434.35171.21928.35-450.69296.35

[back to top]

Change From Baseline in Specific Activity Scale (SAS) Score at Week 4, Months 2, 3, 4, 5, 9, 13, 17 21, 25, 29, 33, 37, 42, 48 and Final Visit

Specific activity scale was estimated by pre-specified questionnaire (for different activities) to assess the exercise capability of the participants. Answers provided by participants were transformed in terms of number of metabolic equivalents (METs).1 MET was defined as the amount of oxygen consumed while sitting at rest and is equal to 3.5 ml oxygen per kg body weight* minute. Scale ranged from 1 (less than (<) 2 METs) = lowest level of exercise tolerance to 6 (>=8METs) = highest level of tolerance and higher score indicated more tolerance. (NCT01115855)
Timeframe: Baseline, Week 4, Months 5, 9, 13, 17, 21, 25, 29, 33, 37, 42, 48, Final Visit (up to Month 48)

,
Interventionmetabolic equivalents (METs) (Mean)
Baseline (n=111,110)Change at Week 4 (n= 111,108)Change at Month 5 (n=104,106)Change at Month 9 (n=99,104)Change at Month 13 (n=94,102)Change at Month 17 (n=81,82)Change at Month 21 (n=72,73)Change at Month 25 (n=63,63)Change at Month 29 (n=53,48)Change at Month 33 (n=46,40)Change at Month 37 (n=40,33)Change at Month 42 (n=30,26)Change at Month 48 (n=16,16)Change at Final Visit (n=111,110)
Eplerenone4.850.150.460.410.520.460.340.480.420.370.530.39-0.130.14
Placebo4.890.270.330.370.440.470.590.630.650.510.680.470.640.25

[back to top]

Change From Baseline in Urine Albumin-to-Creatinine Ratio at Months 5, 9, 13, 17, 21, 25, 29, 33, 37, 42, 48 and Final Visit

(NCT01115855)
Timeframe: Baseline, Months 5, 9, 13, 17, 21, 25, 29, 33, 37, 42, 48, Final Visit (up to Month 48)

,
Interventionmicrogram per gram creatinine (mg/gCr) (Mean)
Baseline (n=111,108)Change at Month 5 (n=104,103)Change at Month 9 (n=98,101)Change at Month 13 (n=94,98)Change at Month 17 (n=80,82)Change at Month 21 (n=72,73)Change at Month 25 (n=62,63)Change at Month 29 (n=50,47)Change at Month 33 (n=43,39)Change at Month 37 (n=39,33)Change at Month 42 (n=27,25)Change at Month 48 (n=16,16)Change at Final Visit (n=109,110)
Eplerenone169.82-21.14-11.10-41.56-13.66-63.6517.1718.51-47.07-80.21-162.18-303.19-29.30
Placebo154.9346.2323.79-19.0479.2828.8430.08-4.58-3.3834.20-29.95-41.03-31.56

[back to top]

Number of Participants With First Occurrence of New Onset Diabetes Mellitus

New onset diabetes mellitus was defined as the diagnosis of diabetes mellitus in a participant after randomization. Hazard ratio of Eplerenone versus placebo for first occurrence of the event was obtained from a Cox proportional hazards model. (NCT01115855)
Timeframe: Randomization up to the date when the last enrolled participant had been followed up for 1 year (up to 1744 days)

Interventionparticipants (Number)
Eplerenone1
Placebo2

[back to top]

Number of Participants With First Occurrence of Fatal/Non-Fatal Myocardial Infarction (MI)

Hazard ratio of Eplerenone versus placebo for first occurrence of the event was obtained from a Cox proportional hazards model. (NCT01115855)
Timeframe: Randomization up to the date when the last enrolled participant had been followed up for 1 year (up to 1744 days)

Interventionparticipants (Number)
Eplerenone1
Placebo1

[back to top]

Number of Participants With First Occurrence of New Onset Atrial Fibrillation/Flutter

New onset of atrial fibrillation or flutter was defined as the diagnosis of atrial fibrillation or flutter in a participant after randomization. Hazard ratio of Eplerenone versus placebo for first occurrence of the event was obtained from a Cox proportional hazards model. (NCT01115855)
Timeframe: Randomization up to the date when the last enrolled participant had been followed up for 1 year (up to 1744 days)

Interventionparticipants (Number)
Eplerenone4
Placebo2

[back to top]

Number of Participants With First Occurrence of Hospitalization for Hyperkalemia

Hospitalization due to hyperkalemia (as per physician's decision) was defined as an overnight stay, or longer, in a hospital environment (emergency room, observation unit or in-patient care, or similar facility including admission to a day care facility) due to hyperkalemia as the primary reason for hospitalization. Hazard ratio of Eplerenone versus placebo for first occurrence of the event was obtained from a Cox proportional hazards model. (NCT01115855)
Timeframe: Randomization up to the date when the last enrolled participant had been followed up for 1 year (up to 1744 days)

Interventionparticipants (Number)
Eplerenone0
Placebo0

[back to top]

Diagnosis of Heart Failure

The occurrence of first diagnosis of heart failure from the date of randomization. Time-to-event analyses were measured from the date of randomization, and a subject who did not experience the endpoint(s) of interest was censored on the last day the subject was confirmed by the investigator to be endpoint-free. The time-to-event distributions were summarized by treatment group using Kaplan-Meier estimates of cumulative incidence. (NCT01176968)
Timeframe: 0-24 months

InterventionEvents (Number)
Eplerenone Plus Standard of Care7
Placebo Plus Standard of Care11

[back to top]

Electrocardiogram Q Wave to the End of the S Wave Corresponding to Ventricle Depolarization (QRS) Duration at 6 Months Post-randomization.

Electrocardiogram Q wave to the end of the S wave corresponding to ventricle depolarization (QRS) duration at 6 months post-randomization. The continuous endpoints were assessed using analysis of covariance (ANCOVA) model, fitted with corresponding baseline and treatment. These were analyzed at 6 months based on last observation carried forward (LOCF) and also using all available data up to end of study. (NCT01176968)
Timeframe: 6 months

InterventionMilliseconds (msec) (Mean)
Eplerenone Plus Standard of Care93.31
Placebo Plus Standard of Care94.62

[back to top]

First and Each Subsequent Episode (After an Event Free Interval of ≥ 48 Hours) of Sustained Ventricular Tachycardia or Ventricular Fibrillation.

The occurrence of first and each subsequent episode (after an event-free interval of ≥ 48 hours) of sustained ventricular tachycardia or ventricular fibrillation. Time-to-event analyses were measured from the date of randomization. A subject who did not experience the endpoint(s) of interest was censored on the last day the subject was confirmed by the investigator to be endpoint-free. The time-to-event distributions were summarized by treatment group using Kaplan-Meier estimates of cumulative incidence. (NCT01176968)
Timeframe: 0-24 months

InterventionEvents (Number)
Eplerenone Plus Standard of Care0
Placebo Plus Standard of Care0

[back to top]

First Event of Cardiovascular Mortality, Re-hospitalization or Extended Initial Hospital Stay Due to Diagnosis of Heart Failure, Sustained Ventricular Tachycardia or Fibrillation, Ejection Fraction ≤40% or BNP Above Age Adjusted Cut Off

Cardiovascular mortality is defined as any mortality adjudicated as death due to sudden cardiac death, myocardial infarction (MI), worsening heart failure, cardiac arrhythmia, other cause (such as pulmonary embolism, peripheral arterial disease [PAD], etc.). Hospitalization due to congestive heart failure (CHF) and requires extended hospital stay or frequent visits to emergency room, observation unit or in-patient care, due to CHF as the primary or secondary diagnosis supported by a discharge report or clinical summary for hospitalization as determined by the endpoint adjudication committee (EAC). A composite of time to first event of cardiovascular mortality (CV), re-hospitalization or extended initial hospital stay due to diagnosis of heart failure, sustained ventricular tachycardia or fibrillation, ejection fraction ≤40% after 1 month or BNP >200 pg/mL or NT-proBNP >450 pg/mL (age <50 years); >900 pg/mL (age 50 to 75 years) or >1800 pg/mL (age >75 years) after 1 month. (NCT01176968)
Timeframe: 0-24 months

InterventionEvents (Number)
Eplerenone Plus Standard of Care92
Placebo Plus Standard of Care149

[back to top]

First Recorded Ejection Fraction (EF) of ≤40% (Recorded 1 Month or Later Post-randomization).

The occurrence of first recorded EF ≤40% (recorded 28 days or later post-randomization). Time-to-event analyses were measured from the date of randomization. A subject who did not experience the endpoint(s) of interest was censored on the last day the subject was confirmed by the investigator to be endpoint-free. The time-to-event distributions were summarized by treatment group using Kaplan-Meier estimates of cumulative incidence. (NCT01176968)
Timeframe: 0-24 months

InterventionEvents (Number)
Eplerenone Plus Standard of Care20
Placebo Plus Standard of Care19

[back to top]

Second or Subsequent Non-fatal Myocardial Infarction (MI).

The occurrence of second or subsequent nonfatal MI. Time-to-event analyses were measured from the date of randomization. A subject who did not experience the endpoint(s) of interest was censored on the last day the subject was confirmed by the investigator to be endpoint-free. The time-to-event distributions were summarized by treatment group using Kaplan-Meier estimates of cumulative incidence. (NCT01176968)
Timeframe: 0-24 months

InterventionEvents (Number)
Eplerenone Plus Standard of Care10
Placebo Plus Standard of Care6

[back to top]

Change in Serum Levels of Biomarkers (Aldosterone and Cortisol) at 6 Months Post-randomization.

Change in serum levels of aldosterone and cortisol at 6 months post-randomization. The continuous endpoints were assessed using ANCOVA model, fitted with corresponding baseline and treatment. These were analyzed at 6 months based on LOCF and also using all available data up to end of study. (NCT01176968)
Timeframe: 6 months

,
Interventionnmol/L (Median)
AldosteroneSerum Cortisol
Eplerenone Plus Standard of Care0.355379.0
Placebo Plus Standard of Care0.210366.0

[back to top]

Change in Serum Levels of Biomarkers (PIIINP, Galectin 3, and PINP) at 6 Months Post-randomization.

Change in serum levels of PIIINP, Galectin 3, and PINP at 6 months post-randomization. The continuous endpoints were assessed using ANCOVA model, fitted with corresponding baseline and treatment. These were analyzed at 6 months based on LOCF and also using all available data up to end of study. (NCT01176968)
Timeframe: 6 months

,
Interventionng/mL (Median)
PIIINPGalectin 3PINP
Eplerenone Plus Standard of Care4.2011.2030.0
Placebo Plus Standard of Care4.3010.6032.0

[back to top]

Left Atrial Diameter (LAD) (Recorded on Each Occasion an Echocardiogram is Conducted).

LAD recorded each time an echocardiogram is conducted. The continuous endpoints were assessed using ANCOVA model, fitted with corresponding baseline and treatment. These were analyzed at 6 months based on LOCF and also using all available data up to end of study. (NCT01176968)
Timeframe: 0-24 months

,
InterventionCentimeters (cm) (Mean)
Month 6 (N = 268, 243)Final Visit (N = 393, 378)
Eplerenone Plus Standard of Care3.923.91
Placebo Plus Standard of Care3.903.87

[back to top]

Cardiovascular Mortality

The occurrence of cardiovascular mortality from randomization. Time-to-event analyses were measured from the date of randomization. A subject who did not experience the endpoint(s) of interest was censored on the last day the subject was confirmed by the investigator to be endpoint-free. The time-to-event distributions were summarized by treatment group using Kaplan-Meier estimates of cumulative incidence. (NCT01176968)
Timeframe: 0-24 months

InterventionEvents (Number)
Eplerenone Plus Standard of Care2
Placebo Plus Standard of Care2

[back to top]

Brain (B-type) Natriuretic Peptide (BNP) >200 pg/mL or NT-proBNP >450, >900 or >1800 pg/mL for Ages <50 Years, 50-75 Years and >75 Years, Respectively (Recorded 1 Month or Later Post-randomization).

The occurrence of first occurrence of BNP >200 pg/mL or NT-proBNP >450, >900 or >1800 pg/mL for ages <50 years, 50 to 75 years and >75 years, respectively (recorded 28 days or later post-randomization). Time-to-event analyses were measured from the date of randomization. A subject who did not experience the endpoint(s) of interest was censored on the last day the subject was confirmed by the investigator to be endpoint-free. The time-to-event distributions were summarized by treatment group using Kaplan-Meier estimates of cumulative incidence. (NCT01176968)
Timeframe: 0-24 months

InterventionEvents (Number)
Eplerenone Plus Standard of Care81
Placebo Plus Standard of Care131

[back to top]

Change in Serum Level of Biomarker (ICTP) at 6 Months Post-randomization.

Change in serum level of ICTP at 6 months post-randomization. The continuous endpoint was assessed using ANCOVA model, fitted with corresponding baseline and treatment. It was analyzed at 6 months based on LOCF and also using all available data up to end of study. (NCT01176968)
Timeframe: 6 months

Interventionμg/L (Median)
Eplerenone Plus Standard of Care3.70
Placebo Plus Standard of Care3.70

[back to top]

Change in Serum Level of Biomarker (Interleukin-6) at 6 Months Post-randomization.

Change in serum level of Interleukin-6 at 6 months post-randomization. The continuous endpoint was assessed using ANCOVA model, fitted with corresponding baseline and treatment. It was analyzed at 6 months based on LOCF and also using all available data up to end of study. (NCT01176968)
Timeframe: 6 months

Interventionpg/mL (Median)
Eplerenone Plus Standard of Care1.845
Placebo Plus Standard of Care1.755

[back to top]

Decision to Provide an Implantable Cardioverter Defibrillator (ICD) or Cardiac Resynchronization Therapy (CRT).

The decision to provide an ICD or CRT. Time-to-event analyses were measured from the date of randomization. A subject who did not experience the endpoint(s) of interest was censored on the last day the subject was confirmed by the investigator to be endpoint-free. The time-to-event distributions were summarized by treatment group using Kaplan-Meier estimates of cumulative incidence. (NCT01176968)
Timeframe: 0-24 months

InterventionEvents (Number)
Eplerenone Plus Standard of Care3
Placebo Plus Standard of Care3

[back to top]

Number of Participants With Clinically Significant Effects (Adverse Events)

A summary of serious adverse events and other nonserious adverse events are located in the Reported Adverse Event section. (NCT01237899)
Timeframe: Baseline through 7 days for each treatment period

,,,,,
InterventionParticipants (Count of Participants)
Serious Adverse EventsNonserious Adverse Events
0.3 mg LY262309102
1 mg LY262309105
10 mg LY262309104
25 mg LY262309106
50 mg Eplerenone09
Placebo06

[back to top]

Pharmacokinetics of LY2623091: Maximal Concentration (Cmax) at Day 6

Cmax estimated for LY2623091. (NCT01237899)
Timeframe: Day 6: Predose,1hr, 2hr, 3hr, 4hr, 8hr and 12 hr Postdose

Interventionnanograms per milliliter (ng/mL) (Mean)
0.3 mg LY26230917.57
1 mg LY262309127.5
10 mg LY2623091324
25 mg LY2623091812

[back to top]

Pharmacokinetics LY2623091: Area Under the Concentration-Time Curve (AUC) at Day 6

AUC from time 0, extrapolated to infinity, estimated for LY2623091. (NCT01237899)
Timeframe: Day 6: Predose,1hr, 2hr, 3hr, 4hr, 8hr and 12 hr Postdose

Interventionmicrogram*hour per milliliter (µg*h/mL) (Mean)
0.3 mg LY26230910.123
1 mg LY26230910.444
10 mg LY26230915.50
25 mg LY262309113.7

[back to top]

Pharmacodynamics: Serum to Urine Potassium Area Under the Concentration-Time Curve (AUC) Standardized for Urinary Excretion at Day 7

A measure of the renal clearance of the potassium ion (K+). The Least Squares (LS) Mean value was adjusted for pre-challenge renal K+ clearance. (NCT01237899)
Timeframe: Day 7: 24 Hour (hr), 48hr and 72hr Postdose

Interventionliter per hour (L/h) (Least Squares Mean)
Placebo2.098
0.3 mg LY26230911.940
1 mg LY26230911.981
10 mg LY26230911.788
25 mg LY26230911.551
50 mg Eplerenone1.838

[back to top]

Change From Baseline in Cardiovascular Autonomic Function

Modified oxford procedures was performed in duplicate immediately prior to start of the hypoglycemic clamp and during the last 30 min of the clamp (i.e. during the last 30 min of exposure to 2 hours of hypoglycemia).. We calculated the baroreflex sensitivity (the relationship between RR interval and change in systolic blood pressure defined as the change in the inter-beat cardiac interval in milliseconds per unit change in blood pressure in mmHg) at each time point and then the change in baroreflex sensitivity (BRS during hypoglycemia minus BRS at baseline) (NCT01394627)
Timeframe: Baseline and 2 hours after hypoglycemia

Interventionms/mmHg (Mean)
Eplerenone-16.00
Placebo-16.59

[back to top]

Change From Baseline in Inflammation

Change in interleukin-6 (NCT01394627)
Timeframe: Baseline and 2 hours after hypoglycemia

Interventionpg/ml (Mean)
Eplerenone2.03
Placebo2.61

[back to top]

Plasminogen Activator Inhibitor 1

(NCT01405456)
Timeframe: 6 months

Interventionng/mL (Mean)
Eplerenone and Lifestyle35
Placebo and Lifestyle35

[back to top]

C-Reactive Protein

(NCT01405456)
Timeframe: 6 months

Interventionmg/L (Median)
Eplerenone and Lifestyle2.8
Placebo and Lifestyle2.8

[back to top]

Adiponectin

(NCT01405456)
Timeframe: 6 months

Interventionpg/mL (Median)
Eplerenone and Lifestyle4015
Placebo and Lifestyle4014

[back to top]

Hemoglobin A1c

(NCT01405456)
Timeframe: 6 months

Interventionpercentage (Median)
Eplerenone and Lifestyle5.7
Placebo and Lifestyle5.8

[back to top]

Insulin Stimulated Glucose Uptake

(NCT01405456)
Timeframe: 6 months

Interventionmg/min per μIU/ml (Median)
Eplerenone and Lifestyle7.70
Placebo and Lifestyle8.58

[back to top]

Flow Mediated Vasodilation

(NCT01405456)
Timeframe: 6 months

Interventionpercentage of maximum change (Median)
Eplerenone and Lifestyle15.3
Placebo and Lifestyle9.6

[back to top]

Intramyocellular Lipid

(NCT01405456)
Timeframe: 6 months

Interventionpercentage of intramyocellular lipid (Median)
Eplerenone and Lifestyle0.4
Placebo and Lifestyle0.4

[back to top]

Liver Fat

(NCT01405456)
Timeframe: 6 months

Interventionpercentage of intrahepatic lipid (Median)
Eplerenone and Lifestyle6
Placebo and Lifestyle4

[back to top]

Markers of Immune Activation

MCP-1 (NCT01405456)
Timeframe: 6 months

Interventionpg/mL (Mean)
Eplerenone and Lifestyle205
Placebo and Lifestyle210

[back to top]

Visceral Adipose Tissue

(NCT01405456)
Timeframe: 6 months

Interventioncm^2 (Median)
Eplerenone and Lifestyle231
Placebo and Lifestyle233

[back to top]

Potassium

(NCT01405456)
Timeframe: 6 months

InterventionmEq/L (Mean)
Eplerenone and Lifestyle4.2
Placebo and Lifestyle4.2

[back to top]

Markers of Systemic Inflammation

IL-6 (NCT01405456)
Timeframe: 6 months

Interventionpg/mL (Median)
Eplerenone and Lifestyle9.8
Placebo and Lifestyle8.9

[back to top]

The Number of Participants Who Died While on Study

(NCT01427972)
Timeframe: Baseline up to end of Treatment Period 2 plus 10-day follow-up (80 days)

InterventionParticipants (Count of Participants)
0.2 mg LY26230910
1.5 mg LY26230911
10 mg LY26230910
50 mg Eplerenone0

[back to top]

PK: Maximum Plasma Concentration (Cmax) of LY2623091

(NCT01427972)
Timeframe: Predose, 1, 2, 4, 8, 12, and 24 hours postdose on Day 20 of Treatment Periods 1 and 2

Interventionnanograms/milliliter (ng/mL) (Mean)
0.2 mg LY26230914.540
1.5 mg LY262309131.722
10 mg LY2623091187.441

[back to top]

Pharmacokinetics (PK): Area Under the Plasma Concentration Time Curve During the Dosing Period of LY2623091 (AUC0-τ)

(NCT01427972)
Timeframe: Predose, 1, 2, 4, 8, 12, and 24 hours postdose on Day 20 of Treatment Periods 1 and 2

Interventionhours*nanogram/milliliter (h*ng/mL) (Mean)
0.2 mg LY262309175.321
1.5 mg LY2623091526.640
10 mg LY26230913096.658

[back to top]

Change From Baseline to Day 21 in Proteinuria Based on 24-hours Pooled Urine

Proteinuria was the presence of excess serum protein in the urine. Proteinuria was calculated for each participant after each treatment period. Change was calculated as (Day 21 post-treatment value) minus (baseline value). (NCT01427972)
Timeframe: Over 24 hours at Baseline and on Day 21

Interventionmilligrams/24 hours (mg/24 h) (Mean)
0.2 mg LY2623091-98.9
1.5 mg LY2623091-19.7
10 mg LY2623091119.4
50 mg Eplerenone273.7

[back to top]

Change From Baseline to Day 21 in Potassium Clearance Following an Oral Potassium Challenge

Urine potassium clearance is defined as the amount of renal potassium excreted per volume of urine from participant's pooled urine. The oral potassium challenge consisted of 35 milliequivalents (mEq) potassium administered over 10 minutes as a flavored potassium chloride solution. Change was calculated as (Day 21 values) minus (baseline values). (NCT01427972)
Timeframe: Over 0-6 hours at Baseline and on Day 21

InterventionHour*millimoles per liter (h*mmol/L) (Mean)
0.2 mg LY26230910.097
1.5 mg LY2623091-0.122
10 mg LY2623091-0.174
50 mg Eplerenone-0.019

[back to top]

12-month Change in Myocardial Strain

a sensitive measurement of heart function using cardiac MRI, change was 12 months minus baseline. (NCT01521546)
Timeframe: baseline and 12 months

Interventionpercent change in heart dimension (Median)
Placebo2.2
Eplerenone1.0

[back to top]

Vascular and Systemic Inflammation as Measured by Interleukin-6 (IL-6) Serum Levels

At Visit 1, blood was drawn before and then 2h and 4h after a high-fat/high-glucose meal (50 g fat, 75 g glucose). Participants then followed a low-dose eplerenone treatment (50 mg daily) for 14 days. At Visit 2, blood was drawn again before, 2h, and 4h after a high-fat/high-glucose meal after 14 days. (NCT01786551)
Timeframe: Baseline, 2 hours, and 4 hours, measured before and after 2 weeks of eplerenone treatment

Interventionng/mL (Mean)
Pre-eplerenone, baselinePre-eplerenone, 2 hoursPre-eplerenone, 4 hoursPost-eplerenone, baselinePost-eplerenone, 2 hoursPost-eplerenone, 4 hours
Eplerenone1.701.511.651.781.471.75

[back to top]

Post-prandial Insulin Serum Levels

At Visit 1, blood was drawn before and then 2h and 4h after a high-fat/high-glucose meal (50 g fat, 75 g glucose). Participants then followed a low-dose eplerenone treatment (50 mg daily) for 14 days. At Visit 2, blood was drawn again before, 2h, and 4h after a high-fat/high-glucose meal after 14 days. (NCT01786551)
Timeframe: Baseline, 2 hours, and 4 hours, measured before and after 2 weeks of eplerenone treatment

InterventionuU/ml (Mean)
Pre-eplerenone, baselinePre-eplerenone, 2 hoursPre-eplerenone, 4 hoursPost-eplerenone, baselinePost-eplerenone, 2 hoursPost-eplerenone, 4 hours
Eplerenone4.533.010.45.723.28.7

[back to top]

Post-prandial Glucose Serum Levels

At Visit 1, blood was drawn before and then 2h and 4h after a high-fat/high-glucose meal (50 g fat, 75 g glucose). Participants then followed a low-dose eplerenone treatment (50 mg daily) for 14 days. At Visit 2, blood was drawn again before, 2h, and 4h after a high-fat/high-glucose meal after 14 days. (NCT01786551)
Timeframe: Baseline, 2 hours, and 4 hours, measured before and after 2 weeks of eplerenone treatment

Interventionmg/dl (Mean)
Pre-eplerenone, baselinePre-eplerenone, 2 hoursPre-eplerenone, 4 hoursPost-eplerenone, baselinePost-eplerenone, 2 hoursPost-eplerenone, 4 hours
Eplerenone91105938910292

[back to top]

Ratio of BNP at Specified Visits to BNP at Baseline

B-type natriuretic peptide (BNP) levels in the blood are used for screening, diagnosis of acute chronic heart failure (CHF) and may be useful to establish prognosis in heart failure. (NCT01807221)
Timeframe: Day 30, Day 60, Day 90, Premature discontinuation (only for participants who have discontinued the study prematurely, to be performed as soon as possible after withdrawal of study drug) and Follow-up (30 days post-last dose, assessed up to Day 120)

,,,,,
InterventionRatio (Geometric Mean)
Day 30Day 60Day 90Premature discontinuationFollow-up
Eplerenone (INSPRA®)0.9250.7830.7230.8960.795
Finerenone (BAY94-8862) 10-20 mg OD0.8520.7110.7060.8480.729
Finerenone (BAY94-8862) 15-20 mg OD0.8790.8240.7711.0440.852
Finerenone (BAY94-8862) 2.5-5 mg OD0.9440.8640.8131.1040.815
Finerenone (BAY94-8862) 5-10 mg OD0.8780.8540.8391.0060.886
Finerenone (BAY94-8862) 7.5-15 mg OD0.8320.790.7190.8840.726

[back to top]

Number of Participants With Emergency Presentations for Worsening Chronic Heart Failure (WCHF)

Emergency presentations for WCHF were defined as newly developing signs and symptoms of WCHF after start of treatment with study drug, requiring an additional emergency presentation to hospital and IV treatment with diuretics and/or positive inotropic agents. (NCT01807221)
Timeframe: Day 30, Day 60, Day 90 and Follow-up (30 days post-last dose, assessed up to Day 120)

,,,,,
InterventionParticipants (Count of Participants)
Day 30Day 60Day 90Follow-up
Eplerenone (INSPRA®)21353747
Finerenone (BAY94-8862) 10-20 mg OD7141826
Finerenone (BAY94-8862) 15-20 mg OD15222834
Finerenone (BAY94-8862) 2.5-5 mg OD19303240
Finerenone (BAY94-8862) 5-10 mg OD12202230
Finerenone (BAY94-8862) 7.5-15 mg OD9172430

[back to top]

Number of Participants With Death Due to Any Cause

Death due to any cause include cardiovascular (CV) death and Non-CV death. Non-CV death was classified by 2 subcategories: non-malignant causes and malignant causes. (NCT01807221)
Timeframe: Day 30, Day 60, Day 90 and Follow-up (30 days post-last dose, assessed up to Day 120)

,,,,,
InterventionParticipants (Count of Participants)
Day 30Day 60Day 90Follow-up
Eplerenone (INSPRA®)67915
Finerenone (BAY94-8862) 10-20 mg OD0012
Finerenone (BAY94-8862) 15-20 mg OD2458
Finerenone (BAY94-8862) 2.5-5 mg OD571016
Finerenone (BAY94-8862) 5-10 mg OD1347
Finerenone (BAY94-8862) 7.5-15 mg OD12411

[back to top]

Ratio of NT-proBNP at Specified Visits to NT-proBNP at Baseline

N-terminal pro-B type natriuretic peptide (NT-proBNP) levels in the blood are used for screening, diagnosis of acute chronic heart failure (CHF) and may be useful to establish prognosis in heart failure. (NCT01807221)
Timeframe: Day 30, Day 60, Day 90, Premature discontinuation (only for participants who have discontinued the study prematurely, to be performed as soon as possible after withdrawal of study drug) and Follow-up (30 days post-last dose, assessed up to Day 120)

,,,,,
InterventionRatio (Geometric Mean)
Day 30Day 60Day 90Premature discontinuationFollow-up
Eplerenone (INSPRA®)0.8830.7490.6880.9480.747
Finerenone (BAY94-8862) 10-20 mg OD0.8220.7480.7281.1330.746
Finerenone (BAY94-8862) 15-20 mg OD0.9210.8290.7710.9650.849
Finerenone (BAY94-8862) 2.5-5 mg OD0.980.8220.7891.3690.747
Finerenone (BAY94-8862) 5-10 mg OD0.8740.8140.7651.2670.887
Finerenone (BAY94-8862) 7.5-15 mg OD0.8880.810.7830.9270.809

[back to top]

Percentage of Participants With a Relative Decrease in NT-proBNP of More Than 30% From Baseline to Day 90

N-terminal pro-B type natriuretic peptide (NT-proBNP) levels in the blood are used for screening, diagnosis of acute and chronic heart failure (CHF) and may be useful to establish prognosis in heart failure. (NCT01807221)
Timeframe: Baseline and Day 90

InterventionPercentage of participants (Number)
Eplerenone (INSPRA®)37.2
Finerenone (BAY94-8862) 2.5-5 mg OD30.9
Finerenone (BAY94-8862) 5-10 mg OD32.5
Finerenone (BAY94-8862) 7.5-15 mg OD37.3
Finerenone (BAY94-8862) 10-20 mg OD38.8
Finerenone (BAY94-8862) 15-20 mg OD34.2

[back to top]

Change From Baseline in Diastolic Blood Pressure at Specified Visits

(NCT01807221)
Timeframe: Baseline,Day 7,14,30,60,90,Premature discontinuation (only for participants who have discontinued the study prematurely, to be performed as soon as possible after withdrawal of study drug) and Follow-up (30 days post-last dose, assessed up to Day 120)

,,,,,
Interventionmillimeter for mercury (mmHg) (Mean)
BaselineDay 7Day 14Day 30Day 60Day 90Premature discontinuationFollow-up
Eplerenone (INSPRA®)71.633-1.351-3.442-0.503-0.613-0.716-3.185-1.218
Finerenone (BAY94-8862) 10-20 mg OD70.343-0.738-2.387-0.0940.17-0.545-2.96-0.298
Finerenone (BAY94-8862) 15-20 mg OD71.145-1.166-0.625-1.163-0.575-0.877-0.083-0.172
Finerenone (BAY94-8862) 2.5-5 mg OD71.044-1.693-0.5370.146-0.199-0.1060.8680.696
Finerenone (BAY94-8862) 5-10 mg OD71.442-2.1431.608-0.845-2.144-1.738-2.194-0.444
Finerenone (BAY94-8862) 7.5-15 mg OD70.610.013-0.083-0.068-0.85-1.1214.101-1.16

[back to top]

Change From Baseline in EQ-5D-3L Questionnaire Scores at Specified Visits

EuroQol Group 5-Dimension, 3-Level (EQ-5D-3L): participant rated questionnaire to assess health-related quality of life. It consists of EQ-5D descriptive system and EQ-5D Visual Analog Scale (VAS). EQ-5D-3L descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: no problems (1), some problems (2), and extreme problems (3). For this population, the possible EQ-5D-3L index scores ranges from -0.11 (that is, 3 for all 5 dimensions) to 1.0 (that is, 1 for all 5 dimensions), where higher scores indicate a better health state. (NCT01807221)
Timeframe: Baseline, Day 30, Day 90, Premature discontinuation (only for participants who have discontinued the study prematurely, to be performed as soon as possible after withdrawal of study drug) and Follow-up (30 days post-last dose, assessed up to Day 120)

,,,,,
InterventionScores on scale (Mean)
BaselineDay 30Day 90Premature discontinuationFollow-up
Eplerenone (INSPRA®)0.580.060.08-0.120.06
Finerenone (BAY94-8862) 10-20 mg OD0.560.060.1-0.050.07
Finerenone (BAY94-8862) 15-20 mg OD0.590.020.0600.04
Finerenone (BAY94-8862) 2.5-5 mg OD0.590.020.03-0.060.01
Finerenone (BAY94-8862) 5-10 mg OD0.620.020.04-0.090.01
Finerenone (BAY94-8862) 7.5-15 mg OD0.580.070.08-0.10.08

[back to top]

Change From Baseline in KCCQ Questionnaire Scores at Specified Visits

The Kansas City Cardiomyopathy Questionnaire (KCCQ) was the leading health related quality of life measure for subjects with CHF. KCCQ was a 23 item questionnaire that independently measures the impact of subjects HF, or its treatment, on 7 distinct domains: self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life. KCCQ clinical summary score is a composite assessment of physical limitations and total symptom scores. Results from the total symptom summary score are presented. Scores are transformed to a range of 0-100, in which higher scores reflect better health status. In the below table, categorical data represents change from baseline data at respective time points. (NCT01807221)
Timeframe: Baseline, Day 30 and Day 90

,,,,,
InterventionScores on a scale (Mean)
BaselineDay 30Day 90
Eplerenone (INSPRA®)43.720.524.3
Finerenone (BAY94-8862) 10-20 mg OD42.324.928.3
Finerenone (BAY94-8862) 15-20 mg OD43.220.622.2
Finerenone (BAY94-8862) 2.5-5 mg OD42.818.221.3
Finerenone (BAY94-8862) 5-10 mg OD45.419.324.5
Finerenone (BAY94-8862) 7.5-15 mg OD42.12329.3

[back to top]

Change From Baseline in Serum Potassium at Specified Visits

(NCT01807221)
Timeframe: Baseline, Day 30, Day 60, Day 90 and Follow-up (30 days post-last dose, assessed up to Day 120)

,,,,,
Interventionmillimoles per liter (mmol/L) (Mean)
BaselineDay 30Day 60Day 90Follow-up
Eplerenone (INSPRA®)4.1590.0570.1790.3070.117
Finerenone (BAY94-8862) 10-20 mg OD4.1310.210.2740.2750.175
Finerenone (BAY94-8862) 15-20 mg OD4.1170.1930.2160.2450.036
Finerenone (BAY94-8862) 2.5-5 mg OD4.0810.1350.0910.1840.226
Finerenone (BAY94-8862) 5-10 mg OD4.2110.0750.1310.1530.054
Finerenone (BAY94-8862) 7.5-15 mg OD4.1740.0850.1710.1640.05

[back to top]

Change From Baseline in Heart Rate at Specified Visits

(NCT01807221)
Timeframe: Baseline,Day 7,14,30,60,90,Premature discontinuation (only for participants who have discontinued the study prematurely, to be performed as soon as possible after withdrawal of study drug) and Follow-up (30 days post-last dose, assessed up to Day 120)

,,,,,
InterventionBeats per minute (Beats/min) (Mean)
BaselineDay 7Day 14Day 30Day 60Day 90Premature discontinuationFollow-up
Eplerenone (INSPRA®)74.957-0.8-3.1090.2940.297-0.189-2.278-1.281
Finerenone (BAY94-8862) 10-20 mg OD73.852-0.5480.423-0.8020.192-0.714.7330.834
Finerenone (BAY94-8862) 15-20 mg OD74.329-1.176-3.969-1.633-1.608-1.145-2.072-1.317
Finerenone (BAY94-8862) 2.5-5 mg OD73.3691.0730.5991.064-0.975-1.647-1.424-2.057
Finerenone (BAY94-8862) 5-10 mg OD72.681-0.631.8420.435-1.741-2.89-0.222-0.626
Finerenone (BAY94-8862) 7.5-15 mg OD74.184-0.719-1.324-0.349-2.318-2.2121.101-1.326

[back to top]

Change From Baseline in Systolic Blood Pressure at Specified Visits

(NCT01807221)
Timeframe: Baseline,Day 7,14,30,60,90,Premature discontinuation (only for participants who have discontinued the study prematurely, to be performed as soon as possible after withdrawal of study drug) and Follow-up (30 days post-last dose, assessed up to Day 120)

,,,,,
Interventionmillimeter of mercury (mmHg) (Mean)
BaselineDay 7Day 14Day 30Day 60Day 90Premature discontinuationFollow-up
Eplerenone (INSPRA®)120.554-0.541-3.4420.0670.684-0.967-2.9910.188
Finerenone (BAY94-8862) 10-20 mg OD116.0240.162-3.0991.7860.9811.216-2.322.041
Finerenone (BAY94-8862) 15-20 mg OD116.941-0.546-2.9060.8990.6670.956-0.0283.037
Finerenone (BAY94-8862) 2.5-5 mg OD119.492-3.178-4.488-0.8240.3370.922-0.412.869
Finerenone (BAY94-8862) 5-10 mg OD118.498-2.5654.142-0.367-1.2490.047-2.1671.95
Finerenone (BAY94-8862) 7.5-15 mg OD119.0870.5681.2410.374-1.811-0.6649.391-0.928

[back to top]

Number of Participants With Cardiovascular Hospitalization

Hospitalizations were defined as any unplanned admission to hospital, i.e. completion of hospital admission procedures and one overnight [i.e. date change] stay or until the death of subject occurred. Hospitalizations and deaths were classified by 2 primary categories: CV and non-CV. The pre-specified subcategories for CV hospitalizations were as follows: 1. Worsening heart failure, 2.Acute myocardial infarction, 3. Arrhythmia, 4.Transient ischemic attack and stroke, 5. Other CV hospitalizations. (NCT01807221)
Timeframe: Day 30, Day 60, Day 90 and Follow-up (30 days post-last dose, assessed up to Day 120)

,,,,,
InterventionParticipants (Count of Participants)
Day 30Day 60Day 90Follow-up
Eplerenone (INSPRA®)28434556
Finerenone (BAY94-8862) 10-20 mg OD7152227
Finerenone (BAY94-8862) 15-20 mg OD15232834
Finerenone (BAY94-8862) 2.5-5 mg OD23333543
Finerenone (BAY94-8862) 5-10 mg OD14232638
Finerenone (BAY94-8862) 7.5-15 mg OD8212936

[back to top]

Change in Serum Potassium

Eplerenone can cause elevation of serum potassium. After initial screening, serum potassium was evaluated at 1 and 4 weeks after baseline. (NCT01822561)
Timeframe: Baseline and 1 month after treatment

InterventionmEq/L (Mean)
Patients That Received Eplerenone0.11

[back to top]

Change in Best Corrected Visual Acuity

Visual acuity will be measured with standard eye charts, with manifest refraction at the initiation and conclusion of treatment. Although an important measure, this was not chosen as the primary outcome measure, as some patients with central serous chorioretinopathy may have a normal visual acuity when properly refracted (refraction can change with elevation of the macula by sub-retinal fluid) (NCT01822561)
Timeframe: Baseline and 1 month after treatment

InterventionlogMAR (Mean)
Patients That Took Eplerenone-0.03

[back to top]

Change in Macular Thickness

Automated software to calculate the thickness of the macula is standard on commercial OCT devices. Macular thickness before and after treatment will be assessed and compared. (NCT01822561)
Timeframe: Baseline and 1 month after treatment

InterventionMicrons (Mean)
Patients That Received Eplerenone-26

[back to top]

Change in Subfoveal Choroidal Thickness, Study Eye

Choroidal thickness can be measured using optical coherence tomography, and is known to be affected in patients with central serous chorioretinopathy. Thickness of the choroid under the fovea will be manually calculated in both the study eye. (NCT01822561)
Timeframe: Baseline and 1 month after treatment

Interventionmicrons (Mean)
Patients That Received Eplerenone29.8

[back to top]

Complete Resolution of Subretinal Fluid

Optical coherence tomography is an imaging technique capable of extremely high resolution (~5-7 microns) imaging of the macula, and is able to detect the presence and amount of subretinal fluid present, the key anatomic abnormality in Central Serous Chorioretinopathy (NCT01822561)
Timeframe: Baseline and 1 month after treatment

Interventionparticipants (Number)
Patients That Took Eplerenone0

[back to top]

6 Minute Walk

(NCT01971593)
Timeframe: Baseline, 6 months, 12 months from eplerenone administration

InterventionFeet (Mean)
Baseline6 Months12 Months
Total Study Group162916301680.2

[back to top]

Galectin 3

(NCT01971593)
Timeframe: Baseline, 6 months and 12 months from eplerenone administration

Interventionng/ml (Mean)
Baseline6 Months12 Months
Total Study Group10.011.611.2

[back to top]

Procollagen III N-Terminal Peptide

(NCT01971593)
Timeframe: Baseline, 6 months and 12 months from eplerenone administration

Interventionug/ml (Mean)
Baseline6 Months12 Months
Total Study Group4.64.44.4

[back to top]

Quality of Life

Rand 36-item Short Score Physical Domain Scale (SF-36) Range: 0-100, Higher scores suggest better function (NCT01971593)
Timeframe: Baseline, 6 months, 12 months from eplerenone administration

InterventionScore on a scale (Mean)
Baseline6 Months12 Months
Total Study Group87.59085

[back to top]

Serum Creatinine

(NCT01971593)
Timeframe: Baseline, 6 months, 12 months from eplerenone administration

Interventionmg/dl (Mean)
Baseline6 Months12 Months
Total Study Group0.90.90.9

[back to top]

Procollagen N-terminal Peptide 1

(NCT01971593)
Timeframe: Baseline, 6 months and 12 months from eplerenone administration

Interventionug/ml (Mean)
Baseline6 Months12 Months
Total Study Group45.148.942.7

[back to top]

Proportion of Eyes Demonstrating a Reduction in Subretinal Fluid on OCT

Proportion of eyes having a decrease in subretinal fluid on spectral domain OCT from baseline to month 2 in chronic CSCR patients receiving placebo versus eplerenone. (NCT01990677)
Timeframe: Baseline and Month 2

InterventionEyes (Count of Units)
25mg Eplerenone- Chronic CSCR Diagnosis11
Placebo- Chronic CSCR Diagnosis1

[back to top]

Mean Change in Maximal Subretinal Fluid Height Based on Spectral Domain Optical Coherence Tomography (OCT) Measurement.

Mean change in maximal subretinal fluid height based on spectral domain OCT from baseline to month 2 in chronic central serous chorioretinopathy (CSCR) patients receiving placebo versus eplerenone. (NCT01990677)
Timeframe: Baseline and 2 months

,
Interventionmicrons (Mean)
BaselineMonth 2
25mg Eplerenone- Chronic CSCR Diagnosis139.351.8
Placebo- Chronic CSCR Diagnosis135.9172.3

[back to top]

Mean Change in Subfoveal Fluid Height Based on OCT Measurement

Mean change in subfoveal fluid height based on spectral domain OCT measurement from baseline to month 2 in chronic CSCR patients receiving placebo versus eplerenone. (NCT01990677)
Timeframe: Baseline and Month 2

,
Interventionmicrons (Mean)
BaselineMonth 2
25mg Eplerenone- Chronic CSCR Diagnosis121.429.4
Placebo- Chronic CSCR Diagnosis92.1134.0

[back to top]

Muscle Sympathetic Nerve Activity at Rest

measurement of sympathetic nerve activity by microneurography (intraneural microelectrodes) (NCT01996449)
Timeframe: 8 weeks post treatment initiation

Interventionbursts/minute (Mean)
Amlodipine41
Eplerenone43.8

[back to top]

Muscle Sympathetic Nerve Activity During Exercise

measurement of sympathetic nerve activity by microneurography (intraneural microelectrodes) during arm cycling exercise (NCT01996449)
Timeframe: 8 weeks post treatment initiation

Interventionbursts/minute (Mean)
Amlodipine47
Eplerenone51

[back to top]

Left Ventricular Strain

a sensitive measure of heart muscle function (NCT02354352)
Timeframe: 12 months

InterventionPercent change in circumference (Median)
Eplerenone0.2
Spironolactone0.4

[back to top]

Change in Calcium Levels

Change in serum calcium levels before and after intervention when compared to placebo (NCT02525796)
Timeframe: Change in serum calcium levels before and after 4 weeks of double-blinded monotherapy intervention when compared to placebo (calcium at 4 weeks minus calcium at baseline)

Interventionmg/dL (Median)
Eplerenone0.1
Amiloride0.0
Placebo0.1

[back to top]

Change in Parathyroid Hormone Levels

Change in circulating PTH levels before and after 4 weeks of double-blinded intervention when compared to placebo (NCT02525796)
Timeframe: Change in circulating PTH levels before and after 4 weeks of double-blinded monotherapy intervention when compared to placebo (PTH at 4 weeks minus PTH at baseline)

Interventionpg/mL (Median)
Eplerenone4.0
Amiloride-3.7
Placebo0.8

[back to top]

Time to Reach Maximum Concentration (Tmax) of Eplerenone.

Pre IMP dose and post IMP dose at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16 and 24 hours (NCT02532998)
Timeframe: From 2 hours post dose to 8 hours post dose

Interventionh (Median)
Treatment C1.98
Treatment D2.00

[back to top]

Apparent Clearance (CL/F) of AZD9977.

Pre IMP dose and post IMP dose at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16 and 24 hours (NCT02532998)
Timeframe: From 2 hours post dose to 8 hours post dose

InterventionL/h (Geometric Mean)
Treatment D23.78
Treatment B26.20

[back to top]

Apparent Clearance (CL/F) of Eplerenone.

Pre IMP dose and post IMP dose at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16 and 24 hours (NCT02532998)
Timeframe: From 2 hours post dose to 8 hours post dose

InterventionL/h (Geometric Mean)
Treatment C10.87
Treatment D9.360

[back to top]

Apparent Volume of Distribution at Terminal Phase (Vz/F) of AZD9977.

Pre IMP dose and post IMP dose at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16 and 24 hours (NCT02532998)
Timeframe: From 2 hours post dose to 8 hours post dose

InterventionL (Geometric Mean)
Treatment B246.7
Treatment D220.4

[back to top]

Apparent Volume of Distribution at Terminal Phase (Vz/F) of Eplerenone.

Pre IMP dose and post IMP dose at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16 and 24 hours (NCT02532998)
Timeframe: From 2 hours post dose to 8 hours post dose

InterventionL (Geometric Mean)
Treatment C49.11
Treatment D44.77

[back to top]

Area Under Plasma Concentration-time Curve From Zero Extrapolated to Infinity (AUC) of AZD9977.

Pre IMP dose and post IMP dose at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16 and 24 hours (NCT02532998)
Timeframe: From 2 hours post dose to 8 hours post dose

Interventionh*nmol/L (Geometric Mean)
Treatment D21060
Treatment B19120

[back to top]

Area Under Plasma Concentration-time Curve From Zero Extrapolated to Infinity (AUC) of Eplerenone.

Pre IMP dose and post IMP dose at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16 and 24 hours (NCT02532998)
Timeframe: From 2 hours post dose to 8 hours post dose

Interventionh*ng/mL (Geometric Mean)
Treatment C9199
Treatment D10680

[back to top]

Area Under the Plasma Concentration-time Curve From Time Zero to t Hours After Dosing (AUC(0-t)) of Eplerenone.

Pre IMP dose and post IMP dose at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16 and 24 hours (NCT02532998)
Timeframe: From 2 hours post dose to 8 hours post dose

Interventionh*ng/mL (Geometric Mean)
Treatment C9035
Treatment D10510

[back to top]

Area Under the Plasma Concentration-time Curve From Time Zero to t Hours After Dosing (AUC[0-t]) of AZD9977.

Pre IMP dose and post IMP dose at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16 and 24 hours (NCT02532998)
Timeframe: From 2 hours post dose to 8 hours post dose

Interventionh*nmol/L (Geometric Mean)
Treatment D19970
Treatment B18520

[back to top]

Number of Participants With Clinically Significant Blood Pressure Values.

"Clinically significant blood pressure values (if available) were recorded for all participants.~The systolic blood pressure (mmHg) and diastolic BP (mmHg) was obtained after each subject had rested in the supine position for at least 5 minutes and was performed in accordance with the Schedule of Assessments of study protocol.~Abnormal findings in blood pressure after 10 minutes resting in the supine position was defined as following:~Systolic blood pressure (SBP) < 90 mmHg or ≥ 140 mmHg~Diastolic blood pressure (DBP) < 50 mmHg or ≥ 90 mmHg." (NCT02532998)
Timeframe: From screening to post-study visit, up to 10 weeks

InterventionParticipants (Number)
Treatment A0
Treatment D0
Treatment B0
Treatment C0

[back to top]

Number of Participants With Clinically Significant Electrocardiogram.

"Clinically significant electrocardiogram values were recorded for all participants in the study.~A 12-lead ECG was obtained after each subject had rested in the supine position for at least 10 minutes and was performed in accordance with the Schedule of Assessments of study protocol.~The investigator judged the overall interpretation as normal or abnormal. If abnormal, it would have been decided as to whether or not the abnormality was clinically significant and the reason for the abnormality would have been recorded. The investigator could add extra 12-lead resting ECG safety assessments if there were any abnormal findings of if the investigator considered it was necessary for any other safety reason. These assessments would have been entered as an unscheduled assessment." (NCT02532998)
Timeframe: From screening to post-study visit, up to 10 weeks

InterventionParticipants (Number)
Treatment A0
Treatment D0
Treatment B0
Treatment C0

[back to top]

Number of Participants With Clinically Significant Physical Examination Values.

"Number of participants with clinically significant physical examination values.~The complete physical examinations included an assessment of the general appearance, respiratory, cardiovascular, abdomen, skin, head, and neck (including ears, eyes, nose, mouth and throat), lymph nodes, thyroid, musculoskeletal and neurological systems. The brief physical examinations included an assessment of the general appearance, skin, abdomen, cardiovascular and respiratory systems. The results of the physical examination were listed by body system for each subject. Body weight was listed by participant and time-point. Any new or aggravated clinically relevant abnormal medical finding at a physical examination as compared with the baseline assessment were reported as an adverse event (AE)." (NCT02532998)
Timeframe: From screening to post-study visit, up to 10 weeks

InterventionParticipants (Number)
Treatment A0
Treatment D0
Treatment B0
Treatment C0

[back to top]

Number of Participants With Clinically Significant Pulse Rate.

"Clinically significant pulse rate (if available) was recorded for all participants in the study.~The pulse was obtained after each subject had rested in the supine position for at least 5 minutes and was performed in accordance with the Schedule of Assessments of study protocol.~Abnormal findings in pulse rate, after 10 minutes resting in the supine position, was defined as following:~• Pulse < 45 or > 85 beats per minute (bpm)" (NCT02532998)
Timeframe: From screening to post-study visit, up to 10 weeks

InterventionParticipants (Number)
Treatment A0
Treatment D0
Treatment B0
Treatment C0

[back to top]

Number of Participants With Clinically Significant Safety Laboratory Tests Values.

Clinically significant safety laboratory test values included hematology, clinical chemistry, urinalysis and urine chemistry, including urine creatinine and uric acid measurements. Viral serology and urine drugs of abuse, alcohol and cotinine were assessed for eligibility. If deterioration in laboratory value was associated with clinical symptoms and/or signs, the symptom or sign were reported as an adverse event and the associated laboratory result was considered as additional information. Laboratory results were listed and summarized according to change from baseline and repeat/unscheduled measurements. Any out of range laboratory results were flagged in the individual listings. (NCT02532998)
Timeframe: From screening to post-study visit, up to 10 weeks

InterventionParticipants (Number)
Treatment A0
Treatment D0
Treatment B0
Treatment C0

[back to top]

Observed Maximum Concentration (Cmax) of AZD9977

Pre IMP dose and post IMP dose at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16 and 24 hours (NCT02532998)
Timeframe: From 2 hours post dose to 8 hours post dose

Interventionnmol/L (Geometric Mean)
Treatment D6238
Treatment B5816

[back to top]

Observed Maximum Concentration (Cmax) of Eplerenone.

Pre IMP dose and post IMP dose at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16 and 24 hours (NCT02532998)
Timeframe: From 2 hours post dose to 8 hours post dose

Interventionng/mL (Geometric Mean)
Treatment C1557
Treatment D1729

[back to top]

Pharmacodynamics of AZD9977 Assessed Per Sodium/Potassium Ratio in Urine in AZD9977 Treatment With Placebo Versus Treatment With AZD9977.

"The sum over the urine collection intervals of the logarithm of the urinary sodium/potassium ratio from two hours to eight hours post-dose.~NOTE: Note: Data are presented as the sum of the difference between ln(Na+) and ln(K+) over the collected intervals 2-4, 4-6 and 6-8 hours." (NCT02532998)
Timeframe: From 2 hours post dose to 8 hours post dose

Interventionsodium/potassium ratio (Mean)
Treatment A-4.09
Treatment B-0.694

[back to top]

Pharmacodynamics of AZD9977 Assessed Per Sodium/Potassium Ratio in Urine in Eplerenone Treatment Versus a Combination Treatment of Eplerenone and AZD9977.

"The sum over the urine collection intervals of the logarithm of the urinary sodium/potassium ratio from two hours to eight hours post-dose.~NOTE: Data are presented as the sum of the difference between ln(Na+) and ln(K+) over the collected intervals 2-4, 4-6 and 6-8 hours." (NCT02532998)
Timeframe: From 2 hours post dose to 8 hours post dose

Interventionsodium/potassium ratio (Mean)
Treatment C-0.545
Treatment D0.694

[back to top]

Terminal Half-life (t½λz) of AZD9977.

Pre IMP dose and post IMP dose at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16 and 24 hours (NCT02532998)
Timeframe: From 2 hours post dose to 8 hours post dose

Interventionh (Mean)
Treatment D6.753
Treatment B6.726

[back to top]

Terminal Half-life (t½λz) of Eplerenone.

Pre IMP dose and post IMP dose at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16 and 24 hours (NCT02532998)
Timeframe: From 2 hours post dose to 8 hours post dose

Interventionh (Mean)
Treatment C3.232
Treatment D3.419

[back to top]

Time to Reach Maximum Concentration (Tmax) of AZD9977.

Pre IMP dose and post IMP dose at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16 and 24 hours (NCT02532998)
Timeframe: From 2 hours post dose to 8 hours post dose

Interventionh (Median)
Treatment D0.52
Treatment B0.50

[back to top]

Pharmacodynamics of AZD9977 Assessed by Estimating the Fractional Sodium Excretion in Urine for Each Urine Collection Time Interval.

"Pharmacodynamics of AZD9977 by assessment of fractional sodium excretion in urine for each urine collection time interval.~Pharmacodynamics of AZD9977 after single dosing of AZD9977 with fludrocortisone and/or eplerenone." (NCT02532998)
Timeframe: From 0 to 8 hours after dosing

,,,
Intervention% value (Mean)
0 to 2 hours2 to 4 hours4 to 6 hours6 to 8 hours
Treatment A0.340.220.150.16
Treatment B0.320.350.360.36
Treatment C0.330.370.380.48
Treatment D0.330.480.580.66

[back to top]

Pharmacodynamics of AZD9977 Assessed Per Total Sodium Excreted Cumulatively and During Each of the Urine Collection Intervals.

"Pharmacodynamics of AZD9977 by assessment of total sodium excreted cumulatively and during each of the urine collection intervals.~Pharmacodynamics of AZD9977 after single dosing of AZD9977 with fludrocortisone and/or eplerenone." (NCT02532998)
Timeframe: From 0 to 24 hours after dosing

,,,
Interventionmmol (Mean)
0 to 2 hours2 to 4 hours4 to 6 hours6 to 8 hours8 to 10 hours10 to 12 hours12 to 14 hours14 to 16 hours16 to 24 hours
Treatment A71215192328323646
Treatment B71523323946515466
Treatment C71523344755626779
Treatment D817314663748287103

[back to top]

Pharmacodynamics of AZD9977 Assessed Per Urine Production for Each Urine Collection Time Interval.

"Pharmacodynamics of AZD9977 assessed per urine production for each urine collection time interval.~Pharmacodynamics of AZD9977 after single dosing of AZD9977 with fludrocortisone and/or eplerenone." (NCT02532998)
Timeframe: From 8 hours before dosing until 24 hours after dosing

,,,
InterventionmL (Mean)
-8 to -2 hours-2 to 0 hour0 to 2 hour2 to 4 hour4 to 6 hours6 to 8 hours8 to 10 hours10 to 12 hours12 to 14 hours14 to 16 hours16 to 24 hours
Treatment A321.4303.5307.4272.2178.8216.6266.0337.1280.2357.3296.0
Treatment B284.5274.3305.0245.6229.9273.6246.6309.0306.0326.5292.2
Treatment C294.9284.5298.8272.6202.2291.5300.2324.5306.3354.2290.6
Treatment D309.3288.6320.2236.1246.0115.7326.6361.9300.7345.9302.8

[back to top]

Pharmacodynamics of AZD9977 by Assessment of Total Potassium Excreted Cumulatively and During Each of the Urine Collection Intervals

"Pharmacodynamics of AZD9977 by assessment of total potassium excreted cumulatively and during each of the urine collection intervals.~Pharmacodynamics of AZD9977 after single dosing of AZD9977 with fludrocortisone in comparison to AZD9977 placebo." (NCT02532998)
Timeframe: From 0 to 24 hours after dosing

,,,
Interventionmmol (Mean)
0 to 2 hours2 to 4 hours4 to 6 hours6 to 8 hours8 to 10 hours10 to 12 hours12 to 14 hours14 to 16 hours16 to 24 hours
Treatment A13.629.038.349.961.471.180.787.7101.8
Treatment B14.027.135.544.653.863.372.579.294.4
Treatment C13.727.435.945.154.964.073.579.795.4
Treatment D14.526.735.244.454.462.171.377.592.1

[back to top]

Pharmacodynamics of AZD9977 by Assessment of Total Urine Volume Excreted Cumulatively and During Each of the Urine Collection Intervals

"Pharmacodynamics of AZD9977 by assessment of total urine volume excreted cumulatively and during each of the urine collection intervals.~Pharmacodynamics of AZD9977 after single dosing of AZD9977 with fludrocortisone and/or eplerenone" (NCT02532998)
Timeframe: From 8 hours before dosing until 24 hours after dosing

,,,
InterventionmL (Mean)
0 to 2 hour2 to 4 hour4 to 6 hours6 to 8 hours8 to 10 hours10 to 12 hours12 to 14 hours14 to 16 hours16 to 24 hours
Treatment A307.4579.5758.3974.91242.21574.41865.12221.02506.6
Treatment B305.0550.7780.61054.21300.81609.81915.82242.32534.5
Treatment C298.8571.4773.61065.11365.31689.81996.12350.32640.9
Treatment D320.2556.3802.21099.01425.21791.72091.72435.72741.2

[back to top]

Pharmacodynamics of AZD9977 Assessed Per Fractional Potassium Excretion in Urine for Each Urine Collection Time Interval.

"Pharmacodynamics of AZD9977 assessed per fractional potassium excretion in urine for each urine collection time interval.~Pharmacodynamics of AZD9977 after single dosing of AZD9977 with fludrocortisone and/or eplerenone" (NCT02532998)
Timeframe: From 0 to 8 hours post dosing

,,,
Intervention% value (Mean)
0 to 2 hours2 to 4 hours4 to 6 hours6 to 8 hours
Treatment A21.7222.2614.6018.08
Treatment B21.1418.9512.1213.34
Treatment C21.6621.1512.4813.48
Treatment D22.1920.3012.4913.35

[back to top]

Improvement of Cardiac Steatosis: Mean Change in Intraventricular Septum Percentage of Lipid by MR Spectroscopy.

Mean change in intraventricular septum percentage of lipid by MR spectroscopy. This was calculated by subtracting the baseline intraventicular septum percentage value of lipid from the week 24 intraventicular septum percentage value of lipid by MR spectroscopy. (NCT02629094)
Timeframe: 24 weeks

Interventionpercentage of lipid (Mean)
Eplerenone-0.33

[back to top]

Improvement of Hepatic Steatosis: Mean Change in Hepatic Percentage of Lipid by MR Spectroscopy

Mean change in hepatic percentage of lipid by MR spectroscopy. This was calculated by subtracting the baseline hepatic percentage value of lipid from the week 24 hepatic percentage value of lipid by MR spectroscopy. (NCT02629094)
Timeframe: 24 weeks

Interventionpercentage of lipid (Mean)
Eplerenone13

[back to top]

Markers of Vascular Dysfunction

Change (value at 12 months minus value at baseline) in serum hs-cTnT (NCT02740179)
Timeframe: 12 Months

Interventionng/L (Median)
Eplerenone0.00
Placebo0.00

[back to top]

Myocardial Inflammation

Change (value at 12 months minus value at baseline) in myocardial inflammation measured by extracellular mass index (a measure of the inflammation within the heart) via cardiac magnetic resonance imaging (NCT02740179)
Timeframe: 12 Months

Interventiong/m^2 (Median)
Eplerenone0.9
Placebo-0.7

[back to top]

Markers of Systemic Inflammation hsCRP

Change (value at 12 months minus value at baseline) in plasma hsCRP (NCT02740179)
Timeframe: 12 Months

Interventionng/mL (Median)
Eplerenone189
Placebo591

[back to top]

Myocardial Perfusion by MRI

Change (value at 12 months minus value at baseline) in myocardial perfusion assessed by myocardial blood flow measured via cardiac magnetic resonance imaging (NCT02740179)
Timeframe: 12 Months

InterventionmL/min/g (Mean)
Eplerenone0.09
Placebo-0.53

[back to top]

Myocardial Perfusion by PET

Change (value at 12 months minus value at baseline) in myocardial perfusion assessed by coronary flow reserve measured via cardiac positron emission tomography. Coronary flow reserve is given by the ratio of blood flow at stress during maximal dilation of the coronary arteries to blood flow at rest. (NCT02740179)
Timeframe: 12 Months

Interventionunitless (Mean)
Eplerenone0.01
Placebo-0.07

[back to top]

Markers of Subclinical Injury

Change (value at 12 months minus value at baseline) in serum NT-proBNP (NCT02740179)
Timeframe: 12 Months

Interventionng/L (Median)
Eplerenone19.4
Placebo2.8

[back to top]

Markers of Immune Activation sCD163

Change (value at 12 months minus value at baseline) in plasma sCD163 (NCT02740179)
Timeframe: 12 Months

Interventionng/mL (Median)
Eplerenone-275
Placebo-160

[back to top]

Markers of Immune Activation MCP-1

Change (value at 12 months minus value at baseline) in plasma MCP-1 (NCT02740179)
Timeframe: 12 Months

Interventionpg/mL (Median)
Eplerenone285
Placebo292

[back to top]

Markers of Fibrosis

Change (value at 12 months minus value at baseline) in myocardial fibrosis measured by T1 (a signal intensity that measures fibrosis) via cardiac magnetic resonance imaging (NCT02740179)
Timeframe: 12 Months

Interventionms (Median)
Eplerenone25
Placebo1

[back to top]

Markers of Arterial Inflammation

Change (value at 12 months minus value at baseline) in plasma LpPLA2 (NCT02740179)
Timeframe: 12 Months

Interventionng/mL (Median)
Eplerenone3.0
Placebo2.6

[back to top]

Coronary Plaque

Change (value at 12 months minus value at baseline) in coronary plaque measured via coronary computed tomography angiogram assessed by coronary calcium score Scale: minimum 0 to maximum no limit, higher score indicates more plaque (NCT02740179)
Timeframe: 12 Months

Interventionscore on a scale (Median)
Eplerenone0
Placebo5

[back to top]

Assessment of Cardiac Systolic Function Via Cardiac Imaging

Change (value at 12 months minus value at baseline) in global circumferential strain (GCS) on cardiac magnetic resonance imaging (NCT02740179)
Timeframe: 12 Months

Interventionpercentage GCS (Median)
Eplerenone-1.3
Placebo2.3

[back to top]

Assessment of Cardiac Structure by Left Ventricular Mass on Cardiac Imaging

Change (value at 12 months minus value at baseline) in left ventricular mass on cardiac magnetic resonance imaging (NCT02740179)
Timeframe: 12 Months

Interventiong (Median)
Eplerenone1
Placebo9

[back to top]

Assessment of Cardiac Diastolic Function Via Cardiac Imaging

Change (value at 12 months minus value at baseline) in left ventricular end diastolic volume on cardiac magnetic resonance imaging (NCT02740179)
Timeframe: 12 Months

InterventionmL (Mean)
Eplerenone-13
Placebo10

[back to top]

Arterial Inflammation

Percentage change (value at 12 months minus value at baseline) in target to background ratio (a measure of arterial inflammation) of the index vessel measured via positron emission tomography/computed tomography (NCT02740179)
Timeframe: 12 Months

Interventionpercentage change (Median)
Eplerenone-12.4
Placebo5.1

[back to top]

Markers of Systemic Inflammation hsIL-6

Change (value at 12 months minus value at baseline) in plasma hsIL-6 (NCT02740179)
Timeframe: 12 Months

Interventionpg/mL (Median)
Eplerenone-0.8
Placebo0.2

[back to top]

Percentage of Participants With Adverse Drug Reactions in Chronic Heart Failure Participants With Moderate Renal Impairment

An adverse drug reaction (ADR) was any untoward medical occurrence attributed to Selara in a chronic heart failure participant with moderate renal impairment (≥30 mL/min and <50 mL/min in eCLCr) who received Selara. A serious ADR was an ADR resulting in any of the following outcomes or deemed significant for any other reason: death; life-threatening experience (immediate risk of dying); initial or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly. Relatedness to Selara was assessed by the physician. (NCT03342690)
Timeframe: 52 weeks from the start date

InterventionPercentage of Participants (Number)
ADRSerious ADR
Selara Tablets (Eplerenone)9.491.58

[back to top]

Percentage of Participants With Adverse Drug Reactions in Chronic Heart Failure Participants

An adverse drug reaction (ADR) was any untoward medical occurrence attributed to Selara in a chronic heart failure participant who received Selara. A serious ADR was an ADR resulting in any of the following outcomes or deemed significant for any other reason: death; life-threatening experience (immediate risk of dying); initial or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly. Relatedness to Selara was assessed by the physician. (NCT03342690)
Timeframe: 52 weeks from the start date

InterventionPercentage of Participants (Number)
ADRSerious ADR
Selara Tablets (Eplerenone)5.970.79

[back to top]

The Overall Mortality Rate

The overall mortality rate was calculated by the incidence of all-cause death per observation time based on the person-year method (the number of deaths in 100 person-year). (NCT03342690)
Timeframe: 52 weeks from the start date

Interventionevents per 100 patient-year (Number)
Selara Tablets (Eplerenone)4.4

[back to top]

The Number of Deaths (Overall Deaths)

Overall deaths were described with the number of deaths from any cause at the time of 52 weeks after the start of administration, regardless of the treatment status (completed or discontinued). (NCT03342690)
Timeframe: 52 weeks from the start date

InterventionParticipants (Number)
Selara Tablets (Eplerenone)44

[back to top]

The Number of Deaths (Cardiovascular Deaths)

Cardiovascular deaths were described with the number of deaths defined as any death due to cardiac failure, myocardial infarction, arrhythmia (atrial fibrillation, atrial flutter, arrhythmia supraventricular, or ventricular arrhythmia), stroke or cerebrovascular attack, and other causes related to cardiovascular system at the time of 52 weeks after the start of administration, regardless of the treatment status (completed or discontinued). (NCT03342690)
Timeframe: 52 weeks from the start date

InterventionParticipants (Number)
Selara Tablets (Eplerenone)15

[back to top] [back to top]

Kansas City Cardiomyopathy Questionnaire (KCCQ-12)-Quality of Life Score

The Kansas City Cardiomyopathy Questionnaire (KCCQ-12) is a self-administered health status survey. The KCCQ-12 has 4 domains (physical limitation, symptom frequency, quality of life, social limitation) and one summary score. Score are scaled 0-100, where 1 denotes the lowest reportable health status and 100 the highest. (NCT03923530)
Timeframe: Baseline, 8 weeks

Interventionscore on a scale (Mean)
Baseline8 weeks
Eplerenone54.973.6

[back to top]

Diastolic Blood Pressure

Cuff diastolic blood pressure (NCT03923530)
Timeframe: Baseline, 8 weeks

Interventionmm Hg (Mean)
Baseline8 weeks
Eplerenone56.255.0

[back to top]

Kansas City Cardiomyopathy Questionnaire (KCCQ-12)-Physical Limitation Score

The Kansas City Cardiomyopathy Questionnaire (KCCQ-12) is a self-administered health status survey. The KCCQ-12 has 4 domains (physical limitation, symptom frequency, quality of life, social limitation) and one summary score. Score are scaled 0-100, where 1 denotes the lowest reportable health status and 100 the highest. (NCT03923530)
Timeframe: Baseline, 8 weeks

Interventionscore on a scale (Mean)
Baseline8 weeks
Eplerenone53.061.5

[back to top]

Kansas City Cardiomyopathy Questionnaire (KCCQ-12)-Social Limitation Score

The Kansas City Cardiomyopathy Questionnaire (KCCQ-12) is a self-administered health status survey. The KCCQ-12 has 4 domains (physical limitation, symptom frequency, quality of life, social limitation) and one summary score. Score are scaled 0-100, where 1 denotes the lowest reportable health status and 100 the highest. (NCT03923530)
Timeframe: Baseline, 8 weeks

Interventionscore on a scale (Mean)
Baseline8 weeks
Eplerenone65.680.1

[back to top]

Kansas City Cardiomyopathy Questionnaire (KCCQ-12)-Summary Score

The Kansas City Cardiomyopathy Questionnaire (KCCQ-12) is a self-administered health status survey. The KCCQ-12 has 4 domains (physical limitation, symptom frequency, quality of life, social limitation) and one summary score. Score are scaled 0-100, where 1 denotes the lowest reportable health status and 100 the highest. (NCT03923530)
Timeframe: Baseline, 8 weeks

Interventionscore on a scale (Mean)
Baseline8 weeks
Eplerenone59.474.1

[back to top]

Kansas City Cardiomyopathy Questionnaire (KCCQ-12)-Symptom Frequency Score

The Kansas City Cardiomyopathy Questionnaire (KCCQ-12) is a self-administered health status survey. The KCCQ-12 has 4 domains (physical limitation, symptom frequency, quality of life, social limitation) and one summary score. Score are scaled 0-100, where 1 denotes the lowest reportable health status and 100 the highest. (NCT03923530)
Timeframe: Baseline, 8 weeks

Interventionscore on a scale (Mean)
Baseline8 weeks
Eplerenone63.581.5

[back to top]

Systolic Blood Pressure

Cuff systolic blood pressure (NCT03923530)
Timeframe: Baseline, 8 weeks

Interventionmm Hg (Mean)
Baseline8 weeks
Eplerenone122.5120.0

[back to top]